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Healthcare costs are escalating in the U.S., with a projected 48 trillion dollars by 2021. 
More than ever medical researches are obligated to ensure that costly treatment 
modalities are safe and effective. Chronic obstructive pulmonary disease (COPD) is a 
costly and debilitating disease, ranked as the third leading cause of death in America. 
Currently, treatment for COPD consists of anti-inflammatory agents, bronchodilators, 
antibiotics and supplemental oxygen when hypoxemia or clinical manifestations ensue. 
Oxidative stress is central to the pathology of COPD. Supplemental oxygen has been 
substantiated as an instigator of oxidative stress; however, LFDO has not been evaluated 
as a mechanism of ongoing oxidative stress in individuals with COPD. Isofuran (IsoF), a 
biosynthetic relative of the validated oxidative stress biomarker 8-isoprostane, is 
preferentially synthesized during periods of increased tissue oxygen tension. This sort of 
 specificity allows for refinement in the assessment of supplemental oxygen as a source of 
oxidative stress. To address this potential this study evaluated individuals diagnosed with 
COPD utilizing LFDO. The study also aimed to determine if IsoF possessed clinical 
application in predicting the standard pulmonary function test (PFT) parameters of FEV1, 
FVC, FEV1/FVC and FEF25-75. The exhaled breath condensate (EBC) of 52 individuals 
with COPD was evaluated for the presence of IsoF. An active control group not receiving 
LFDO (n=26) was compared to an active treatment group receiving LFDO for a 
minimum of 6 hrs/day (n=26). The groups showed no statistically significant 
demographic differences in age, gender, height, weight, ethnicity or smoking history or in 
the pulmonary function test parameters of FEV1, FVC, and FEV1/FVC, with the 
exception of the FEF25-75 (P=0.03). The active control group generated a mean EBC 
IsoF level of 35.81 ± 4.91 pg/ml (± SEM) compared to the active treatment group mean 
EBC IsoF level of 51.37 ± 8.27 pg/ml (P=0.057). Currently, no research has been 
conducted that defines baseline EBC IsoF levels in healthy or diseased lungs. No 
statistically significant differences in mean EBC IsoF levels were noted between the 
control and treatment groups; however, the results, in conjunction with the only two 
studies available utilizing EBC IsoF as an oxidative stress biomarker, may serve to 
provide benchmark information for future research regarding individuals with diseased 
lungs, specifically COPD. 
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Chapter 1- Introduction 
 
Introduction 
 Americans may be living longer but not necessarily more healthfully. Some lifestyle 
choices are rife with consequence. Smoking, over eating and lack of exercise are major players 
in our countries overall lack of health and has translated to economic stress. Healthcare 
expenditures in the U.S have been growing at an alarming rate for the past several years. Total 
health expenditure in the U.S. is defined as the sum of public and private expenditure, and covers 
healthcare provision (preventive and curative), family planning, nutrition activities, and 
emergency aid. In the 1960’s the healthcare costs constituted approximately 5.2% of the GDP. 
During the 70’s healthcare costs increased to 7.2% GDP, or approximately 75 billion dollars. 
Currently, 17.3%, or roughly 2.5 trillion dollars, are spent annually on healthcare. A GDP of 
20%, or 48 trillion dollars, is projected by 2021 (CMS Report). The United States is on track to 
spend one-fifth of tax dollars exclusively on healthcare. There are many factors that contribute to 
the escalating costs, such as hospitals, physicians, prescription drugs, nursing/continued care, 
private health insurance administrative costs, etc.; however, this study will focus on those areas 
whose cost most directly impact health care delivery, hospitals and physicians, which comprise 
about 50% of the expenditures are considered the structure and process of healthcare delivery. 
When considering an approach to contain escalating costs it is necessary to understand 
health trends that contribute most significantly to those costs. According to a report published by 
the Agency for Healthcare Research and Quality (AHRQ) (2006), the top five diseases that 
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introduce the greatest economic burden to this country are mood disorders, diabetes, cancer, 
heart disease, lung disease and hypertension. One such disease is chronic obstructive pulmonary 
disease (COPD), which continues to be one of the top five leading causes of death in America.  
Costly treatments, increased hospital stays, loss of functionality leading to inability to work, as 
well as requiring in home assistance contribute to the significant expense of this disease.  A 
deeper understanding of the pathophysiology of the disease, as well as the prescribed 
interventions and management, could aid in improving health states and reducing cost of these 
major health care categories. 
A common denominator exists amongst many disease processes, oxidative stress. 
Oxidative stress, free radical induced damage to proteins, lipids and DNA, has been implicated 
as a key process in the development of heart, lung, and neural disease, cancer, diabetes, arthritis, 
cataracts, and, on a lesser stage, aging. Interestingly, oxidative stress is linked to those disease 
categories that introduce the greatest economic burden in the U.S. As such, it is imperative that 
researchers gain an intimate understanding of this potentially deleterious process in order to 
ameliorate or eliminate its health and economic impact. 
 Chronic obstructive pulmonary disease is one of the major pulmonary diseases that 
proves to be physically, spiritually and economically taxing. It is a progressive and irreversible 
respiratory disease primarily linked to oxidative damage caused by airway irritants, most 
prominently cigarette smoking.  For nonsmokers, long-term exposure to second hand smoke, 
chronic asthma, and environmental pollutants are the most significant contributors. As the 
leading contributor of COPD, it is of value to understand the mechanisms of destruction induced 
by cigarette smoke in the airways in an effort to prevent the destruction. Cigarette smoke 
stimulates the generation of reactive oxygen species (ROS), a molecular form of oxygen 
involved in oxidative stress, and has been linked to alterations in glutathione (GSH), an intra and 
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extracellular antioxidant present in the lungs (Rahman and MacNee, 1999). Disabling the body’s 
protective antioxidant defenses invites oxidative reactions, especially in the presence of 
increased ROS. Ultimately, this imbalance results in lung parenchymal damage through 
alterations in the lipid bilayers induced by oxidative stress. 
 For those who smoke, and for those who are chronically exposed to airway mutagens, it 
is recommended to undergo pulmonary function testing for early detection of COPD. Early 
detection of COPD can produce the greatest opportunity to halt the debilitating disease. 
Pulmonary function testing (PFT) is a simple non-invasive method of assessing lung function. 
Pulmonary function defects can be grouped into two main categories: obstructive and restrictive.  
If expiratory flow is impeded an obstructive disorder may exist; if volume is reduced a restrictive 
disorder may exists. Several pulmonary function tests can be performed to assist in predicting 
pulmonary status, such as the vital capacity (VC), forced vital capacity (FVC), peak expiratory 
flow rates (PEFR), forced expiratory flow rates (FEF), maximal voluntary ventilation (MVV) 
and forced expired volume in 1 second (FEV1). The most frequently used parameters in 
predicting stages of COPD are the FEV1 and FVC values, both of which are useful in detecting 
and quantifying restrictive and obstructive patterns. The FEV1 is the amount of air forcefully 
expelled in the first second of exhalation. Forced vital capacity is the amount of air an individual 
can forcibly and maximally expel until unable to expel any more. The FEV1/FVC represents a 
proportion of an individual’s vital capacity expelled in the first second. When values are 
categorized by age, gender, race, and body height and size a meaningful interpretation can be 
made.  PFTs are effort dependent, therefore, patient compliance and cooperation is required for 
accurate result valuation.  
 The study of oxygen has been a topic of research for literally centuries. It is a perplexing 
and curious notion that an element is necessary for life but contributes to morbidity and 
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mortality. Oxygen delivery is a frequently prescribed therapy in both the acute and chronic care 
in the U.S. Low flow domiciliary oxygen (LFDO) is a prescribed therapy for those afflicted with 
advanced stages of COPD.  Due to ethical implications a safety index for oxygen exposure has 
not been established. Most of the usable data regarding tolerable limits of oxygen exposure have 
been obtained from normal, healthy, young subjects (Klein, 1991). As a result, the effects of 
underlying diseases and other factors that may alter inherent oxidative protective mechanisms 
remain unknown. For the COPD population the benefits of LFDO therapy are well documented. 
Consequences of prolonged exposure to higher concentrations of oxygen has garnered much 
research attention; to date, only a handful of research studies have addressed the consequences of 
chronic exposure to low concentrations of oxygen with regard to oxidative injury. Petty, Stanford 
and Neff in 1971 and Steward, Hood and Block in 1975 both demonstrated histological changes 
in post mortem autopsies of those who had been treated with LFDO for several years. Two 
studies, both performed in 2004 evaluated 30-minute exposure to 28% oxygen. Phillips et al. 
compared healthy subjects and determined a significant (P<0.05) increase in BMAC, a 
biomarker of oxidative stress. Carpagnano et al compared healthy subjects to those with COPD 
and determined a significant (P<0.05) in 8-IsoP between groups. However, to date no studies 
have utilized isofuran, a biomarker synthesized only in the presence of elevated oxygen tensions, 
as a mechanism to determine if oxygen is the culprit for the presence of oxidative stress. 
A disease process that is a direct result of unchecked oxidative stress, COPD is an ideal 
pathology to evaluate to learn more about the potential of LFDO as a mechanism of ongoing 
oxidative stress. It would be unfortunate, negligent and medically irresponsible if a prescribed 
therapy fostered ongoing oxidative stress in this already fragile population. Eradicating costly 
diseases through research and development along with the adherence to healthy lifestyles could 
spare the individual and nation at large significant economic, physical and emotional burden. 
  5 
Purpose 
 Chronic obstructive pulmonary disease, a progressive and irreversible respiratory disease 
resulting from unchecked oxidative processes, in advanced states often requires oxygen 
supplementation to ameliorate distress. The purpose of this study is to identify if ongoing 
oxidative stress is occurring as a result of chronic exposure to low flows of domiciliary oxygen 
(LFDO) as evidenced by the validated biomarker, isofuran. Understanding these mechanisms 
may lead to a more rational basis for clinical prescription of oxygen. 
The goal of this study is to gain insight into the potential of oxygen in order to safely 
prescribe and manage oxygen therapy. The objective of this study is to determine if LFDO as a 
treatment modality in COPD promotes oxidative stress. The specific aims of this study are to 1) 
assess for the presence of isofuran, an oxidative stress biomarker, in the exhaled breath 
condensate (EBC) of COPD patients on LFDO; 2) determine if a correlation exists between 
standard diagnostic spirometry values and exhaled breath condensate EBC biomarker (isofuran); 
3) determine if a correlation exists between length of smoking history, length and concentration 
of oxygen exposure and EBC biomarkers (isofuran levels). 
Background and Significance 
The impact of oxidative stress on the health of U.S. citizens has only recently been 
appreciated. Oxidative stress has been linked to the top five diseases, including heart disease, 
lung disease, cancer, diabetes, and neural disorders, contributing to the greatest healthcare costs 
in terms of treatment, hospitalizations and loss of work (Druss, et al, 2001). While people may be 
living longer it may not necessarily be more healthfully (National Center for Health Statistics, 
2010).  
Chronic obstructive pulmonary disease (COPD) is a progressive disorder resulting in 
irreversible lung damage primarily comprised of two disorders: chronic bronchitis and 
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emphysema, and falls as one of the most economically burdensome.  Approximately 16 million 
Americans have COPD, 14 million with chronic bronchitis and 2 million with emphysema 
(WHO, 2002). According to the American Lung Association June 2008 Fact Sheet, 2008 stated 
that in 2006 12.1 million U.S. adults (ages 18 years and over) were estimated to have COPD but 
that ~24 million U.S. adults have evidence of impaired lung function, indicating an under 
diagnosis of COPD.   
Smoking is considered the major contributor in developing COPD, be it direct smoking 
or indirect second hand smoke exposure (American Lung Association, 2008). Associated health 
care costs linked to cigarette smoking up to 2002 had been estimated at ~50 billion dollars 
annually. More recent reports from the CDC show the economic costs of smoking to be at $3,393 
per smoker, reaching an estimated $157 billion: $81.9 billion in productivity losses due to death 
and $75.5 billion due to excess medical expenditures (CDC 2002).  COPD is the fourth leading 
cause of death and is projected to be the third leading cause of death by 2020 (ALA 2008).  The 
American Lung Association states that an estimated 800,000 adolescents will start smoking 
every year. Statistics like this point to a future of continued and worsening economic and 
healthcare challenges as it relates to the management of those who develop COPD.  
While smoking is implicated as the initial inducer of oxidative stress in COPD pathology, 
continued oxidative stress may be occurring as a result of treatment modalities. Superimposing 
further damage on an individual with COPD through chronic exposure to greater than room air 
concentrations of oxygen via low flow domiciliary oxygen therapy (LFDO) is neither in the best 
interest of the COPD patient nor the community at large. It is well understood that oxygen  
therapy for those suffering with advanced stages of COPD benefit from LFDO, however, it needs 
to be appreciated if this necessary treatment is a contributing factor to ongoing oxidative stress. 
To identify whether or not this phenomenon is occurring as a result can assist in guiding 
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researchers to a better understanding and development of COPD health management modalities, 
as well as a better understanding of the untoward effects of chronic exposure of LFDO and the 
potentially destructive effects of oxygen free radicals. 
Oxidative stress occurs as a result of an imbalance between reactive oxygen species 
(ROS) and the system’s ability to neutralize these highly reactive intermediates. This imbalance 
of a normal redox state has deleterious effects on the surrounding protein, lipid and DNA 
structures as a result of peroxide and free radical production and activity. Oxidative stress has 
been linked to aging, autism, Alzheimer’s, cancer, COPD and cardiac disease to name a few 
(Halliwell, 2007; Valko et al, 2007; Singh et al, 1995; Ramond et al, 2011; Dean et al, 2011). It 
should be understood, however, that ROS are integral in health states as well, such as activation 
of the immune system; it is the imbalance of ROS and endogenous antioxidants that result in 
pathology (Segal, 2005). Although physiologic changes attributable to oxygen toxicity, such as 
decreases in vital capacity, pulmonary compliance, and diffusing capacity, together with 
increases in arteriovenous shunting and ration of dead space to tidal volume, early detection of 
toxicity requires more sensitive, specific, and preferably easy, tests (Klein, 1991). 
In the past decade significant research has been conducted to aid in better understanding 
the inflammatory cascades occurring within the body in response to various stressors, such as 
oxidative stress (Montuschi, 2007; Barnes, 2006). As a result 8-iso-PGF2α, in addition to many 
other nonenzymatically generated prostaglandins, have been identified as a biomarker consistent 
with oxidative stress occurring within the lungs (Montuschi, 2007; Barnes, 2006).  
More recently, research has demonstrated that isofurans, biosynthetic relatives of the 
isoprostanes, are formed under conditions where elevated oxygen tensions exist, allowing for 
research to expand in the area of hyperoxia. Both biomarkers can be evaluated in exhaled breath, 
making them an ideal to study pathologies occurring within the lungs.  
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Breath analysis is not new to medicine.  Hippocrates would assess breath odor to 
diagnose disease states; however, not until the 1970’s was it demonstrated by Linus Pauling that 
over 250 substances were identifiable in exhaled breath via gas chromoatgraphy mass 
spectrometry (GC-MS) (Dweik and Amann, 2008). More efficient devices have been developed 
to collect and store exhaled breath for biomarker analysis.  Researchers suggest using these 
biomarkers to diagnose and prognose, as well as manage disease states (Montuschi, 2007). 
The identification of a biomarker sensitive to endogenous changes to oxygen tension 
within the body provides an opportunity for researchers to better understand oxidative processes. 
Currently there is no information available in the literature that defines basal levels of isofuran in 
the exhaled breath of individuals diagnosed with advanced COPD with or without domiciliary 
oxygen therapy. This study aims to address this gap in foundational knowledge. It also aims to 
gain insight into whether or not chronic exposure to oxygen therapy serves as a mechanism of 
ongoing oxidative stress within the lungs of individuals with advanced COPD. 
Conceptual Framework 
“The well-being of the soul can be obtained only after that of the body has been secured,” 
insight provided by Maimonides, a revered 12th century Jewish author, physician and 
philosopher, in his three volume series entitled The Guide for the Perplexed, demonstrating an 
early appreciation that quality of life is directly linked to physical health (Epstein and Sherwood, 
1996).  Current appreciation of the effect physical health has on quality of life, through outcomes  
research, has expanded to become a multidisciplinary effort involving researchers, 
healthcare providers, epidemiologists, economists, sociologists, statisticians and ethicists 
(Epstein and Sherwood, 1996).   
The idea that quality healthcare can be achieved based on positive health outcomes is 
intuitive; however, the practice of relating quality to outcomes has become a prominent strategy 
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and more widely accepted in the past few decades in healthcare delivery (Hammermeister, 
Shroyer, Sethi, and Grover, 1995; Jennings and Staggers. 1998).  The Donabedian model of 
structure-process-outcome will assist in guiding this research endeavor. This model fosters 
becoming more attuned to all aspects of health care provision, facilitating a more accurate 
interpretation of causal relationships between structure, process and outcomes.  
Avedis Donabedian was born to an Armenian family in Beirut, Lebanon in 1919 and 
grew up in Palestine, narrowly escaping the Armenian Holocaust. He followed his father’s 
footsteps in becoming a physician and eventually became the Chief Medical Officer of the 
American University in Beirut. During his tenure there he became frustrated with the limitations 
as an administrator and turned his interests to quality health care provision and public health. 
Following the Second World War, Donabedian moved to the U.S. from Lebanon and joined the 
faculty at the University of Michigan.  It was then that he was commissioned with the task of 
revising all that had been written on quality assessment and to present it in an organized fashion.  
At that time formal writings on quality assessment were limited, allowing Donabedian to tackle 
this task in a reasonable amount of time and autonomy.  His efforts gave way to the more formal 
model of process-structure-outcome phenomenon, or Donabedian’s Triad.  Donabedian’s 
professional career was dedicated to revising and defining his model and outlining its usefulness 
for quality assessment and management (Donabedian 1966, 1968, 1982, 1985, 1992).  
Elements of quality assessment. Donabedian’s triad of concepts (structure, process and 
outcomes) has been defined in his writings.  Structure is conceptually defined in terms of the 
setting in which care is provided and refers to the organization of health care resources 
(Donabedian, 1966). Structure also includes demographics, the education of providers, the 
adequacy of the facilities and equipment, as well as the overall administrative environment.  
Process is conceptually defined as the actions that constitute healthcare, to include diagnosis, 
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treatment, preventative care, collaboration of services, and patient education (Donabedian, 
1982). Processes can also include the technical aspects of how care is delivered, or interpersonal 
processes of how care is delivered (Donabedian, 1980). Donabedian believes the measurement of 
process is equivalent to the measurement of quality of care as process contains the most relevant 
aspects of healthcare provision (Donabedian, 2003). Outcome is conceptually defined as the end 
result of the process of care to include “those things, either favorable or adverse, in the actual or 
potential health status of persons, groups, or communities that can be attributed to medical care” 
(Donabedian, 1985, p.256) and refers to “states or conditions attributable to antecedent health 
care” (Donabedian, 1992).  In short, outcome is the measurable or observable result of structure 
and process; an assessment as to whether or not a treatment modality offered by providers of an 
institution affected the health state of the consumer. Outcome goals are to prevent progression of 
poor health, and to restore and maintain health states. Donabedian, (1992) states that quality 
outcomes are best achieved when the following attributes are employed: effectiveness (achieving 
the greatest improvements in health currently achievable by the best care), efficiency (the ability 
to provide appropriate care without diminishing improvements in health), optimality (achieving a 
balance between the cost of care and the effects of care on health), acceptability (achieving 
conformity with patient preferences), legitimacy (achieving conformity to social preferences and 
ethical subscriptions), and equity (conformity to principles guiding the fair distribution of health 
care in a population). It is widely agreed upon that defining quality is nearly impossible as each 
individuals value judgments differ one to the next. However, it also believed that most likely the 
majority equates quality with what the medical community perceives as quality.  
Conceptual relationships. The relationship between structure, process and outcome is 
antecedent, or causal, in nature.  In regards to structure and process, Donabedian states that “the 
assumption is made that given the proper settings (structure) and instrumentalities (process), 
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good medical care will follow” and, hence, good and desired outcomes (1966, p. 170). Specific 
attributes of structure, process and outcomes are considered valid for the purpose of quality 
assessment only to the extent that causal relationships can be demonstrated, meaning a quality 
outcome is only valid if it can be directly linked to the structure and/or process (Donabedian, 
1992).  
Structure-Process-Outcome Model used in research. Kunkel, Rosenqvist and 
Westerling (2007) implemented the Donabedian model in a qualitative survey research endeavor 
of 386 hospital departments in Sweden. The goal of this study was to analyze whether process, 
structure and outcome could be used to describe quality systems and whether or not these 
components are related.  It was concluded that the process-structure-outcome model could be 
used to describe and evaluate single quality systems (P=0.095) as well as to compare different 
quality systems. They believe it could also serve as an aid to implement a systematic and 
evidence based system for working with quality improvements in hospital departments. 
Statistical analyses showed that Structure correlated strongly with process (0.72) and outcome 
(0.60).  
In a two-year prospective study of 288 acute stroke patients across 11 VA medical 
centers the structure-process-outcome model was used to examine the quality of health care with 
regard to stroke patient outcomes. The goal of the project was to determine if structure of care is 
associated with process of care, and if structure of care is associated with stroke outcomes after 
adjusting for process. The results demonstrated that both systematic organization (P<0.001) and 
technological sophistication (P<0.001) were independent predictors of process of care. Overall, 
the full structure-process-outcome model with patient covariates considered, process of care was 
statistically associated with 6-month functional outcomes (P<0.01), but structure of care was not 
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shown to be statistically significant. In summary, process appears to be more significant of an 
indicator for quality outcomes than process (Hoenig et al., 2002). 
Model assumptions and limitations. The structure-process-outcome model holds three 
major assumptions with regard to validity and usefulness for quality health care assessment: 1) 
that quality is defined and outcomes are selected, 2) health is a multidimensional concept; and 3) 
multiple causation.  
  It can be assumed that multiple definitions of quality exist. Valuation is an individualized 
phenomenon influenced by many outside forces and variables. According to Donabedian (1982), 
quality as an opinion implies valuation and is directly related to the attainment of proposed goals 
and objectives. When an individual’s goals and objectives are met congruency of quality is 
realized.  
  The “state” of health is multidimensional in that it is comprised of physical, physiologic, 
psychologic, social and spiritual attributes. The influences on each of these attributes are 
essentially limitless resulting in extensive outcome possibilities. Intimate understanding of the 
whole being facilitates the meeting of individual goals and outcomes. 
  Attempting to discern causes of healthcare outcomes is challenging, as the variables of 
input are vast. Therefore, relying solely on outcome measures cannot provide complete accuracy 
to those elements responsible for either positive or negative outcomes. Oversight of structure and 
process, both within and between collaborative disciplines must be considered. 
Structure-Process-Outcome model guiding this study. Current practices for managing 
advanced stages of COPD include the use of low flow domiciliary oxygen therapy for those 
individuals who meet prescribing criteria and demonstrate improvement with its use. However, 
to date minimal research has been performed to assess whether or not chronic exposure to 
oxygen therapy introduces consequences in terms of oxidative injury.  In autopsy studies 
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performed by Petty, Stanford and Neff (1971) and again by Steward, Hood and Block (1975)  
“suspicious” histological changes were noted for those whom had been receiving long term 
oxygen therapy. And more recently, two studies performed in 2004 (Phillips et al and 
Carpagnano et al) assessed for the presence of oxidative stress through a variety of biomarkers, 
all of which demonstrated significant increases following exposure to low concentrations of 
oxygen exposure.  
Determining the outcome of prescribed LFDO therapy can assist in evaluating the current 
structure and process at Phelps County Regional Medical Center.  
Research Questions 
The research questions guiding this study are: 
1.  Does chronic exposure to LFDO contribute to oxidative stress as evidenced by 
elevated isofuran levels within the lungs of COPD patients? 
2. Does a relationship exist between the FEV1, FEV1/FVC ratio, FEF25-75% and isofuran 
levels? 
3. Is there a correlation between length of smoking history, and length of oxygen 
exposure and concentration of oxygen to isofuran levels? 
Hypotheses 
The following hypotheses were formulated to address the research questions: 
1. Ha: Chronic exposure to LFDO will demonstrate ongoing oxidative stress in the lungs   
of COPD patients as evidenced by increased isofuran levels. 
2. Ha: A relationship between FEV1 and isofuran levels will be demonstrated in patients 
diagnosed with moderate to advanced stages of COPD using LFDO 
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3. Ha: A relationship between FEV1/FVC ratios and isofuran levels will be   
demonstrated in patients diagnosed with moderate to advanced stages of COPD using 
LFDO. 
4. Ha: A relationship between FEF25-75% and isofuran levels will be demonstrated in 
patients diagnosed with moderate to advanced stages of COPD using LFDO 
5. Ha: A positive correlation between oxygen concentration and isofuran levels will be 
demonstrated on the day of sampling in patients diagnosed with advanced stages of 
COPD using LFDO. 
6. Ha: A positive correlation between length of oxygen exposure and isofuran levels will 
be demonstrated in patients diagnosed with advanced stages of COPD using LFDO. 
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Chapter 2 - Literature Review 
 
 
 
 
Health care provision in America has claimed center stage for over a decade, with 
escalating costs with lack of insurance and access garnering the greatest attention. There are 
many contributors to the healthcare dilemma in our country; however, for the purposes of this 
paper, attention will be given to those aspects dealing with provision of prescriptive therapies of 
one of the top 5 impacting disease states, COPD.  
There is a history in medicine of implementing treatment modalities only later to learn 
that significant consequences may exist to prescribed therapies, contributing to debilitation and 
compounding costs. This phenomenon is nearly unavoidable as research limitations are many, 
but it remains the responsibility of the scientific research community to monitor implemented 
goal directed therapy.  
Many subscribe to the fallacy that more is better. We are a country of indulgence, best 
demonstrated by an overwhelming epidemic of obesity. While oxygen is absolutely critical to 
human health and survival, too much, however, can increase morbidity and mortality. While 
oxygen supplementation is necessary during periods of compromised health states, a notion that 
more is better is a consequential one. Atmospheric oxygen, approximately 21%, is enough to 
sustain all human metabolic processes. The belief that oxygen is innocuous introduces unwitting 
consequence to its recipients. Educating healthcare providers about the full potential of oxygen 
therapy is imperative.  
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Oxygen is one of the most widely, and necessarily, prescribed therapies used in this 
country. This fact obligates those responsible for its prescription to better understand its 
pathologic potential. An increased understanding of the potential of oxygen exposure may lead to 
a more rational basis for its clinical use as well as the development of therapeutic measures 
effective in preventing or diseasing the effects of oxygen toxicity. Donabedian’s structure-
process-outcome framework can be utilized to guide this research study in assessing the potential 
of low flow domiciliary oxygen therapy in the advanced stages of COPD. In order to begin, 
however, to appreciate what is abnormal we must appreciate what is considered “normal.” 
Normal Respiratory Function 
 The human respiratory system is comprised of a series of structural pathways and 
specialized tissues operated by musculature for the purpose of drawing oxygen into the body for 
delivery to tissues for the manufacturing of energy and the subsequent removal of the waste 
products of metabolism through exhalation.  The structures involved in this process include nasal 
passages (responsible for warming, humidification, and trapping of particles), trachea, bronchi, 
and bronchioles, which ultimately terminate into alveolar sacs or alveoli. Alveoli are specialized 
membranes that are enveloped in pulmonary capillary beds allowing for an intimate relationship 
of gas exchange between the pulmonary circuit and the vasculature. The inward and outward 
movement of air in the lungs is made possible by a specialized dome-shaped muscle called the 
diaphragm, intercostal muscles, as well as the inherent elastic recoil properties of the lungs and 
chest wall. 
Alveoli. Alveoli are the terminal sacs within the pulmonary circuit responsible for gas 
exchange. The alveoli are comprised of three types of specialized cells: type I and type II 
pneumocytes and alveolar macrophages. Type I pneumocytes are thin and flat and comprise 
approximately 97% of the alveolar surface. Their thin (~25mn wide), flat construction allows for 
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a decreased diffusion distance between the alveoli and the blood. Type II pneumocytes cover 
approximately 3% of the alveolar surface, account for ~15% of all parenchymal cells and have a 
variety of functions. These specialized cells contain surfactant phospholipids, surfactant A, B 
and C, lysosomes, and lysosomal enzymes. The primary function of type II pneumocytes is to 
synthesize and secrete surfactant. Surfactant is a lipid-protein mixture, which coats the inner 
walls of the alveoli preventing collapse by decreasing the surface tension. Secondary functions of 
type II pneumocytes include xenobiotic metabolism, the body’s mechanism of neutralizing 
exogenous chemicals/toxins, achieved through the cytochrome P450 system, regulation of 
transepithelial ion transport, extracellular matrix protein and growth factors production (to aid in 
repair), the release of proteinase and proteinase inhibitors (to regulate turnover of alveolar matrix 
proteins), and the expression of cytokines (to mediate inflammation). Type II pneumocytes also 
assist in the epithelial repair process by migrating to an area of denudation, proliferation and 
differentiation into a specific cell type (Aoshiba and Nagai, 2003). Lastly, alveolar macrophages 
are responsible for host defense, immunological homeostasis and tissue remodeling (Lambrecht, 
2006). 
Alveolar ventilation. Alveolar ventilation is the essential process of oxygenation, the 
delivery of oxygen to the tissues, and ventilation, the removal of carbon dioxide via exhalation. 
Normal alveolar ventilation depends on respiratory rate and tidal volume, the amount of air 
inhaled and exhaled during periods of normal breathing. For the average individual the tidal 
volume equals approximately 7ml/kg or toughly 500 ml of air. During normal inspiration the 
pressure within the lungs is slightly negative due to the contraction of the diaphragm resulting in 
air movement into the lungs. Alveoli, in the absence of disease, are fully open during inhalation. 
During exhalation the dynamics contributing to alveolar expansion are lessened and could result 
in alveolar collapse. Alveoli resist collapse during the exhalation phase as a result of the presence 
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of surfactant, a surface-active lipoprotein present at the air-water interface producing a decrease 
in surface tension. Maintaining alveolar integrity during both phases of the breathing cycle 
results in ongoing alveolar ventilation. 
Oxygen. Oxygen is an element belonging to the 16th group, or the Chalcogen group, on 
the periodic table with the atomic number 8 and an atomic weight of ~16 amu.  Oxygen is the 
most plentiful element on the earth’s surface. It is a colorless, odorless gas that comprises 
approximately 21% of earth’s atmosphere.  Twenty-one percent of atmospheric oxygen, in the 
absence of disease or periods of increased demands, fully supports human metabolic processes 
achieved through cellular respiration. The measurement of oxygen is often referred to in terms of 
atmospheres absolute, or Ata. Atmospheric oxygen is 0.21 ata at sea level. 
 Leonardo de Vinci proposed that air consisted of two different gases as it supported both 
flames and life. While several prior to 1772 had repeatedly prepared oxygen they failed to 
recognize it as an element. The discovery of oxygen was ultimately credited to Priestly in 1774, 
achieved by the heating of mercury and lead oxide; Carl Wilhelm Scheele independently 
reported this finding as well.  Like de Vinci, Priestly too recognized the deleterious properties of 
a compound that could support both life and combustion as he made this warning in a six volume 
series on the properties of air entitled Experiments and observations on different kinds of air,  
“ From the greater strength and vivacity of the flame of a candle, in this pure air, 
it may  be conjectured, that it might be peculiarly salutary to the lungs in certain 
morbid cases,  when the common air would not be sufficient to carry off the 
phlogistic putrid effluvium fast enough. But, perhaps, we may also infer from 
these experiments, that though pure dephlogisted air might be very useful as a 
medicine, it might not be so proper for us in  the usually healthy state of the body: 
for, as a candle burns out much faster in dephlogisticated than in common air, so 
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we might, as may be said, live out too fast, and the animal powers be too soon 
exhausted in this pure kind of air. A moralist, at least, may say, that the air which 
nature has provided for us is a good as we deserve” (Priestly, 1775).  
 Priestly shared his findings regarding dephlogisticated air with Antoine Lavoisier, a 
French colleague known now as the father of modern chemistry, who immediately realized the 
significance of this finding. It was Lavoisier who named dephlogisticated air “oxygen,” which 
means acid producer, and by 1786 was publicly denouncing the phlogiston theory (Acott, 1999).  
 Thomas Beddoes, an English physician, followed Lavoisier’s work and in 1794 published 
Considerations on the Medical use and on the production of Factitious Air as a result of 
collaboration with James Watt, a Scottish inventor and mechanical engineer. This is the first 
recorded publication postulating the use of oxygen as a medical therapy, which Beddoes referred 
to as “pneumatic therapy” (Stansfield and Stansfield, 1896).  Beddoes opened the Pneumatic 
Institute in 1799 primarily to treat those with various forms of consumptive disease, such as 
tuberculosis or those stricken by environmental toxins. Watts’ expertise in engineering aided 
Beddoes in developing purified “aires” for inhaled therapy. The first clinical use of oxygen was 
reported in 1868, and considered a treatment for bacterial pneumonia in 1885 (Petty, 2000).   The 
utilization of oxygen flourished from this point as a therapy.   
Cellular respiration. Lungs are the portals of oxygen entry. It is what occurs at the 
cellular level within the lungs that sustains life. Cellular respiration is the process of converting 
food, oxygen and water to usable physiologic energy. The aerobic chemical reaction C6H12O6 + 
6O2 + 6H2O → 12H2O + 6 CO2 + heat (or energy) demonstrates this point.  The energy produced 
as a result is stored in the form of adenosine triphosphate (ATP). The process occurs in three 
phases: 1) glycolysis 2) the Citric Acid Cycle and 3) oxidative phosphorylation, or electron 
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transport. The summation of energy produced during cellular respiration has a maximum yield of 
36-38 ATP molecules (Voet and Pratt, 2006). 
Glycolysis is the splitting of a six-carbon sugar into two molecules of a three-carbon 
sugar.  As a result of this process two molecules of ATP, two molecules of pyruvic acid and two 
high-energy electron-carrying molecules of NADH are produced.  In the presence of oxygen this 
is the initial step in cellular respiration. Glycolysis occurs within the cellular cytosol while the 
remaining processes occur within the mitochondria (Holt, Rinehart and Winston, 2006). 
The mitochondria are highly specialized organelles distributed throughout the cytosol of 
human cells.  A double membrane surrounds the mitochondria.  These membranes are 
phospholipid bilayers embedded with proteins. The outermost membrane is smooth and contains 
the organelle, as well as housing the many proteins that form channels through which a variety of 
molecules can move in and out as necessary.  The innermost layer is folded into cristae for 
enhancing productivity of cellular respiration through increased surface area, and contains the 5 
complexes of necessary membrane proteins: NADH dehydrogenase (Complex I), succinate 
dehydrogenase (Complex II), cytochrome c reductase (Complex III), cytochrome c oxidase 
(Complex IV) and ATP synthase (Complex V) (Holt, Rinehart and Winston, 2006).  
The citric acid cycle is initiated by the conversion of two molecules of three-carbon 
sugars to acetyl CoA, an essential coenzyme of cellular respiration.  Through a series of 
intermediate steps several high-energy storing compounds, such as nicotinamide adenine 
dinucleotide (NAD+) and flavin adenine dinucleotide (FAD+), are produced as well as two ATP 
molecules.  The FAD+ and NAD+ molecules are reduced as a result of this process to a form that 
carries the high-energy electrons to the next state, FADH and NADH respectively.  The citric 
acid cycle only occurs in the presence of oxygen; however, it does not use oxygen directly (Holt, 
Rinehart and Winston, 2006). 
  21 
The electron transport phase of cellular respiration is the stage that directly requires 
oxygen.  The electron transport “chain” is a series of electron carriers aligned within the 
mitochondrial membrane.  High-energy electrons are passed to oxygen during enzymatically 
initiated oxidative phosphorylation reactions resulting in a proton gradient and ATP production 
through the addition of a phosphate to ADP. While oxidative phosphorylation performs the life 
sustaining process of producing energy it also produces reactive oxygen species, highly bio 
reactive molecules, that contribute to senescence and disease (Kregal and Zhang, 2006). 
Cellular homeostasis. The ability of a structure to regulate its environment to maintain 
stability is referred to as homeostasis. Cellular homeostasis must be maintained to support 
organism viability. Programmed cell death, or apoptosis, is a mechanism of cellular preservation 
and, thus, homeostasis. Carl Vogt was the first to describe this phenomenon in 1842, and 
continues to evolve. Apoptosis is a multi-step, multi-pathway process that occurs in all cells of 
the human body. A lack of apoptotic activity is believed responsible for the formation of many 
types of cancers and autoimmune disorders. Apoptosis occurs through cellular signaling, either 
intracellularly or extracellularly. Extracellular signals result from the presence of toxins, 
hormones, growth factors, nitric oxide or cytokines. Intracellular signals include those induced 
by heat, radiation, nutrient deprivation, viral infection, hypoxia and increases in intracellular 
calcium concentrations and stress resulting in the binding of nuclear proteins to glucocorticoids.  
The mitochondria of the cell play a significant role in regulation of apoptosis. The mitochondria 
can achieve cellular homeostasis through the Bcl-2 family, cytochrome c, caspase and Bax 
balancing activities. The Bcl-2 family is a group of proteins that regulate outer membrane 
permeability and can either be pro-apoptotic (Bax, BAD, Bak and Bok) or anti-apoptotic (Bcl-2 
proper, Bcl-xL, and Bcl-w). Cytochrome c is a heme protein involved in apoptosis through the 
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binding of protease activating factor-1. Caspase belongs to the cysteine proteases and are 
essential in cellular apoptosis, necrosis and inflammation (Menrad et al., 2010).  
 Oxygen transport/diffusion. The exchange of oxygen and carbon dioxide between the 
lungs blood and tissues is controlled by diffusion and driven by concentration gradients.  
Dalton’s Law of Partial Pressures illustrates (Ptotal = Pgas a + Pgas b + Pgas c + etc) the total pressure 
of all gases is equal to the sum of the partial pressures of each gas. The gas diffusion principle 
supported by Fick’s Law demonstrates that a gas diffuses from an area of higher partial pressures 
to an area of lower partial pressures. Venous blood returning to the lungs has a lower partial 
pressure of oxygen than the concentration within the alveoli facilitating movement of oxygen 
from the alveoli into the blood.  Poiseuille’s Law describes the relationship between pressure, 
flow and radius of communicating structures (Δ P = r4/v). Poiseuille’s law can be applied to the 
airways to address impedance of airflow. In the diseased lung, such as emphysema where airway 
destruction results in loss of elastic recoil, resistance increases as small airways close during 
exhalation. As the radius decreases in diseased airways the pressure required to move the same 
amount of air through the small tube increase exponentially making alveolar ventilation less 
efficient. When the radii of the airways are reduced by half the resistance is increased sixteen 
times.  
 Finally, transport of oxygen is achieved through the binding of oxygen to the hemoglobin 
molecules in the blood.  The cardiovascular system is responsible for transporting the 
oxygenated hemoglobin molecules in the blood to all the tissues of the body. Alterations in 
hemoglobin and/or cardiac output can be deleterious for individuals with airway disease.  
Protective mechanisms. The respiratory system has inherent mechanisms to control for 
the many particulates and infectious agents that are introduced during inhalation. The nose serves 
as a first line defense by trapping particulates over 10 µm in diameter and approximately half of 
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all particles of 3 µm aerodynamic diameter (referring to behavior vs. actual size) (Rubin, 2011). 
The airway is lined by epithelium that produces a mucociliary blanket responsible for trapping 
and ridding the lungs of particles 2-10 µm in diameter. The cilia, finger-like projections on the 
mucosal wall, move in a direction toward the trachea to facilitate removal. Once particles reach 
the trachea they are expectorated from the lungs through the act of clearing or coughing.  
 For particles that find their way into the alveoli, alveolar macrophages (AMs) come to 
action. Metchnikoff first described the macrophage in the 1800s (Rabinovitch, 1995). 
Macrophages are one of the main mediators of the immune response exhibiting multiple 
functions, such as phagocytosis (engulfing and ingestion of foreign substances), secretion of 
cytokines and chemokines (cell signaling), tumor cytotoxicity, and certain antigen presentation 
(the capture of antigens and enabling their recognition by T-cells).  
 Macrophages are greatly distributed throughout the body and are calcium-mediated 
signaling dependent (Hoyal, et al, 1998). They can be found in the lymphoid organs, liver, lung, 
gastrointestinal tract, central nervous system, serous cavities, bone, synovium and skin (Monick 
and Hunninhake, 2002). As one of the major effector cells of the immune system, macrophages 
are found in abundance at sites where organisms interact with the environment. The immense 
surface area of the adult human lungs (140 m2) allows for a significant exposure to pathogens 
and pollutants on a perpetual basis thereby creating a large reservoir of alveolar macrophages 
(AMs) (Gwinn and Vallyathan, 2006). The macrophages found in the lungs are 
compartmentalized in airways, interstitium, and intravascular spaces derived from pulmonary 
circulating monocytes. Alveolar macrophages are quick responders to many internal and external 
stimuli, such as interferon, cytokines, viruses, viral particles, bacteria, airborne pathogens and 
particles and changes in calcium (Hoyal et al, 1998). Alveolar macrophages are derived from 
bone marrow, undergo a maturation process within the interstitium of the lungs and then enter 
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the alveolar space. Alveolar macrophages are effective in handling particles with an aerodynamic 
diameter under 2 µm. Through highly adaptive properties AMs provide protection by identifying 
offending substances and differentiating to the specific state necessary for pathogen destruction. 
Through phagocytosis, an AM engulfs a pathogen, which initiates a series of processes that 
culminate in death of the microbe. During phagocytosis, the phagocytic cell undergoes an 
increase in glucose and oxygen consumption referred to as respiratory burst, resulting in the 
production of reactive oxygen species (ROS). Three main processes commence as a result of AM 
initiation: 1) Oxygen-dependent myeloperoxidase-independent intracellular killing. During 
phagocytosis, glucose is metabolized via the pentose monophosphate shunt, resulting in the 
formation of nicotinamide adenine dinucleotide phosphate (NADPH), a coenzyme used in 
anabolic reactions. Cytochrome B from the granulocyte specific granule combines with and 
activates plasma membrane NADPH oxidase, a membrane bound enzyme complex found in the 
membranes of phagosomes used by neutrophils to engulf microorganisms. The activated 
NADPH oxidase uses oxygen to oxidize the formed NADPH with a resultant production of 
superoxide anion (O2-). A portion of the superoxide anion is converted to H2O2 plus singlet 
oxygen by superoxide dismutase. Also, superoxide anion can react with H2O2 to form a hydroxyl 
radical as well as more singlet oxygen. In combination these reactions produce the toxic oxygen 
compounds superoxide anion (O2-), H2O2, singlet oxygen (O2) and hydroxyl radicals (OH).  
Ultimately, while the formation of free radicals is toxic to microbes, when left unchecked they 
contribute to the derangement of the lipid bilayers of the lungs. 2) Oxygen-dependent 
myeloperoxidase-dependent intracellular killing. When a particle is absorbed by the phagocyte a 
vesicle is formed call a phagosome. The phagosomes bind with lysosomes, organelles containing 
digestive enzymes, within the phagocyte forming phagolysosomes. The binding of these granules 
with the phagosomes causes release of myeloperoxidase into the phagolysosomes. 
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Myeloperoxidase utilizes H2O2 and halide ions (typically Cl-) to produce highly toxic 
hypochlorite. Some hypochlorite molecules spontaneously break down to yield singlet oxygen. 
Together these reactions produce toxic hypochlorite (ClO-) and singlet oxygen (O2). 
Hypochlorites are very strong oxidizing agents. 3) Detoxification reactions. Neutrophils, first 
responder phagocytes, and macrophages are able to protect themselves by detoxifying the toxic 
oxygen intermediates that they generate. Granulocyte self-protection is achieved in reactions 
employing the dismutation of superoxide anion to hydrogen peroxide by superoxide dismutase 
and the conversion of hydrogen peroxide to water by catalase. The respiratory burst in AMs is of 
significantly greater magnitude than those in other forms of phagocytes, likely due to the life 
sustaining and important boundary between the outside world and the body they provide 
(Baldridge, 1932; Bellavite, 1988; Nauseef, 2004; Fang, 2011). All aforementioned processes 
describe the necessary and life-protecting role of reactive oxygen species.  
The susceptibility of the lungs to environmental toxins and the large surface area can 
result in an overproduction of reactive oxygen species. Antioxidants exist within the lungs to 
balance ROS activity. The most prevalent antioxidant of the lungs is glutathione. Glutathione is 
located in the epithelial lining of the lungs and in the lower respiratory tract. It has four major 
functions, 1) a major endogenous antioxidant produced by the cells participating directly in the 
neutralization of free radicals and reactive oxygen compounds, as well as maintaining exogenous 
oxidants, such as vitamins E and C in their reduced form; 2) regulation of the nitric oxide cycle 
is critical for life but can be consequential if unregulated; 3) involved in biochemical reactions, 
such as DNA synthesis, prostaglandin synthesis, amino acid transport, and enzyme activation; 
and 4) iron metabolism. 
 The protective mechanisms of the human respiratory tract described above are efficient 
and effective in defending against infection and pathology of most offending agents. There are, 
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however, many diverse organisms that prove challenging for the defenses of the human 
respiratory tract, such as adenovirus, respiratory syncytial virus, influenza, measles, pertussis and 
tuberculosis (Rubin 2011). Similarly, irritant gases derived from pollution and industrial 
accidents also challenge our respiratory defense systems. Environmental oxidants include ozone 
and nitrogen oxides, as well as sulfur dioxide. Environmental oxidants, for example, are derived 
from the suns interaction with automobile exhaust. Sulfur dioxide is produced mainly through 
the burning of fossil fuels. It is believed that the combination of these environmental conditions, 
along with cigarette smoke, contributes to pulmonary pathology. For those with existing 
pulmonary disease, such as chronic obstructive pulmonary disease, these pollutants can produce 
serious morphologic and functional effects.  
Respiratory Mechanics 
 Respiratory mechanics refer to the principles of compliance, elastance, resistance, 
impedance, flow, and work of breathing. In respiratory physiology compliance refers ability of a 
hollow organ to distend and resist recoil to its natural resting position by overcoming transmural 
pressure (Grinnan and Truwit, 2005). Compliance can be expressed by the following equation: C 
= ΔV/ΔP, where C = compliance, and ΔV is the change in volume, ΔP is the change in pressure. 
The inverse of compliance is elastance (E~1/C). During inflation airway pressure is influenced 
by volume, chest wall and lung compliance, and thoracic resistance to flow. Resistance to flow 
must be eliminated if compliance is to be measured accurately. This can be achieved by 
measuring pressure and volume during a period of no flow. As a result, compliance is 
determined by taking static measurements of the distending pressure at different lung volumes 
and can be obtained during inflation or deflation. Dynamic compliance can also be calculated. 
Compliance can be affected by chest wall and/or lung stiffness.  
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 Elastance, or elastic recoil, refers to the lungs ability, or the ease, to snap back after the 
stretch of inhalation. During expiration the diaphragm relaxes allowing the lungs to recoil and 
regain the interpleural pressure experienced at rest. The phenomenon occurs due to the elastic 
fibers in the connective tissue of the lungs in conjunction with the surface tension in the alveoli 
provided by surfactant (Sherwood, 2007).  
 Resistance refers to opposition within the respiratory circuit to the inward and/or outward 
flow of air. Resistance can be expressed by the following equation Raw = ΔP/V, where  
ΔP = Patm – PA, so that Raw = Patm – PA/V (Patm = atmospheric pressure, PA = Alveolar pressure 
and V= Volumetric airflow). Determinants of airway resistance, then, are airway diameter and 
whether flow is turbulent or laminar (Kirkby et al., 2010).  
 Flow (Q) is simply the movement of air. Flow is dependent on a pressure gradient (ΔP) 
and is inversely related to resistance of flow (R). This relationship is described by the following 
equation: Q = ΔP/R. Two types of flow exist within the respiratory circuit: laminar flow and 
turbulent flow. The more distal the airway the more laminar the flow becomes. Flow is 
influenced by the rate of flow (V), the airway radius (r), the density of gas (p), and the viscosity 
of gas (η), while factors, such as length of airways and gas density remain essentially constant. In 
the airways governed by laminar flow, resistance is related to the radius (r), airway length (l), 
and gas viscosity (η) through Poiseuille’s Law (R=8ηl/nr4). Poiseuille’s law demonstrates the 
strong relationship of the radius on resistance, showing that the doubling of the radius decreases 
the resistance by 16-fold (Bock, et al, 2000).  
 Impedance refers to the resistance of airflow as well the energy required to overcome the 
elasticity of the lungs and chest wall. Impedance is most accurately assessed through the 
measurements of the work of breathing (WOB). Work is defined as the product of pressure and 
volume (W = P x V).  Since exhalation is generally a passive process WOB is most often 
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referring to inhalation. However, diseases processes, such as COPD, that exhibit prolonged 
expiratory phase, can significantly increase WOB. As WOB increases metabolic demands, 
increased stress is placed on respiratory muscles, which in turn requires increases in cardiac 
output. Increases in cardiac output can result in ischemia for those with concomitant cardiac 
disease. The goal of mechanical ventilation for those in acute respiratory distress is to support the 
vital organs while reducing the WOB. Once the acute phase of distress is resolved ventilatory 
support can be weaned until extubation is possible (Grinnan and Truwit, 2005). 
Spirometry. The ability to quantify the aforementioned respiratory mechanics of 
compliance, resistance, elastance, flow and impedance is particularly useful in detecting, 
diagnosing and managing respiratory health and disease states. Quantification occurs through the 
use of spirometric measurements. Exposing a potential relationship between spirometric 
measurements and the presence of deleterious processes, such as oxidative stress, could hold 
merit in early detection and management.  
Spirometry, or the measuring of breathing, enables us to assess functional changes within 
the respiratory circuit and provide meaning to their numeric value. Spirometry is a tool used to 
measure various lung volumes, capacities, flow rates, patterns and gas exchange. Collectively 
theses measurements taken for the purpose of assessment are referred to as pulmonary function 
tests (PFT). John Hutchinson is credited with the invention of the spirometer in 1846 (Petty, 
2002). This early device could only measure vital capacity, the volume of air exhaled after 
maximal inhalation. The evolution of the spirometer has resulted in the ability to measure nearly 
every aspect of lung function making this device elemental in the diagnosing and management of 
COPD and a host of other respiratory ills. It would not be until the 1950’s that spirometric 
measurements would be given their due when Barach and Bickerman (1956) edited a 
comprehensive text, Pulmonary Emphysema, in which Dayman recognized and described flow 
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volume patterns indicative of expiratory airway collapse consistent with emphysema. In 1956, 
Hinshaw and Garland would demonstrate a 13.5-liter recording spirometer, showing lung 
capacity spirograms that demonstrated the airflow limitations seen with emphysema. The 
sophistication of spirometric assessment grew from then and continues today. 
Each phase of the respiratory cycle has a corresponding volume or capacity, and flow rate 
specific to that given phase. Once adjustments are made for age, gender, height, weight and 
ethnicity particular changes in volumes, capacities and/or flow patterns can be predictive of 
pathology. Pulmonary diagnoses can be made when obtained values are compared to a “normal” 
value. Normal spirometric values vary, depending on environment, culture, gender and physical 
stature. In order to achieve an accurate assessment of an individual, obtained results  
needs to be compared to a subset of healthy patients with the same/similar demographics. It 
should be emphasized that effort is critical when obtaining values for the “normal” and afflicted. 
All individuals obtaining PFTs should be instructed on the importance of maximum respiratory 
effort and cooperation to ensure accuracy of test results. Tests are often repeated in triplicate to 
control for this phenomenon. For those individuals afflicted with COPD respiratory effort is an 
issue due to the debilitating effects of the disease, including muscle wasting and cachexia. 
Results obtained are compared to the normal volumes, capacities and flow rates of a similar 
population (age, gender, height, weight, ethnicity) and given percent of predicted values. Based 
on the aforementioned demographics a “normal” PFT value is assigned. Once a value is obtained 
it is compared to the “normal” PFT value for that individual. Pulmonary function values nearest 
100% are considered most normal. Generally any value less than 80% of “predicted” normal for 
said characteristic can be indicative of underlying disease.  
The past several decades has brought with it research to determine “normal values” for 
lung volumes, capacities and flow rates as it relates to specific demographics, and has greatly 
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facilitated interpretation of the results for accurate diagnosing. The relevant variables in this 
process are age, gender, body height and habitus, and ethnicity. As it relates to age: as a person 
ages the natural elasticity of the lung decreases, translating into smaller lung volumes and 
capacities. Also, aging causes decalcification of the skeletal structure resulting in centimeter 
changes in the thoracic size and subsequent lung size.  In the healthy adult, this does not 
necessarily impede daily function; however, for those with respiratory disease, this phenomenon 
can be a confounding cofactor. As it relates to gender: typically the lung volumes and capacities 
of males exceed those of females even when matched for height and weight. As it relates to body 
height and habitus: size has a significant impact on lung volumes and capacities, as such 
predictive values have been developed to account for those sizes outside the range of ideal body 
weight for given height. Obesity, generally defined as a body mass index (BMI) of > 30 kg/m2, 
can often appear during pulmonary function testing as a restrictive disorder due to the physical 
impediment placed on the chest wall by the chest and abdominal weight. Standing height is 
considered the most important predictor of lung function and is related, to some degree, to the 
other demographics that influence forced vital capacity (FVC) values (the forced exhalation 
following maximal inhalation), such as weight, presence of disease, scarring, etc. (Cotes, 1993). 
Diseases that affect stature, such as kyphosis, scoliosis, osteoporosis, congestive heart failure, 
tuberculosis, etc., will predictably decrease lung capacities. Age also has a confounding 
influence on the FVC as aging often results in further loss of muscle mass resulting in the 
displacement of the diaphragm cephalad causing concomitant decreases in lung volumes and 
capacities. As it relates to ethnicity: different ethnic origins have inherent differences in lung 
volumes and capacities, as such spirometric software has been adjusted to address the related 
differences.  These differences appear to be primarily a result of stature and metabolic indices 
specific to a given culture.  
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 Pulmonary function testing can be used for the screening of obstructive or restrictive lung 
disease states, documenting obstructive or restrictive lung disease progression, evaluating 
therapeutic effectiveness, as a tool for weaning mechanical ventilation, as well as evaluating 
patients prior to surgery, especially if patients are > 60 years old, have known pulmonary 
disease, are obese, have a history of smoking, cough or wheezing, been exposed to prolonged 
surgical times or are undergoing abdominal or thoracic surgeries.  
(http://www2.nau.edu/~daa/lecture/pft.htm).  
 The ability to quantify spirometric measurements aids in assessing lung function. 
Spirometric measurements are obtained with a relatively simple apparatus by which a patient 
inhales and exhales into a mouthpiece.  The force of these two efforts is measured by a 
differential pressure transducer, converting the volume and rate of breathing over a specified 
amount of time into a quantitative value. Parameters, such as rate of breathing and ventilation, 
vital capacity (the maximum amount of air exhaled after maximum inhalation), tidal volume (the 
amount of air exchanged during normal breathing), and variations of expiratory volumes (FEV), 
vital capacity from a maximally forced expiratory effort (FVC), peak expiratory flow rates 
(PEFR), forced expiratory flow rates (FEF), and maximal voluntary ventilation (MVV), and 
many others, can be determined.  As these values are plotted on a graph inferences can be made 
regarding pulmonary functionality. 
The forced expired volume in 1 second (FEV1), FVC, and their ratio to each other 
(FEV1/FVC) are often initially evaluated to assess lung function. The FEV1 is the volume of air 
that can be forcibly exhaled in one second after maximal inhalation and is valuable in assessing 
for obstructive disease. Average values for FEV1 in healthy people depend mainly on gender and 
age. Results between 80% and 120% of the average predicted value or ~ 75-80% of their vital 
capacity (volume of air following maximal inhalation) are considered normal. If the FEV1 value 
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is low (<80%) compared to FEV1% predicted in the normal population in the presence of 
maximal effort obstructive disease is highly suggested. The diagnosis of restrictive vs obstructive 
disease is further refined when expressed in terms of a proportion to the FVC. A low FEV1 
(<75%) in conjunction with a low FEV1/FVC ratio of (70%) is indicative of obstructive disease. 
The FEV1 for the patient with restrictive disease will be lower as well but proportional to the 
FVC and, therefore, if both the FEV1 and the FEV1/FVC ratio is 85% or greater of predicted 
normal, a diagnosis of restrictive disease is highly suggested. 
Spirometric results consistent with obstructive disease, such as chronic bronchitis and 
emphysema, include changes in the FVC. The forced vital capacity is the amount of air that can 
be maximally and forcibly expelled from the lungs after maximal inhalation. For the patient with 
obstructive disease expired volumes will be less than normal and require longer amounts of time 
to achieve. Spirometric results consistent with restrictive disease, or emphysema, include 
changes in the FVC as well; however, the resultant decrease in expired volume is due to a 
reduced ability to maximally inhale normal volume due to the mechanical limitations as a result 
of the loss of alveolar elastic wall integrity inherent with the disease. Since both chronic 
bronchitis and emphysema result in smaller FVC volumes FVC is not a stand-alone diagnostic 
indicator of either disease. Concern does not typically occur until the FVC result in 80-85% of 
the predicted normal values. Delineations can occur with a post-bronchodilator FVC 
measurement. Improvements in the FVC following a bronchodilator suggest obstructive disease, 
while no change suggests restrictive disease.  
Detection of pulmonary changes consistent with COPD can be made with spirometry 
before debilitating stages develop.  According to the National Lung Health Education Program, 
all persons aged 45 or older who currently smoke, or even those who have quit smoking, should 
have spirometric testing (Ferguson et al., 2000).  Additionally, those individuals who present 
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with symptoms of a chronic cough, sputum production, wheezing or dyspnea that is inconsistent 
with the activity being performed should undergo spirometric testing (Ferguson, et al., 2000; Celi 
and MacNee, 2004). 
COPD 
Chronic obstructive pulmonary disease (COPD) is a progressive disorder resulting in 
irreversible lung tissue changes.  Approximately 14 million Americans have COPD and an 
estimated 40 million cases are believed to be undiagnosed (CDC, 2008).  COPD is currently the 
fourth leading cause of death and projected to be the 3rd leading cause of death by 2020 (Doherty 
et al., 2007).  COPD kills approximately 120,000 Americans annually (Mannino et al., 2002). 
Normal tidal breathing for the average adult occurs approximately 17,000 times per day. 
Depending upon the stage of the disease the effort to take those 17,000 breaths increases, 
resulting in fatigue, anxiety and general discomfort. As the disease progresses microscopic 
changes occur to the multiple organ systems within the body. Identifying a method to detect the 
early presence of COPD to thwart its progression is ideal; an effort that would improve quality of 
life and lessen the economic burden on the afflicted individual, their family and the healthcare 
system. 
Descriptions of COPD can be traced back to 1679 in Bonet’s description of the 
“voluminous” lungs (Bonet, 1679). In 1769 Morgagni described 19 cases in which the lungs 
were “turgid” or dull with air. Baille, an early pathologist, utilized the investigation of post 
mortem human tissue to better understand the pathology that may have claimed lives. In his 1795 
manuscript, The morbid anatomy of some of the most important parts of the human body, Baille 
described the morbid appearance of each organ and correlated autopsy reports with case 
histories. Included in this compilation is the first documented observed physical description of 
the emphysematous lung.  
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Badham first offered clinical understanding of COPD in 1814 when he used the word 
“catarrh” to refer to the classic symptoms of COPD, cough and hyper secretion of mucus. He 
noted this condition to be disabling. Laennec (1821), a clinician, pathologist and inventor, 
eloquently describes emphysema in his Treatise of diseases of the chest, noting that 
emphysematous lungs were hyper inflated. Laennec dissected patients he followed during the 
course of their illness. Part of his assessment was the utilization of a stethoscope, his own 
invention. He described his auscultative assessments in A treatise on the disease of chest and on 
mediate auscultation and provided this anecdote,  
“The disease which I designate by this title is very little known and has not 
 hitherto been  correctly described by any author. I for a long time thought it 
 very uncommon, because I had observed only a few cases of it: but since I 
 have made use of the stethoscope, I have verified its existence as well on 
 the living as the dead subject, and am led to consider it as by no means 
 infrequent. I consider many cases of asthma, usually deemed nervous, as 
 depending on this cause. The chief reason of this affection having been so 
 completely overlooked is, that it is in some sort of merely the exaggeration  
of the natural condition of the viscous.” 
Laennec also reported that upon autopsy it was not unusual to find that the lungs did not 
collapse for those with symptomatic disease but rather filled up the chest cavity completely on 
either side of the heart. Further inspection would show that the lungs were full of air while the 
bronchus was filled with mucus. This description appears to describe both bronchitis and 
emphysema.  
The 1950’s ushered in significant contributions to the understanding of COPD and its 
effects on related organs. Dickerson Richards, Nobel Laureate, described the relationship 
  35 
between a diseased pulmonary circuit leading and right sided heart failure, or cor pulmonale; 
Cherniack described the diseases effect on the acid-base system; Menelee and Callaway 
described pulmonary function test results as it related to the emphsymic patient (Petty, 2006).  
In an effort to develop a comprehensive and accurate definition of the disease two 
historical meetings took place: The CIBA Guest symposium in 1959 and the American Thoracic 
Society Committee on Diagnostic Standards in 1962. The definition provided by the American 
Thoracic Society (ATS) is the most widely accepted definition and states, “a diagnosis of chronic 
bronchitis can be made with the presence of a chronic cough lasting at least three months for at 
least two years; and that the diagnosis of emphysema can be made when evidence of enlarged 
alveolar spaces and loss of alveolar walls is made.”  
These ambiguous definitions prompted continued research in order to better understand 
optimal recognition, diagnosis and management. In 1998 a group of committed scientists 
encouraged the US National Heart, Lung and Blood Institute and the World Health Organization 
to come together to combat COPD. This group is now formally recognized as the Global 
Initiative for Obstructive Lung Disease, or GOLD. 
Global initiative for obstructive lung disease: GOLD. The Global Initiative for 
Obstructive Lung Disease (GOLD), a group of dedicated health care providers, continually work 
with healthcare professionals and public health officials to raise COPD awareness and to assist in 
improving treatment of the disease worldwide. 
The first task undertaken by GOLD was to prepare a consensus report, Global Strategy 
for the Diagnosis, Management and Prevention of COPD, published in 2001. Revisions are 
continually made to reflect ongoing research (GOLD 2006).  
With the goal to provide an individual with the appropriate management therapy, GOLD 
developed a classification of COPD by dividing it into 4 stages: mild, moderate, severe and very 
  36 
severe. Certain normal values have been assigned as it relates to age, gender, height, weight and 
ethnicity. The ratio is used to diagnose obstructive and restrictive disease. Table 1 defines the 
stages in terms of pulmonary function test results. 
Table 1  
Stages of COPD 
Stage I Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal 
Stage II Moderate COPD FEV1/FVC<0.70 FEV1 50-79% 
normal 
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% 
normal 
Stage IV Very Severe COPD FEV1/FVC<0.70 FEV1 <30% 
normal, or <50% 
normal with 
chronic respiratory 
failure present 
 
Stages of COPD. In an effort to accurately assess and appreciate an individual’s stage on 
the COPD spectrum a series of stages are defined. During Stage I of COPD there may be only 
mild airflow obstruction with no awareness of functional decline. Parenchymal, or lung tissue, 
changes are typically insidious leaving patients unaware that lung damage is occurring. 
Treatment is rarely sought during this stage. Airflow worsens during Stage II as parenchymal 
damage worsens and symptoms become increasingly detectable, particularly shortness of breath 
upon exertion and cough with sputum production. It is typically during this stage that patients 
become aware of the presence of the disease. Upon entering Stage III, or the severe phase of the 
disease, the patient experiences airflow obstruction that significantly worsens, shortness of 
breath occurs with less and less exertion, and COPD exacerbations becoming more frequent.  It 
is during this stage that people begin to battle constant fatigue.  Stage IV may lead to chronic 
respiratory failure, the inability of the lungs to effectively oxygenate and/or ventilate, cor 
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pulmonale and death (Leader 2011). To better understand the stages of COPD it is necessary to 
understand the physics of the pulmonary circuit and the concomitant changes.  
In a review performed by Tuder, et al (2006) a literature search ranging from 1949 to 
2005 revealed that 40,309 papers were published on COPD, in which 1637 involved the worked 
“inflammation” and 187 involved “protease” or “matrix.” Forty-six papers directly addressed 
inflammation and protease imbalance. It is important to consider these factors when formulating 
an understanding about the pathology that results in emphysema and chronic bronchitis. 
When considering the mechanics of airflow the pulmonary circuit is inherently affected 
by tubular diameter and pressure changes, two variables directly impacted by inflammation and 
matrix changes within the pulmonary infrastructure. As a result reduced airway diameters 
produce increases in resistance, whereas loss of elastic recoil results in diminished pressure on 
exhalation.  Airway narrowing occurs in chronic bronchitis or asthma, whereas emphysema 
exhibits a loss of elastic recoil, resulting in decreased alveolar ventilation and air trapping.   
Emphysema. Emphysema is characterized by the loss of alveolar wall integrity resulting 
in increases in work of breathing in response to increases in compliance and increases in airway 
resistance. Airway mutagens, such as cigarette smoke or environmental pollutants incite 
apoptosis, oxidative stress and a protease/antiprotease imbalance resulting in a breakdown in 
alveolar infrastructure (Tuder, et al., 2006). Progressive deterioration of wall integrity ultimately 
manifests as loss of elastic recoil. Many alveolar sacs will merge into large singular bleb-like 
sacs and will lose their pulmonary capillary architecture. The subsequent inability of alveolar 
recoil results in outflow obstruction; air becomes trapped in the alveoli resulting in poor gas 
exchange (Petty, 2006). Stagnation of air movement means decreased oxygen supply and 
retention of carbon dioxide. Low oxygen states within the body are compensated by increasing 
hemoglobin concentrations and through hyperventilation.  
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As more and more alveoli break down hyperventilation is no longer an effective 
compensatory mechanism and worsening hypoxia ensues. Hypoxic vasoconstriction, the 
rerouting of blood to functional alveoli, occurs as the body’s last resort to restore equilibrium.  
Chronic hypoxic vasoconstriction can result in pulmonary hypertension, or high blood pressure, 
within the pulmonary vascular circuitry.  A significant consequence of pulmonary hypertension 
is right-sided heart failure, or cor pulmonale.  The right ventricle must overcome the increased 
pulmonary pressure to maintain perfusion pressure. In an already hypoxic environment, the heart 
is vulnerable to increased metabolic demands. The accessory musculature of the respiratory 
system experience increased oxygen demands as a result of increased work of breathing to 
compensate, placing even greater strain on the heart and lungs. 
While there are some genetic predispositions associated with emphysema, such as alpha-
1 antitrypsin disorder, it is most directly linked to smoking.  Most individuals diagnosed with 
emphysema are over 60 years old and present with a long history of smoking, exertional dyspnea 
with use of accessory muscles, tachypnea with a prolonged expiratory phase, minimal 
nonproductive cough, and weight loss and cachexia. Cachexia presents a vicious cycle as the 
malnourishment contributes to ongoing weakness that in turn contributes to ongoing anorexia. 
Those individuals who suffer from advanced stages of the disease may require low flow 
domiciliary oxygen therapy (LFDO) therapy to assist in ameliorating symptoms demonstrating 
the properties of Dalton’s Law of partial pressure, supporting diffusion through an increase in the 
partial pressure of oxygen, and Poiseuille’s Law of increased rates of flow by air being forcibly 
delivered into the nasal passages and down the airways. 
Chronic bronchitis. Chronic bronchitis is characterized by inflammation of the bronchi 
resulting in a copious production of thick mucus, hypertrophy of mucous glands and recurrent 
respiratory infections. The mucus produced in this disorder, as well as the chronically inflamed 
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bronchioles, creates a physical obstruction to airflow as well as a constant predisposition to 
pulmonary infections.  Patients who are diagnosed with chronic bronchitis have exhibited 
symptoms for greater than three months in a year for two consecutive years in a row.  Cough and 
sputum production are initially more severe in the winter; however, as the disease progresses, the 
productive cough remains present. The chronic obstruction to airflow produced by COPD states 
predisposes these patients to low oxygen blood states, or hypoxia, as well as high carbon dioxide 
blood states, or hypercarbia (Chiang et al., 2002).    
Chronic hypercarbia places the COPD patient at risk of cardiovascular and central 
nervous system compromise (Petty 2006).  Blood CO2 levels are responsible for communicating 
with the respiratory center in the brain to determine rate and depth of breathing.  When CO2 
levels are chronically elevated respiratory center receptors become desensitized, thus, 
dependence on oxygen levels for respiratory stimulation ensues.  Although hypercarbia is a 
compensatory mechanism to manage respiratory stimulation, elevated levels of CO2 can produce 
anxiety, irritability, confusion, stupor, coma, hypertension, hypotension, dysrhythmias and death 
(Petty, 2006).  
Patients in advanced stages of chronic bronchitis are vulnerable to opportunistic 
infections. Low oxygen states, the presence of mucous and compromised respiratory immune 
systems puts this patient population at a particular risk for bacterial infections, particularly 
Hemophilus influenza and S. pneumonia (Murphy, 2000). Chronic hypoxemia predisposes the 
COPD patient to a wide range of complications including metabolic and electrolyte disturbances, 
erythrocytosis or polycythemia and, perhaps the most detrimental, pulmonary hypertension and 
right sided heart failure, or cor pulmonale (Chaouat, 2008). The development of cor pulmonale is 
often accompanied with cyanosis and edema giving the afflicted patient a blue and swollen 
appearance, oftentimes referred to as the “blue bloater.” Many patients in the advanced stages of 
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the disease are placed on LFDO in an effort to provide them with needed support to maintain 
independence and functionality.  Oxygenation is impaired in this patient population.  Optimizing 
oxygenation through LFDO via a nasal cannula has significantly improved symptomatology and 
activities of daily living (ADL’s). Patients with advanced COPD often become easily fatigued 
and short of breath.  Domiciliary oxygen therapy can boost energy levels and lessen labored 
breathing by increasing oxygen concentration in the lungs and blood (Croxton et al., 2006; 
Sandland, 2008).  
Hypoxia. Hypoxia is the state of insufficient oxygen delivery necessary to support 
cellular respiration, and cannot be long tolerated. Mechanisms of hypoxia/hypoxemia include 
hypoventilation, low inspired oxygen, anemia, right to left shunt, and perfusion/ventilation 
mismatching (V/Q mismatch) (Osborne, 2000). There are several causes for hypoventilation: 
drugs that depress the CNS, such as narcotics, anxiolytics and sleep aids, trauma to the 
brainstem, abnormal spinal cord pathways, and brain stem motor neuron disease, such as 
amyotrophic lateral sclerosis (ALS) (Phukan, et al., 2007); diseases affecting the respiratory 
muscles, such as Guillain-Barre’ syndrome; diseases of the neuromuscular junction, such as 
Myasthenia Gravis; abnormalities of the chest wall, such as scoliosis (Laghi and Tobin, 2003); 
and upper airway obstruction, such as epiglottitis. Low inspired oxygen can be a result of altitude 
changes or medical mismanagement for a dependent patient. A right to left shunt refers to 
phenomena where a “rerouting” of blood results in reduced oxygenation of the blood. This 
phenomenon can occur through an anatomic shunt, such as a coronary sinus, where 
unoxygenated blood drains into the left heart and mixes with saturated blood. A physiologic 
shunt refers to disease states by which blood cannot come into communication with gases within 
the alveoli due to filling of the alveolar spaces as seen with pulmonary edema, pneumonia, etc. 
Ventilation/perfusion (V/Q mismatch) refers to the disparity between alveoli that are well 
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ventilated but poorly perfused, or poorly ventilated and well perfused. This phenomenon can 
occur from something as benign as positioning to the presence of atelectasis. Diffusion 
impairment refers to interruptions in the rate of diffusion of the gases across the alveolar 
membrane. This phenomenon can occur with a variety of interstitial lung diseases. Anemia 
results in hypoxemia due to the absence of sufficient oxygen carrying capacity in the form of 
hemoglobin. Anemia is prevalent in such processes as kidney disease, uterine fibroid disease and 
trauma. 
Compensatory mechanisms. In the presence of acute low oxygen states, or cellular 
hypoxia, a series of mitochondrial protective mechanisms will occur to maintain cellular 
homeostasis. Likely considered the most important rate-limiting step in mitochondrial oxygen 
consumption is the decrease in cytochrome c oxidase activity. Cytochrome c oxidase is 
responsible for converting molecular oxygen into two molecules of water. The mitochondria, the 
site responsible for initiating biochemical processes that determine cell survival or death, will 
maintain ATP production temporarily via anaerobic glycolysis.   The untoward effects of the 
decreased cytochrome c oxidase activity and anaerobic glycolysis is a backlog of protons at all 
the redox points along the electron transport chain and the production of pyruvate respectively, 
both of which will ultimately result in the build up of cellular acids and eminent cell death 
(Galkin et al., 2009, Wheaton and Chandel, 2011). 
In the acute phase of hypoxia the release of cytochrome c oxidase allows for the 
adaptation to altered oxygen concentrations through the inhibition of proton transportation, thus 
decreasing the membrane potential. The decrease in ATP production and a hyper permeable state 
of the inner mitochondria is a result of the release calcium and cytochrome c through the Bcl-2-
associated X (BAX) system, a process that can also lead to caspase activation and programmed 
cellular death (apoptosis). 
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The maladaptive response of cytochrome c initiated cell death in the presence of 
prolonged hypoxia converts to an adaptive process over time by the inhibition of BAX and the 
generation of nitric oxide. Nitric oxide binds to a reduced form of cytochrome a3 in the 
mitochondria, the same binding site of oxygen, resulting in inhibited cytochrome c activity and 
thus reducing oxygen consumption. Furthermore, the presence of nitric oxide changes the 
membrane potential due to the increased production of reactive oxygen species (ROS). Oxygen 
free radicals, through superoxide dismutase (SOD), are converted to H2O2, which exerts a 
protective influence on cellular enzymes, such as the kinase of monophosphate adenine (AMPK) 
resulting in cellular energy homeostasis. (Mungai, 2011). 
In the presence of chronic low oxygen states cells will continue to adapt through oxygen- 
dependent enzymes: the hypoxia inducible factor (HIF)-prolyl and asparaginyl hydroxylases, 
prolyl hydroxylases domain (PHDs), and factor inhibiting HIF (FIF). The result of chronic 
hypoxia is a “pooling” of PHDs and an over activation of the three PHD isoforms (HIF1α, 
HIF2α and HIF3α), mediated by an increase in intracellular oxygen availability (Ginouves, 
2008). The desensitization of HIFα triggers a negative feedback mechanism that results in 
cellular protection against cell death. 
Cigarette smoking. Tobacco use is the leading preventable cause of death globally, 
claiming 5 millions deaths annually and a projected 8 million annually by 2030 (WHO, 2011). A 
reported 480,000 people die annually in the U.S, with 41,000 of those from exposure to second 
hand smoke (US Dept of Health & Human Resources 2013 Report). Cigarette smoke has been 
implicated as the single most significant contributor to the development of COPD. Cigarette 
smoke induces two particular processes within the lung tissue that contribute to structural 
changes associated with COPD: inflammatory responses and oxidative stress. It is, therefore,	
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important to consider the implications and role smoking in the development of COPD in order to 
better develop appropriate strategies of prevention, treatment, and cure.  
In a study by Fletcher and Peto (1977) it was projected that 15-20% of those who smoke 
would be vulnerable to the long-term deleterious effects of smoking and would subsequently 
develop airflow limitations. The GOLD 2005 Report from the NHLBI/WHO workshop reported 
that cigarette smoke-induced airway inflammation is considered to be an important variable in 
the pathogenic process of COPD.  
When toxicants, such as cigarette smoke, are breathed into the lungs, particles are trapped 
in the alveoli and initiate an inflammatory cascade that includes the activation of neutrophils. 
Neutrophils contain serine elastase and other proteases that serve to catabolize proteins resulting 
in the breakdown of the alveolar infrastructure. Neutrophils also contribute to the development of 
reactive oxygen species (ROS), otherwise known as free radicals. Reactive oxygen species 
overwhelm lung antioxidant defenses, a situation confounded by cigarette smoke induced 
decreases in glutathione, the lungs antioxidant defense, and oxidative stress ensues.  
 Cigarette smoke has been linked to alterations in glutathione (GSH), an intra and 
extracellular antioxidant present in the lungs (Rahman and MacNee, 1999). Disabling the body’s 
inherent protective antioxidant defenses invites unchecked oxidative reactions, especially in the 
presence of increased ROS. Ultimately, this imbalance results in lung parenchymal damage 
causing irreversible alterations in the lipid bilayers induced by oxidative stress. 
Cigarette smoke contains ROS with considerable oxidative power, which serves as direct 
toxins as well as precursors to other toxins. The primary free radicals, or ROS, in cigarette 
smoke are superoxide (O2-), hydroxyl radical (OH), and hydrogen peroxide (H2O2) (Pryor, 
1997). Smoking also interferes with α1-antitrypsin activity, a protease inhibitor, by oxidizing 
MET358 and MET 351 residues to methionine sulfoxide (Johnson and Travis, 1979) interrupting 
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the check and balance system for elastase activity within the lungs (Janoff et al., 1979; Hill et al., 
2000; Sullivan et al., 2005). The combination of increases in elastase activity introduced by 
neutrophils, ROS generation compounded with the decreased ability of α1-antitrypsin activity to 
control for of these processes can lead to extensive wall destruction.  
According to a study by Tuder, et al (2006) cigarette smoke houses over 5000 offending 
chemicals. They purport that each puff of cigarette smoke contains ~ 1015 free radicals in the gas 
phase and 1018 free radicals per gram of tar, and includes potent oxidants such as hydrogen 
peroxide, hydroxyl anion, and organic radicals. Chronic exposure to these deleterious toxicants 
result in the disruption of the normal functions of the pneumocyte type I and II cells leading to 
increases in epithelial permeability, decreases in surfactant production, and inappropriate 
generation of cytokines leading to the initiation of chronic inflammation (Aoshiba and Nagai, 
2003). Nitrogen oxide and superoxide radicals are short-lived oxygen free radicals that readily 
react to form peroxynitrites. Peroxynitrites are anions with a chemical formula of OONO- that 
are oxidizing agents, making it a threat to surrounding cells including DNA and other proteins as 
they trigger cellular responses ranging from cell signaling to oxidative injury, inducing cellular 
necrosis and apoptosis. Peroxynitrite generation has been implicated in such disease processes as 
stroke, myocardial infarction, chronic heart failure, diabetes, circulatory shock, chronic 
inflammatory diseases, cancer, and neurodegenerative disorders (Pacher, Beckman and Liaudet, 
2007). 
Cigarette smoke contains two different forms of free radicals, one in the tar phase and 
one in the gas phase. The tar phase contains the long-lived hydroquinones that undergo a redox-
cycle to form superoxide radicals and hydrogen peroxides via semiquinones. Semiquinones are 
highly reactive free radicals formed by the removal of one hydrogen atom with its electron 
during the process of dehydrogenation of a hydroquinone to quinone. This phenomenon results 
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in persistent oxidative stress. (Pryor and Stone 1993; Cross et al., 1997; Nakayama 1989)  The 
gas phase of cigarette smoke contains small oxygen and carbon-centered radicals that are more 
reactive than those in the tar phase. It is thought that these free radicals contribute to the 
inactivation of α1-antitrypsin proteinase inhibitor (Church and Pryor, 1985). 
It has been reported that 85-90% of those diagnosed with chronic bronchitis or 
emphysema are smokers, occurring in less than 5% of nonsmokers, and that moderate to severe 
emphysema is rare in nonsmokers (ALA COPD Fact Sheet, 2011). According to the CDC, 
smoking is the most important preventable cause of death in the United States and is responsible 
for over 480,000 deaths each year, with 41,000 of those deaths related to second-hand smoke. 
Long-term cigarette smoking is a key contributor to heart disease, peripheral vascular disease, 
diabetes, chronic lung disease and strokes, as well as a variety of cancers. Significant focus 
should be represented in the structure and process of healthcare delivery systems in order to 
affect the best possible outcomes with regard to reducing smoking and its wide array of 
implications. 
COPD treatment. Diseased lungs impact the overall human experience. As such a 
multimodal treatment regimen is employed. The treatment and management of COPD aims to 1) 
improve pulmonary function; 2) decrease symptoms; 3) improve exercise tolerance; 4) decrease 
exacerbations; and, 5) reduce mortality (WHO, 2013). Simultaneous approaches often optimize 
the health state of those afflicted to achieve these goals. Depending on where the individual falls 
on the spectrum of the disease dictates how much quality is added back to their life with 
management of their disease (Scuirba, 2008). 
The global initiative for chronic obstructive lung disease (GOLD) guidelines recommend 
a staged approach to the management of COPD; however, the American Thoracic Society (ATS) 
and European Respiratory Society (ERS) suggest the continuum of symptoms and FEV1 should 
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dictate treatment regimens. All agree, however, that smoking cessation is first and foremost to 
any level of recovery.  
Smoking cessation is critical in significantly slowing the progression of the disease and 
exercise improves overall functionality of respiratory mechanics and oxygen delivery (Shea and 
Martinez, 2009).  Smoking cessation is the only disease modifying therapy for management of 
mild to moderate COPD (Ind, 2005). It has been demonstrated that smoking cessation slows the 
accelerated decline of the FEV1 (Fletcher and Peto, 1977; Simmons et al., 2005).  According to 
the Lung Health Study the rate of decline in FEV1 was reduced by ~50% of those who 
permanently quit smoking (Anthonisen et al., 1994). Kanner et al., (2001) reported that those 
with COPD who quit smoking experienced fewer exacerbations of their illness.  
 Respiratory infections are always a significant threat to those with COPD. Those with 
chronic bronchitis are particularly vulnerable due to the persistent presence of inflammatory 
mucus exudates. As a result microbial pathogens harbor in the lower respiratory tract, disrupt 
ciliary function, trigger enhanced mucus secretion, and further damage the epithelium (Sethi, 
2000). Recent research suggests the addition of daily antibiotics can significantly reduce the 
incidence of acute microbial induced exacerbations and improve the quality of life for COPD 
sufferers. The New England Journal of Medicine (2011) published the results of a randomized 
clinical trial including 1577 participants, 570 received azithromycin and 572 received a placebo 
for 1 year. The treatment group reported a significant (P<0.01) reduction in acute exacerbations. 
A small portion of the participants reported small decrements of hearing loss with azithromycin 
prophylaxis. 
 Once the disease has progressed to advanced stages, acute exacerbations of symptoms are 
often managed with supplemental oxygen; inhaled beta agonists, long acting beta agonists 
(LABA) and anticholinergics to aid in bronchodilation; corticosteroids to reduce inflammation; 
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and antibiotics to treat infections (Hunter and King, 2001). Approximately one half of patients 
diagnosed with COPD have high concentrations of bacteria in their lower airways (Rave, et al., 
2007; Sethi, et al., 2002). The most frequently offending bacteria include Streptococcus 
pneumonia, Hemophilus influenza, Moraxella catarrhalis, Mycoplasma pneumonia, as well as a 
variety of viruses (Rave, et al., 2007; Sethi, et al., 2002). It has been suggested that the use of 
antibiotics for those with moderate or severe disease with COPD exacerbations have a reduced 
risk of treatment failure and death (Ram, et al., 2006). 
 For patients who cannot be managed successfully with medication therapy, surgery may 
be warranted.  Three types of surgery are offered to patients with end-stage COPD suffering 
from severe symptoms: bullectomy for bullae that compress on more viable tissue; lung volume 
reduction surgery (LVRS) to removed ineffective and diseased lung to allow more effective 
tissue to function; or a lung transplant. Patients <65 years old with end-stage lung disease in the 
absence of other significant disease could be considered for transplantation. Chronic stable 
COPD patients who are hypoxemic often require LFDO to assist in maintaining activities of 
daily living (Tiep and Carter, 2008). 
Low-flow domiciliary oxygen. Low flow domiciliary oxygen therapy has long been in 
use as a means of ameliorating respiratory distress and shortness of breath for those afflicted 
with chronic lung disease. While the medical community is very aware of the risks associated 
with exposure to high concentrations of oxygen, even for relatively short periods of time, the 
research is sparse regarding to long-term exposure to low flows of oxygen. Understanding this 
dichotomous drug is the responsibility of the healthcare providers. 
 Following his 1913 scientific expedition to the summit of 14,210-foot Pike’s Peak in 
Colorado, the venerable British physiologist, John Haldane wrote, “partial anoxia means not a 
mere slowing down of life, but progressive, and perhaps irreparable damage to human structure” 
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(Haldane, 1919). Haldane went on to predict that someday the use of oxygen therapy would 
become commonplace in hospitals. In 1956 Cotes and Gibson of the UK were providing 
ambulatory patients with supplemental oxygen via portable cylinders. Increased walking time 
and improved arterial saturation with the administration of supplemental oxygen was noted 
(Cotes and Gibson, 1956).  In 1958, Alvan Barach was credited to be the first in the U.S. to 
develop transfillable oxygen cylinders, as well as inspiring the advent and continued evolution of 
LFDO (Petty, McCoy and Doherty 2005). 
 In 1980, a major randomized clinical trial took place to determine the effects of nocturnal 
oxygen therapy treatment.  The study enrolled 203 COPD patients with a blood oxygen level 
<50mmHg.  The results showed a significant difference (P<.01) in survival outcomes between 
those patients on continuous oxygen therapy (COT) and those on nocturnal oxygen therapy 
(NOT) only (Timms, et al., 1981).   
 In 2006 T.J. Ringbaek completed a mixed methods analysis of the domiciliary oxygen 
research from 16 different countries between the years of 1994 and 2000 in an effort to better 
understand the types of home therapies offered, the adherence to guidelines, the effects of 
continuous oxygen therapy (COT), the presence of predictors of survival and hospitalizations of 
COPD patients on COT, as well as the effect of nocturnal COT as it related to hypoxemia. Over 
17,000 people with advanced COPD were analyzed in this study. Results from this analysis 
demonstrated the following: the prevalence of patients on domiciliary oxygen was greater when 
prescribed by a general practitioner vs. a pulmonologist; adherence to oxygen therapy was 
greater when prescribed by a pulmonologist; the incidence of prescribed domiciliary oxygen 
therapy increased between 1995 and 2000 in all evaluated countries; most patients had mobile 
liquid oxygen systems; the median survival time of all COPD patients who started domiciliary 
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oxygen therapy between 1995 and 1999 was 1.27 years  (95% CI; 1.20-1.34) longer than those  
compared to those with same diagnosis and no domiciliary oxygen therapy.  
 Consistently research demonstrates that symptoms of those utilizing LFDO improve 
activities of daily living (ADLs), as well as ameliorate shortness of breath; however, there is no 
evidence that lung functionality improves or that life is lengthened (Strom, 1993; Dubois, 1994; 
Croxton and Bailey, 2006). 
 The American Thoracic Society has provided the following criteria for the 
implementation of LFDO therapy as outlined in Table two.  
Table 2  
LFDO Prescription Guidelines 
PaO2 mmHg Sa, O2 % LFDO Qualifying Condition 
≤ 55 ≤ 88 Absolute None 
55-59 89 Relative with qualifier cor pulmonale, 
polycythemia > 55%, 
History of edema 
> 60 > 90 None except with qualifier Exercise desaturation 
Sleep desaturation not 
corrected by CPAP 
Lung disease with severe 
dyspnea responding to O2 
PaO2: arterial oxygen tension, SaO2: arterial oxygen saturation; CPAP: continuous positive airway pressure; O2: 
oxygen. 
 
 The multiple factors that contribute to the morbidity and mortality of COPD have 
confounded finding a cure. It remains, however, the responsibility of the research community to 
better understand the disease and treatment therapies to bring us nearer to a cure. A step in that 
direction includes a better understanding of the dichotomous drug, oxygen. Understanding the 
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biochemical risks and benefits of oxygen therapy could result in the discovery of control for 
those qualities that contribute to pathology. 
 Based on information already understood about oxygen utilization, therapeutic guidelines 
have been developed. According to the ATS the goal of LFDO therapy is to optimize 
ventilation/perfusion (V/Q) matching as a means of correcting hypoxemia, particularly after an 
acute exacerbation of symptoms. Prior to initiating LFDO an arterial blood gas (ABG) should be 
obtained after breathing room air for 30 minutes. An ABG result will provide insight into arterial 
oxygen saturation as well as provide information on the presence of hypercarbia, or respiratory 
acidosis. Ventilation/perfusion mismatching can also be calculated by the alveolar-arterial 
gradient. The ATS recommends oxygen therapy for 24 hours/day with ambulatory capability. 
Exceptions to continuous administration include patients who: 1) are incapable or unwilling to be 
mobile; 2) only require oxygen during sleep; 3) require oxygen only during exercise. Liters of 
flow are gauged by the ABG result, and can be adjusted according to exertional needs. Flow 
rates should be adjusted to a target SpO2 of > 90% during periods of rest. This value should be 
calibrated with the initial ABG to assess relationship between SpO2 and PaO2. During sleep flow 
rates can be determined by two strategies: 1) the flow can be increased 1 L/min above the 
daytime resting prescription; or 2) nocturnal polysomnography or nocturnal pulse oximetry can 
be performed to support a more accurate prescription. The latter is especially important for those 
patients with cor pulmonale. During periods of exertion flow rates goals should be to maintain a 
PaO2 > 60mmHg or SaO2 >90%. Increasing overnight prescription of oxygen flow rates by 1 
L/min above the day was challenged in a study by Nisbet et al, (2006) stating overnight 
desaturation was not an issue if daytime flow rates were used during sleep. 
Consequences of oxygen therapy. While many treatment interventions are effective at 
addressing and improving specific symptoms, oftentimes the treatment can predispose a patient 
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to undesired consequences. As a supplemental therapy that is prescribed to nearly 800,000 
individuals annually at an estimated cost of 1.8 billion dollars it is necessary to appreciate any 
consequences that occur as a result of LFDO (Kim, et al., 2008). 
It is well understood that high concentrations of oxygen therapy for relatively short 
periods of time can result in lung pathology. Chronic exposure of lung tissue to moderate oxygen 
concentrations can create pathologic changes such as bronchopulmonary dysplasia (BPD) and 
fibrotic scarring resulting in deficiencies in ventilation and oxygenation (Chen, 2007).  In 
experimental BPD models, ROS-induced damage stemming from exposure to supraatmospheric 
oxygen tensions manifested in pulmonary epithelial DNA oxidation, accumulation of HO, lipid 
peroxidation, and protein oxidation (Liao et al., 2006; Auten, Whorton and Mason, 2003; Luo, et 
al., 1999; Vozzelli, 2004). Human BPD studies strongly support a role for ROS mediated 
damage (Ballard, et al., 2008). Plasma-3nitotyrosine, a marker for ONOO- formation, and 
protein carbonyls, a marker of protein oxidation, are elevated in premature newborns at the 
highest risk for developing BPD. ROS may inactivate antioxidant enzymes, with oxidized or 
nitrated proteins critical to lung function (Martin and Walsh, 2004). Retinopathy of prematurity 
(ROP) implicates oxygen therapy as central to its pathology. According to a study by Chen and 
Smith (2007) excessive oxygen contributes to ROP through regulation of vascular growth factor 
suppression. It is also speculated that due to decreased levels of antioxidants in the premature 
retina allows for oxygen radicals to accumulate resulting in retinal pathogenesis (Sira, 
Nissenkorn & Kremer, 1988).  
A standard for directly assessing lung pathology was through the collection and 
evaluation of bronchoalveolar lavage  (BAL). In a study by Davis, et al (1983) volunteers were 
exposed to 50% oxygen for 17 hours after which increased amounts of albumin were measured 
in their BAL, demonstrating a pulmonary-capillary membrane compromise. In 1986, Griffith et 
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al, conducted a study that yielded similar results in when individuals were exposed to 
concentrations of 30-50% oxygen for 45 hour with dose dependent increase in albumin in the 
BAL. In the same study, to measure lung epithelial permeability, inhaled technetium-labeled 
diethyentriamine pentaacetate was assessed; increases were detected in individuals exposed to 
50% oxygen.  
Historically it was believed that only high concentrations of oxygen were offensive to 
lung parenchyma, however, more recent research demonstrated concentrations as low as 40% 
have been implicated as well (Nagatomo, et al., 2012). The 1970’s offered the “60%” rule, 
delivering oxygen at 60% or less as an acceptable guideline for management of hypoxemia, after 
previous studies of higher concentrations of oxygen clearly demonstrated pathologic 
consequences.  This practice has been essentially unchallenged due to ethical considerations. 
Results from animal studies have provided significant insight into the deleterious effects of 
oxygen exposure (Martin and Kachel, 1989); however, in 1989 a study using cultured human 
pulmonary artery endothelial cells it was demonstrated that cytotoxicity occurred as early as 8 
hours following exposure to 0.95 FiO2, and after 48 hours of exposure to concentrations as low 
as 60% (Martin and Kachel, 1989).  
Oxygen toxicity causes damage to the lungs through a series of progressive stages. 
Initially, epithelial integrity is interrupted resulting in transudate in the alveoli; subsequently, 
capillary damage results in exudate between the alveolar sacs leading to fibrosis of the type I 
epithelial cells (Campbell, 2002). It is well documented in the literature that interstitial 
pulmonary changes occur after exposure to elevated concentrations of oxygen; however, there is 
a paucity of research to addresses the consequences associated with chronic exposure to low 
concentrations of oxygen. 
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An exhaustive Medline data search regarding the risks and benefits of long-term oxygen 
therapy revealed 14 studies assessing the value of dating from 1970 to 2010. Multiple variables 
were employed with only four studies clearly addressing the presence of an oxidative injury. 
In 1971, Petty, Stanford and Neff evaluated 20 patients diagnosed with severe COPD 
who were placed on continuous oxygen therapy to correct hypoxemia to a goal of a PaO2 
between 50 and 75mm Hg.  Multiple blood gases were drawn until desired range was achieved, 
which usually resulted in 1-2 L of oxygen per nasal cannula. Survival ranged between 7 and 61 
months, with 14 patients dying after an average of 26.7 months. Upon autopsy it was noted that 6 
of the deceased showed exudative or proliferative tissue injury commensurate with oxygen 
toxicity. Survival was not shortened in those with histologic changes, but quality of life was not 
defined. Five patients went on to live an average of 42.4 months with continued excellent 
benefit. In 1975, Steward, Hood and Block performed a similar study that evaluated 12 patients 
receiving portable oxygen therapy for a mean period of 25.2 months. The overall impression of 
the researchers was that oxygen therapy was beneficial. The variables evaluated were pulmonary 
function testing, electrocardiogram and cor pulmonale, and hospital admissions. Decline in 
pulmonary function tests was not demonstrated, an electrocardiogram exhibited an improvement 
in cor pulmonale in 5 patients, and a reduction in hospitalizations for respiratory illnesses. Six 
study participants died during the study period demonstrating a 56% survival rate for the 
remainder. However, five of the 6 deceased presented with histologic changes consistent with 
oxygen toxicity upon autopsy. 
A study published in 2004 in the European Respiratory Journal by Phillips et al, aimed to 
determine if short-term exposure to a low concentration of supplemental oxygen (28%) had an 
induced oxidative stress in nonhypoxic subjects. Breath methylated alkane contour (BMAC) was 
the marker utilized in this study. Thirty-one healthy subjects were recruited for this study and 
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served as the control and treatment groups in a pre and posttest design. Exhaled breath was 
collected prior to oxygen exposure and then after exposed to 28% oxygen at 2L/min via nasal 
cannula for 30 minutes while at rest. The results showed a significant (p<0.05) increased in the 
oxidative stress biomarker, BMAC. 
A similar study performed in 2004 by Carpagnano et al, recruited 23 healthy subjects and 
23 subjects with COPD. The control group consisted of 5 healthy subjects and 5 COPD subjects 
who breathed ambient air through a facemask for one hour; the treatment group consisted of 18 
healthy subjects and 18 COPD subjects (7 of which were receiving domiciliary oxygen 
treatment) and exposed them to 28% oxygen via a facemask for one hour. The exhaled breath 
was collected from both groups and compared for the presence and quantification of 8-
isoprostane and interleukin-6, biomarkers of oxidative stress and inflammation. The outcomes of 
this study showed a significant increase (p<0.05) in both biomarkers following exposure to one 
hour of 28% oxygen. 
Oxygen is one of the most widely used therapeutic agents and is a considered a drug in 
the truest sense of the word as it has specific biochemical actions, a distinct range of effective 
doses, and a well defined consequence at higher doses; however, a therapeutic range as it relates 
to dose and time, has not been established. The cost of use is low, yet it has been reported that in 
many hospitals the annual expenditure of oxygen therapy exceeds those of most other high-
profile agents (Bitterman, 2009). Sufficient evidence-based data does not exist to address the 
potential of this dichotomous drug.  
Hyperoxia. Oxygen is so central to human existence that it was once intuitive to believe 
it incapable of being dangerous, let alone lethal. As such, oxygen was/is administered liberally 
within hospital settings, used as a pretreatment prior to deep sea diving or piloting an aircraft, 
and even offered at oxygen bars for patrons to imbibe in its protective and healing powers. The 
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dangers of prolonged exposure to high concentrations of oxygen are now very well documented.  
Oxygen is no longer considered innocuous but rather as a formidable and dichotomous drug that 
can give life or take it away. To not adhere to meticulous therapeutic protocols would be medical 
negligence. Oxygen continues to be one of the most widely used therapeutic agents but the 
margin of safety for various conditions remains to be clearly defined.  
 Hyperoxia is the term used to describe the presence of excessive oxygen in the lungs and 
vasculature for delivery to the tissues of the body. This can occur when inspired oxygen is 
delivered at higher than necessary concentrations or at higher than atmospheric pressure, as with 
positive pressure ventilation or hyperbaric chambers, and increased fractions of inspired 
concentrations. The standard atmosphere is unit of pressure and is defined as being equal to 
101.325 kPa or 760 mmHg.  The pressure of oxygen of inspired air at sea level is 0.21 
atmospheres absolute, or Ata (Saltzman, 1973). Oxygen exposure at 1 atm of pressure, the lung 
is the most severely damaged as pulmonary tissue PO2 is the highest in the body. Since 
pulmonary tissue PO2 is directly determined by the alveolar PO2 arterial hypoxemia does not 
delay the development of pulmonary oxygen toxicity at 1 atm (Nunn, 1987). 
 While prolonged periods of hyperoxia can cause damage to various structures of the 
body, such as the central nervous system (CNS), the retina, hemolysis of erythrocytes, 
myocardium, the pulmonary structures are particularly vulnerable to the consequences of 
prolonged periods of high-pressure ventilation and increased fractions of inspired oxygen as they 
are directly exposed to the offending variables without buffer (Yusa et al., (1987); Gu et al., 
2003; Mengal and Kann, (1966); Sen et al., (2006). Individuals exposed to 1.0 Ata of oxygen for 
24 hours will display discernible symptoms of respiratory distress (Saltzman, 1973; Klein, 1990; 
Miller et al., 1970). If inspired pressures exceed 2.5 Ata, as possible in a hyperbaric chamber, 
neurologic symptoms, such as confusions and coma, will occur abruptly, but are reversible; 
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however, pulmonary toxicity is more insidious and, therefore, less reversible (Behnke, 1935).  As 
early as 1899 J.L. Smith was able to demonstrate that animals exposed to uninterrupted exposure 
to one Ata of oxygen for several days would experience respiratory distress, hypoxia and even 
death. Upon necropsy these animals displayed severe parenchymal damage. 
 Paul Bert (1943), a French physiologist, first described central nervous system toxicity in 
his publication Barometric pressure: Researches in Experimental Physiology. CNS toxicity is 
often referred to, as the “Paul Bert effect.” In his research he showed oxygen was toxic to 
insects, arachnids, myriapods, molluscs, earthworms, fungi, germinating seeds, birds, etc. Bert 
was able to demonstrate that the deleterious effects of oxygen exposure were a result of increases 
in partial pressure vs. concentration, a theory that was essentially unchallenged for decades. In 
more recent years a biochemical process resulting in the production of oxygen metabolites has 
been implicated as the likely culprit in oxygen toxicity (Klein, 1990).  
Oxygen toxicity. The mechanism of oxygen toxicity at the molecular level is now 
attributable to free radical interactions with cellular components. As a naturally occurring 
phenomenon with physiologic functions, their highly reactive nature makes them formidable 
when left unchecked. The oxygen molecule is normally susceptible to univalent reduction 
reactions within the cell to form a superoxide anion and hydrogen peroxide. While both of these 
compounds can have direct toxic effects, they interact to form more dangerous species through a 
process called the Fenton reaction, a reaction resulting in the formation of radicals from 
nonenzymatic processes. Due to the deleterious potential of free radicals, or reactive oxygen 
species, a complex and layered defense of enzyme systems and low-molecular weight radical 
scavengers exists. 
It is difficult to fully appreciate the whole process of oxygen toxicity in humans for 
obvious ethical reasons. As a result, most studies conducted regarding this deleterious process 
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have utilized animal models, including ultrastructural morphometry, or the measurement of an 
external form. Human studies consist of autopsies following a severe illness requiring high 
concentrations of oxygen, usually delivered by high-pressure ventilation. In animal models 
researchers have been able to track oxygen toxicity from the mild to severe stages; however, only 
the end stages have been studied in humans during autopsy. Fortunately, relevant relationships 
exist between the animal and human studies with regard to morphologic changes (Lambertson, 
1971; Crapo, et al., (1980); Crapo, 1986; Kapanci, et al., (1969); Thet & Parra, (1986); Kapanci, 
et al., (1972). In most species, exposure to 100% oxygen at 1 atm for 24-72 hours is associated 
with the initial phase of injury in all species. 
It has been proposed that the alveolar destruction that occurs as a result of oxygen 
toxicity is compromised of multiple processes: apoptosis, oxidative stress, and protease 
antiprotease imbalance. In the pages that follow these mechanisms will be addressed in an effort 
to better understand the cascade of events that result in COPD. 
 During periods of hyperoxic pathologic conditions, a large influx of ROS is produced, 
disrupting the balance between oxidants and antioxidants, making surrounding tissues vulnerable 
to pathologic changes. Exposure time, atmospheric pressure, and fraction of inspired oxygen 
(FiO2) determine the cumulative oxygen dose predisposing toxicity (Mach, et al., 2010).   
 Pulmonary capillary endothelial and alveolar epithelial cells are targets for ROS. The 
earliest morphologic changes seen in the initial, or inflammatory, phase involve subtle changes 
in endothelial cell structure, which result in pericapillary accumulation of fluid. If left unchecked 
interaction can result in excessive edema, alveolar flooding, hemorrhage, and collagen, elastin, 
and hyaline membrane deposits (Yee, et al., 2006; Kan, Lee and Kim, 2005; Pagano and 
Barazzone-Argiroffo, 2003). The initial phase is associated with, or rapidly followed by, 
accumulation of thrombocytes, macrophages and neutrophils in the lungs accompanied by the 
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release of soluble mediators of inflammation resulting in ongoing edema and cellular signaling 
(de los Santos, et al., (1987); Barry & Crapo, (1985); Fox, et al., (1981); Rinaldo, et al., (1988); 
Forman, York & Fisher, (1960); Ozawa, et al., (1988)). The hemoglobin-oxygen buffering 
mechanisms fail when the PAO2 reaches a critical level and the tissue PO2 rises above hundreds 
of mmHg. At high levels of oxygen, protective endogenous antioxidant enzyme systems become 
overwhelmed by ROS resulting in cell death (Mantell, et al., (1999).  
 Pulmonary oxygen toxicity can be explained occurs in 5 phases: 1) Initiation: during this 
phase there are increases in production of toxic oxygen metabolites, depletion of antioxidant 
stores, decreases in flow of tracheal mucus lending to infection and no obvious evidence of lung 
injury; 2) Inflammation: during the inflammation phase damage occurs to the pulmonary 
capillary endothelial lining, increases in inflammatory mediators rush to site of insult and the 
development of pulmonary edema ensues; 3) Destruction: during the destruction phase there is 
amplified damage to the endothelial lining with the accumulation of platelets, neutrophils, a 
continued release of inflammatory mediators, and this is the phase most associated with 
mortality; 4) Proliferation: the proliferation phase becomes evident after prolonged exposure to 
oxygen concentrations between 60-85% with hypertrophy occurring to the remaining pulmonary 
capillary endothelial cells, increases in monocytes, increases in type II pneumocyte activity, or 
surfactant production; 5) Fibrosis: permanent lung damage occurs during this phase as collagen 
deposition occurs in the lung interstitium, increases in the thickness of the pulmonary interstitial 
space and increases in interstitial fibrosis (Mensack and Murtaugh, 1999). 
 The pulmonary epithelial surface is vulnerable to a destructive inflammatory response. 
Inflammation damages the alveolar capillary barrier leading to impaired gas exchange and 
edema. Reactive oxygen species induces pulmonary secretion of chemo attractants, and 
cytokines stimulate macrophage and monocytes mobilization and accumulation into the lungs, 
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leading to further ROS production, extending injury. As highly reduced cell layers become 
increasingly oxidized and levels of antioxidants fall, ROS-induced activation of signal 
transduction pathways regulates cellular responses of adaptation, repair or cell death by 
apoptosis, oncosis, or necrosis (Romashko, et al., 2003; Kannan, et al., 2006).  
 Cellular response to ROS signaling occurs as a result of mitogen-activated protein kinase 
(MAPK), toll-like receptor 4 (TLR4), signal transducers and activators of transcription (STAT), 
and nuclear factor kappa beta (NFkß) communicating with the DNA of the cell and eliciting a 
response. The MAPK pathway regulates cell death genes, stress and transformation and growth 
regulation. The TLR4, STAT pathways are associated with survival gene expression and 
antioxidant response. The NFkß pathway is an up-stream signal for inflammation and survival 
genes: antioxidant enzymes, Bcl-2, hemeoxygenases, and heat shock proteins (Mach, et al., 
2010). 
    Oxidative stress. Oxidative stress occurs as a result of the cumulative effects of an 
excess of reactive oxygen species (ROS).  Prolonged exposure to higher than normal 
concentrations and partial pressures of oxygen than the lungs are normally exposed to will result 
in the production of ROS (Fridovich, 1998). Conditions that precipitate oxidative stress through 
different ROS producing mechanisms include pneumonias, sepsis, acid aspiration, hyperoxia, 
high-pressure ventilation, pulmonary contusion, reperfusion injury and/or bleomyocin exposure 
(Matute-Bello, Frevert and Martin, 2008). When the body is unable to control for an excess of 
these highly bioactive intermediates that result from these pathologic processes significant 
cellular damage and pathology can ensue.  Ironically, the precipitating conditions typically 
require prolonged oxygen exposure as a support therapy placing them at an even greater risk of 
oxidative damage.  
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 Research regarding high concentration oxygen exposure in healthy patients has not 
demonstrated permanent results when exposure was less than 24 hours. In a 1970 study 
performed by van der Water et al, nine young healthy men were exposed to 100% normobaric 
oxygen for 6-12 hours. Following this exposure the alveolar-arterial 02 gradient, pulmonary artery 
pressure, total pulmonary resistance, cardiac output, pulmonary vascular volume, and CXR were 
evaluated with no pathologic findings noted. However, unpublished research conducted on 
exceptionally fit pilots that routinely inspired 100% oxygen immediately pre flight suggests the 
pilots experienced symptoms consistent with inflammatory lung injury, such as cough, substernal 
chest pain and burning. Pulmonary function tests in this group indicated that pathologic changes 
had occurred in those who had participated in repeated, pre-flight, short-term inspiration of high 
oxygen concentrations (Vacchiano, personal communication). 
The symptoms primarily observed in conscious patients with oxygen toxicity is 
tracheobronchial irritation resulting in a cough and substernal discomfort. The onset of 
symptoms of tracheal irritation occur ~4-22 hours after the start of oxygen exposure (Comroe et 
al., 1945). According to Sackner et al, (1975) these symptoms precede changes in pulmonary 
function tests.  
Historically, the most commonly used index of oxygen toxicity in humans has been vital 
capacity (VC) (Comroe, et al., (1945); Caldwell, et al., (1966). Vital capacity is measured as the 
total volume of expired air from the lungs following maximal inhalation. Early respiratory 
physiologists reported that subjects who were suspected to have suffered oxygen poisoning had 
concomitant decreases in their VC (Comroe et al., 1945; Caldwell et al., 1966, Clark and 
Lambertsen, 1971). However, more current research has abandoned this index as a primary 
indicator as too many variables confound accuracy.  
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Hyperoxic lung damage. Oxygen exposure at concentrations greater than 50% 
administered between 4 and 22 hours can induce lung injury between (Bitterman, 2009) via two 
mechanisms: 1) the formation of cytotoxic oxygen free radicals; and 2) absorption atelectasis 
(Carvalho et al., 1998). The formation and activity of oxygen free radicals is the topic of interest 
for this research study and, therefore, will be addressed exclusively. 
Most research addressing the subject of pulmonary oxygen toxicity has been performed 
almost exclusively on animal models for obvious ethical reasons. Research performed on 
humans is typically carried out during autopsy (Klein, 1990).  In most species, exposure to 100% 
at one atm for a period of 24-72 hours results in the initial phase of lung injury. Normally this 
phase displays no outward symptoms of injury but is characterized by increases in production of 
oxygen metabolites, such as reactive oxygen species, through the recruitment and activation of 
neutrophils (Jamieson et al, 1986; Rinaldo et al., 1988, Vacchiano et al., 1997; Wheaton and 
Chandel, 2011). The presence of neutrophils in the lungs is commensurate with parenchymal 
damage (Crapo et al., 1980; De los Santos et al., 1987, Steinberg, K.P. et al., 1994; Reutershan et 
al., 2005). Neutrophils release inflammatory mediators, which, in this environment, result in the 
production of reactive oxygen species via various oxidases (Zmiljewski et al., 2008; Wheaton 
and Chandel, 2011). The ROS also mediate increased mucous production, decreased ciliary 
function, fibroblast injury, gene expression of pro-inflammatory mediators (TNG-a, IL-8, IL-1, 
NO), and diminished pulmonary mechanics and lung repair (Barnes, 1990; Barnes, 1996; 
Keatings et al., 1996; Barnes, 2004; Cross, et al., 1994; Macnee and Rahman, 1999).  
The major cellular mediators in pulmonary oxygen toxicity are considered alveolar 
macrophages (AMs), neutrophils (PMNs), and vascular endothelial cells (VECs) (Vacchiano, 
Osborne and Temple, 1997). The consequence of cytotoxic free radical activity is fibrotic 
changes to the parenchyma.  Parenchymal fibrosis results in disrupted wall integrity and 
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impaired gas exchange. Alveolar macrophages have been implicated as the initial metabolic 
source producing reactive oxygen species (Vacchiano, Osborne, and Temple, 1997; Grommes 
and Soehnlein, 2011).  
The discontinuation of hyperoxic exposure can result in three ways: 1) Type II 
pneumocytes proliferate to begin restructuring of the alveoli; 2) fibroblast proliferation that may 
lead to interstitial fibrosis, and 3) development of pulmonary hypertension as a result of the 
derangement of large and small arterial walls (Coflesky, et al., (1987); Shaffer, et al., (1987). 
The role of oxidative stress is now widely recognized as a key component of airway 
inflammation in a variety of pulmonary ailments (Riedl and Nel, 2008). Through the excessive 
production of ROS structural cellular damage occurs through the oxidation of proteins, lipids and 
DNA (Riedl and Nel, 2008). Continued attention needs to be given to this pervasive process as it 
undermines the human infrastructure making it vulnerable to disease and discomfort. 
Acute Respiratory Distress Syndrome. Ashbaugh et al, (1967) were the first to describe 
and report a syndrome with a set of pulmonary pathologies that presented with such symptoms as 
diffuse lung infiltrates and respiratory failure and referred to as adult respiratory distress 
syndrome (ARDS). During that time those who identified this syndrome included cases of battle 
trauma, severe sepsis, pancreatitis, and massive transfusions. Following ongoing research, 
Ashbaugh and Petty (1971) refined their definition to include clinical features of severe dyspnea, 
cyanosis refractory to oxygen therapy, decreases in pulmonary compliance, atelectasis, 
pulmonary vascular congestion and hemorrhage, pulmonary edema and hyaline membranes at 
autopsy.  
By 1988 a 4-point physiologic quantification system was introduced to stratify lung 
injury: 1) level of positive end expiratory pressure (PEEP); 2) P/F Ratio (ratio of arterial oxygen 
concentration to the fraction of inspired oxygen; 3) static lung compliance; and 4) degree of 
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pulmonary infiltrations on chest x-ray (CXR).  Other considerations with this point system 
included the examination of nonpulmonary organ dysfunction (Murray et al., 1988). 
Shortcomings, however, existed with this definition as it did not clearly delineate ARDS from 
cardiogenic pulmonary edema or offer predictive outcomes. In 1994 the American-European 
Consensus Conference Committee (AECC) developed the now widely accepted definition of this 
collection of phenomenon and changed the name to acute respiratory distress syndrome to reflect 
that all are vulnerable to the possibility of experiencing this pathologic process.  
The current definition of ARDS is as follows: acute onset, bilateral pulmonary infiltrates 
on CXR, pulmonary capillary wedge pressure (PCWP) <18 mmHg, P/F ratio <200. Adult 
respiratory distress syndrome occurs in four stages: exudative (acute phase), proliferative, 
fibrotic and recovery, if recovery is possible.  Management of ARDS includes oxygen, 
mechanical ventilation, fluid therapy and a variety of medications to combat and support the 
various manifestations associated with the pathology. Ventilatory management, to include 
elevated oxygen concentrations, serves a dichotomous role. The patient will not survive without 
positive pressure ventilation and increases in supplemental oxygen, however, these treatments 
introduce potentially irreversible sequelae. Higher concentrations of inspired oxygen at 
atmospheric pressure are associated with pulmonary oxygen toxicity. 
Reactive oxygen species. Reactive oxygen species (ROS) are free radicals containing 
oxygen in multiple forms to include oxygen ions, peroxides, superoxides, dioxylgenals and 
ozone. Free radicals are atoms, molecules or ions characterized by unpaired electrons in their 
outer orbits, making them highly reactive.  Oxygen free radicals are continuously being produced 
intracellularly by oxidation-reduction reactions (Southorn and Powis, 1988).  
 Normal cellular metabolic processes are the major source of ROS production, with 
electron transport chain of the mitochondria the largest contributor. ROS generation also occurs 
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endogenously during activation of circulating inflammatory cells or phagocytes, or exogenously 
due to interactions with noxious chemicals (Kirkham and Rahman, 2006).  
 It should be understood that ROS have essential homeostatic responsibilities, such as 
regulation in signal transduction cascades, cellular phosphorylation, gene expression, and DNA 
synthesis (Upham and Trosko, 2009). Specific roles of ROS are dependent upon location, 
neighbors and timing (Auten and Davis, 2009). Of particular value, as it relates to this study, is 
the role of ROS in the antimicrobial activity of phagocytic cells for host defense (Fang, 2011). In 
contrast, however, in an unregulated environment, all components of the cell (lipid, protein and 
DNA) are vulnerable to irreparable changes (Bowler and Crapo, 2002).  The lipid bi-layer is 
particularly vulnerable to the activity of oxygen free radicals due to the presence of multiple 
double bonds lending to increased reactivity. The oxidative degradation of lipids is referred to as 
lipid peroxidation. 
 Due to the unique molecular structure of oxygen and its abundance within cells oxygen 
has powerful potential. It readily accepts free electrons generated by normal oxidative 
metabolism within the cell, producing ROS. Processes causing uncoupling of electron transport 
can further enhance ROS production. However, other entities, such as the endoplasmic 
reticulum-bound enzyme systems, cytoplasmic enzyme systems, and the surface of the plasma 
membrane contribute. Contributions by multiple enzyme systems, such as the cytochrome P450 
monoxygenase system, xanthine oxioreductase system, nitric oxide synthases, and several others 
involved in the inflammatory process (cyclooxygenase and lipoxygenase), can also increase the 
generation of ROS. While several forms of ROS are produced, concern of over the production of 
the more toxic radicals, such as HO, especially in the presence of reduced transition metals such 
as iron, exists. Also, important to note, rapidly reacts with nitric oxide to form peroxynitrite  
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(ONOO-), a strong nitrating and oxidizing compound. These highly reactive species can react 
with membrane lipids to cause more complex radicals through the initiation of lipid peroxidation, 
the non-enzymatic degradation of lipids.  
The endogenous production of O2- arises from NADPH oxidases (NOX 1-3) at low 
levels in the smooth muscle and vascular endothelium, with dual oxidases 1,2, and 4 in the 
epithelial cells. Reactive oxygen species have an important role in regulating nitric oxide 
availability, influencing airway and vascular reactivity (Auten and Davis, 2009). 
Free radical induced oxidative stress has been implicated in many disease processes such 
as cardiovascular, pulmonary, autoimmune, inherited metabolic disorders as well as cancers and 
aging. However, the lungs and pulmonary vasculature are particularly vulnerable to the effects of 
free radical mediated tissue injury due to the increased presence of unsaturated fatty acids (the 
substrate for lipid peroxidation) and exposure to higher concentrations of oxygen than any other 
organ in the body (Torres, 2004).  
Numerous pathways are initiated when stress is experienced leading to free radical 
production. A cascade of free radical activity leads to lipid peroxidation, protein oxidation, DNA 
damage, all of which contribute to pathology and cell death (Kappus and Sies, 1981; Bowler and 
Crapo, 2002). 
Reduction-oxidation reaction. Reduction-oxidation, or redox, reactions are those that 
refer to chemical reactions in which atoms have their oxidation state changed. Oxidation state 
refers to the charge an atom would have if all bonds to atoms of different elements were 100% 
ionic, the chemical bond created by the attraction of opposite charges. The increase in the 
oxidation state of an atom as a result of a chemical reaction with a net loss of electrons is 
referred to as oxidation. The decrease in the oxidation state of an atom as a result of a chemical 
reaction with a net gain in electrons is referred to as reduction (Voet, Voet and Pratt, 2006).  
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Metabolic redox reactions within the body can result in the formation of molecules that 
are missing electrons. When a system is overwhelmed and there is an imbalance of antioxidants 
present new molecules are formed. In an effort to neutralize, these highly reactive and unstable 
molecules (or free radicals) will react with the first available source, such as DNA, lipid 
membranes, often resulting in irreparable damage and cell death (Kappus and Sies, 1981).  
 The direct effects of ROS on signaling pathways include redox-sensitive transcription 
factors, such as HIF, Nrf-2, and Nf-κB, as well as through direct effects through the inactivation 
of NO-based signaling (Auten and Davis, 2010). 
 To demonstrate the pathologic potential of unchecked ROS an example is provided. The 
developing retina is especially sensitive to ROS-mediated damage, contributing to retinopathy of 
prematurity in newborns. Vascular growth into the developing posterior retina is normally driven 
by redox-sensitive pathways that upregulate vascular endothelial growth factor (VEGF). 
Following birth, the neonate experiences increases in oxygen tension that suppresses VEGF. In 
the premature infant the suppression of VEGF in conjunction with altered autoregulation of 
retinal blood flow, as well as a deficiency in antioxidants, results in cessation of angiogenic 
budding, while apoptosis of developing vessels occurs secondary to the formation of ROS and 
nitrogen species (Gu, et al., 2002; Gu, et al., 2003; Saugstad, 2006).  
Antioxidant systems. All aerobic organisms have enzymatic and non-enzymatic cellular 
defenses, collectively referred to as antioxidants, to maintain cellular homeostasis. Regulation of 
ROS activity is provided by antioxidants (Bowler and Crapo, 2002; Southorn and Powis, 1988).  
 Antioxidants are both water-soluble and lipid soluble. Water-soluble antioxidants 
generally react with oxidants in the cell cytosol and the blood plasma. Lipid soluble antioxidants 
protect cell membranes from lipid peroxidation. With regard to function there are four main 
classifications: 1) Preventative, which suppress the formation of ROS, 2) radical scavenging, 
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which suppress chain initiation and/or halt propagation reactions, 3) repair and restore, such as 
proteases, and 4) those that allow for adaptation that occurs when the signal for the production 
and reactions of ROS induces oxidant formation and transport (Rahman, Biswas & Kode, 2006). 
 The enzymatic antioxidants include superoxide dismutase (SOD), catalase, glutathione 
peroxidase, glutathione S-transferase and thioredoxin (Kirkham and Rahman, 2006). The non-
enzymatic antioxidants include low molecular weight compounds, such as glutathione, urate, 
ascorbate, α-tocopherol, bilirubin, and lipoic acid, and high molecular weight compounds, such 
as the proteins albumin and transferrin.  
 Glutathione (GSH), a tripeptide thiol, is the primary intra and extracellular antioxidant in 
the lungs and is markedly up regulated in the presence of oxidative stress (Barnes, 2004; Rahman 
and MacNee, 2000; Deneke and Fanburg, 1989; Meister and Anderson, 1983). Alterations in 
alveolar and lung GSH metabolism are recognized as a central feature of many inflammatory 
lung diseases, such as COPD (Rahman and MacNee, 1999).  
 A delicate balance must be maintained between ROS production and the antioxidant 
defenses to ensure cellular stability. The balance is disturbed by conditions of hyperoxia, 
inflammation, or ischemia-reperfusion, or in the presence of impaired antioxidant defenses, such 
as seen with smoking (Auten and Davis, 2009). Mechanisms of ROS-related cell death include 
direct injury to proteins, lipids, and nucleic acids. For example, nitrosylation and protein 
oxidation impair a variety of enzymatic process and growth factors leading to cellular 
dysfunction (Stadtman and Levine, 200).  Lipid peroxidation has been linked to cell death 
through the effects on cellular phospholipids through the activation of sphingomyelinase and the 
release of ceramide, which result in apoptosis (Fruhwirth and Hermetter, 2008). Nucleic acid 
oxidation has been linked with physiologic and premature aging as well as DNA strand breaks, 
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which leads to necrosis and/or maladaptive apoptosis (Auten, Whorten and Mason, 2002). The 
ability of the cell to handle changes determines whether or not it is adaptive or maladaptive.  
 In the proper location and concentrations, ROS can function as second messengers and 
activate multiple signal transduction pathways within the cell, such as growth factors, cytokines 
and calcium signaling. Possibly through the production of lipid peroxide intermediates, ROS can 
activate protein kinases, which phosphorylates and releases to Bcl-2-related proteins sequestered 
within cells (Parinandi, et al., 2003; Lei and Davis, 2003). The release of these key proteins can 
activate the Bax system resulting in apoptosis.  
 Significantly high levels of O2- are generated by NOX in phagocytes, such as the 
neutrophils and microphages (~1000-fold higher than nonphagocytic cells) (Auten and Davis, 
2009). Blocking neutrophil influx induced by hyperoxia resulted in mitigating oxidative DNA 
damage, HO formation, and O2- accumulation, while simultaneously enhancing alveolar 
development (Auten, Whorton and Mason, 2002; Belik, et al., 2004; Auten et al., 2001; Ning et 
al., 2006). It has been demonstrated that when the NADPH oxidases are genetically ablated 
reduction in pulmonary ROS accumulation occurs; however, this has not been proven to be 
protective as accompanying inflammation ensues (Gao et al., 2002; Yao et al., 2008).     
Lipid Metabolism 
Lipid metabolism can occur from both enzymatic and nonenzymatic processes. In the 
increased presence of reactive oxygen species enzymatically driven lipid metabolic pathways 
may be bypassed for the nonenzymatic lipid peroxidation pathway (Voet, Voet and Pratt, 2006).   
Enzymatic lipid metabolism. Enzymatic lipid peroxidation occurs when 
cyclooxygenase and lipoxygenase control the peroxidation of various fatty acid substrates. These 
cyclooxygenase derived fatty acid substrates include prostaglandins. Enzyme generated products 
mediate specific bioactivities via receptor-dependent pathways that are under tight regulation. 
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Cyclooxygenase is the precursor to prostaglandin synthesis, and are pro-inflammatory. Non-
steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen or naproxen, are cyclooxygenase 
(COX) inhibitors, antagonizing prostaglandin synthesis, thwarting inflammation and relieving 
associated pain perception.  
Non-enzymatic lipid metabolism. An overabundance of ROS can lend to non-enzymatic 
lipid peroxidation, the metabolism of fatty acids, primarily arachidonic acid, resulting in the 
oxidative degradation of lipids. This is a process by which free radicals readily bind with 
electrons of the lipids in cell membranes resulting in cellular damage (Repetto, Semprine and 
Boveris, 2012).  Since this process does not involve cyclooxygenase no current therapies are 
available to ameliorate the inflammatory response caused by these mediators.  
Lipid peroxidation most readily affects polyunsaturated fatty acids due to the presence of 
multiple double bonds that are positioned between methylene groups and highly reactive 
hydrogen atoms. Products of ROS initiated non-enzymatic lipid peroxidation are 
proinflammatory prostanoids, which can generate more radicals that are capable of releasing 
damaging enzymes (Auten and Davis, 2010). Radical reactions consist of three main steps: 
initiation, propagation, and termination (Repetto, Semprine and Boveris, 2012).  
 Initiation is the step in which a fatty acid radical is produced. Of these the most notable 
initiators in living cells are reactive oxygen species, such as OH and HO2, which readily bind 
with a hydrogen atom to form water and a fatty acid radical (Porter, Caldwell and Mills, 1995). 
 Propagation is the step by which the newly formed unstable fatty acid radical readily 
binds with molecular oxygen to form an unstable peroxyl-fatty acid radical. This process 
continues, or propagates, producing a different fatty acid radical and lipid peroxide, or cyclic 
peroxide if it reacts with itself (Porter, Caldwell and Mills, 1995).  
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 Termination occurs when two radicals react to form a non-radical.  This can only occur 
when the concentration of radical species is high enough to potentiate the interaction between 
two radicals. When a radical reacts with a non-radical the interaction will always produce a 
radical, thus the chain reaction phenomenon. Organisms have evolved to protect themselves by 
speeding up termination through scavenging free radicals with antioxidants, such as vitamin E 
(α-tocopherol), as well as the enzymes superoxide dismutase, catalase and peroxidase (Porter, 
Caldwell and Mills, 1995). 
 The location the initial hydrogen atom abstraction takes place along the carbon chain 
determines the by-product produced. By-products of ROS generated non-enzymatic lipid 
peroxidation include isoprostane compounds, which are non-classical eicosanoids, such as 8-Iso-
PGF2α, a biomarker now used extensively to assess for the presence of oxidative stress in a 
variety of conditions.  In conditions where increased oxygen tensions exist, the formation of 
isofurans is favored over 8-Iso-PGF2α (Fessel, et al., 2002). The isofurans are a more sensitive 
indicator of oxidative injury. These biomarkers can be detected in multiple media: serum, urine 
and exhaled breath. 
Eicosanoids 
 Eicosanoids are oxidative derivatives of 20-carbon chain essential fatty acids (EFA), 
specifically omega-3 (ω -3) and omega-6 (ω-6), which are primarily responsible for immune and 
inflammatory responses as well as serving as central nervous system messengers.  Eicosanoids 
are comprised of four main families: prostaglandins, prostacyclins, leukotrienes and 
thromboxanes, all of which have bioactive subcategories.  Prostaglandins, prostacyclins and 
thromboxanes comprise a group called prostanoids.  Eicosanoids are not stored in cells but rather 
are synthesized in response to hormonal stimulation.  Synthesis occurs through a series of steps. 
Initially, a fatty acid substrate, such as arachidonic acid, is released from cellular phospholipids 
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via phospholipase A2; the free fatty acids are then acted upon by either cyclooxygenase 1 or 2 
(COX1 or COX2) forming a hydroperoxide. The newly formed hydroperoxide is then reduced 
through a peroxidase reaction resulting in PGH2, an unstable intermediate from which all other 
prostanoids are derived via various enzymatic reactions (Voet, Voet and Pratt, 2006). 
Prostanoids. Prostanoids are biologically active lipids formed from cyclooxygenases or 
prostaglandin synthases acting on the 20-carbon EFA chain by adding two oxygen molecules as 
two peroxide linkages and forming a 5-carbon ring approximately midway in the structure. 
Prostanoids are comprised of prostaglandins, prostacyclins and thromboxanes, all of which have 
a specific role with regard to the immune/inflammatory response and homeostasis. Prostanoid 
activity is achieved through autocrine and paracrine stimulation, meaning they exert their 
activities through cellular signaling among same cells and adjacent cells, respectively. 
Homeostatic functions of prostanoids include cytoprotection of gastric mucosa, regulatory 
influence on the renal, cardiovascular, and pulmonary physiology, protein metabolism and 
gestation and parturition regulation; however, they are involved in pathologic processes, such as 
inflammation, cardiovascular disease, cancer, dementia and Alzheimer’s as well as aging to 
name a few (http://lipidlibrary.aocs.org/Lipids/eicprost/file.pdf). 
Prostaglandins. Prostaglandins were identified in the 1930’s and named so as they were 
thought to originate in the prostate gland. It was discovered by the 1960’s that prostaglandins 
exist in nearly all cells of the human body as a result of the biosynthesis of specific EFAs.  While 
cellular concentrations of prostaglandins are low-level, measuring only in nanomoles, their 
biologic activities are profound. 
 An important chemical distinction of prostaglandins is the 5-carbon ring positioned 
between the 8 and 12 carbons.  Dependent upon subgroups, the prostaglandin family is 
comprised of at least 11 variations: PGA, PGB, PGC, PGD, PGE, PGFα, PGG, PGH, PGI, PGJ, 
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and PGK.  Further distinctions can be made by the absence or presence of double bonds, denoted 
by the subscript 1, 2, or 3.  Typically, double bonds are located with the alkyl substituents.  The 
number of double bonds is directly related to the fatty acid precursor. For example, PGE1, PGE2 
and PGE3 are derived from linoleic, arachidonic and eicosapentaenoic acids respectively 
(http://lipidlibrary.aocs.org/lipids/eicprost/file.pdf). Greek subscripts α and β are used with the 
PGF series to describe the stereochemistry of the hydroxyl group on carbon 9 
(http://lipidlibrary.aocs.org/Lipids/eicprost/file.pdf). 
Thromboxanes. Thromboxanes are lipid molecules in the eicosanoid family responsible 
for clot formation and vasoconstriction following endothelial trauma.  The two major 
thromboxanes are thromboxane A2 and B2. Platelets contain an enzyme, thromboxane-synthase 
A, which converts arachidonic acid into thromboxane. Thromboxane promotes platelet 
aggregation, facilitated by vasoconstriction (Voet, Voet and Pratt, 2006).   
Prostacyclins. Prostacyclins are lipid molecules and, though considered independent 
mediators, in eicosanoid nomenclature are referred to as PGI2, derived from ω-6 arachidonic acid, 
and are, therefore, grouped with prostanoids.  Prostacyclins are produced in endothelial cells 
from prostaglandin H2 (PGH2) via prostacyclin synthase. The primary function of prostacyclin in 
the inflammatory cascade is inhibition of platelet aggregation and vasodilation, balancing 
thromboxane activity and resulting in homeostasis. Unopposed thromboxane activity could result 
in significant vascular consequence (Voet, Voet and Pratt, 2006).   
Non-classical Eicosanoids 
Isoprostanes. Isoprostanes (IsoPs) are prostaglandin F2-like compounds formed in vivo 
in abundance as a result of non-enzymatic lipid peroxidation of EFAs, primarily arachidonic 
acid, in the presence of oxidative stress.  Reactive oxygen species attack the fatty acid, 
prostaglandin, resulting in the chemically altered compound with a prostane ring, making up a 
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series of isomers named F2-isoprostane. Isoprostanes possess powerful inflammatory, 
vasoconstrictive and hyperalgesic properties capable of significant pathology. These compounds 
were discovered as a result of reevaluating plasma samples from health subjects stored at -20C 
for several months, while the peak times were the same on the chromatogram the peak levels had 
increased by ~100-fold. This occurred as a result of autoxidation, a non-enzymatic free radical 
metabolism, of plasma lipids during storage. Further investigation confirmed these compounds to 
be isomeric to PGs and possess an F-type cyclopentane (prostane) ring, leading to the 
nomenclature F2-isoprostanes (Morrow, et al., 1990). 
Since that time over a thousand studies have been performed using the 8-isoprostane as a 
biomarker of oxidative stress and are considered accurate markers of lipid peroxidation in both 
animal and human models of oxidative stress with the isoprostane 8-iso-PGF2α consistent with 
pulmonary oxidative stress are (Barnes, 2006) during periods of normoxia and the isofurans 
(IsoF) in circumstances where elevated oxygen tension levels are present (Roberts et al, 2004).  
The production of isoprostanes is self-limiting making isofurans a better biomarker of oxidative 
stress in the presence of hyperoxia. 
Isofurans. Isofurans, like isoprostanes, are a result of non-enzymatic free radical 
metabolism of arachidonic acid but are differentiated by a substituted tetrahydrofuran ring. IsoPs 
and IsoFs share a carbon-centered radical as an intermediate. The generation of IsoPs at the 
carbon-centered radical undergoes a 5-exo cyclization to form a cyclopentane ring; IsoFs are 
generated when the carbon-centered radical interacts with molecular oxygen, which is why IsoF 
formation is favored during periods of increased oxygen tension. Elevated oxygen 
concentrations, greater than 21%, favor isofuran over isoprostane production, such as during 
periods of hyperoxic therapies or with disorders of the mitochondria where oxygen utilization is 
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impaired (Roberts et al., 2004). This unique differentiation allows for more sensitive evaluation 
of pathologic processes meeting these criteria.   
 In a study by Fessel et al, (2002) steps were taken to determine the mechanism of 
formation of IsoPs compared to IsoFs when assessing for hyperoxic induced oxidative stress, as 
noted with hyperoxia-induced acute lung injury, retinopathy of prematurity, etc. In the pathway 
for IsoP formation a carbon-centered radical must undergo intramolecular rearrangement to form 
a cyclopentane ring. Competition from molecular oxygen in this reaction prevents the formation 
of an IsoP. The researchers presumed this limited IsoP formation at higher oxygen 
concentrations. Fessel and colleagues hypothesized that an independent pathway would be 
modulated by higher oxygen tensions. To test the hypothesis they measured IsoP and IsoF 
formation in vitro from the oxidation of arachidonic acid in the presence of increasing oxygen 
tensions. It was concluded that IsoPs and IsoFs increased comparably up to 21% oxygen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
as oxidation requires the presence of oxygen; however, IsoF formation continued to increase 
significantly as oxygen tension increased to 100% with a ratio of ~6:1 IsoF to IsoP formation. 
Further experiments were then undertaken to assess for in vivo IsoF formation. Using the well-
established liver oxidant injury animal model CCl4-treated rats was utilized to assess for IsoF 
formation. The results showed much lower levels of IsoFs than IsoPs. Concerned that this may 
be due to the fact that liver tissue has a low oxygen tension they opted to repeat the experiment 
in rat kidney and brain tissue. These results were 2-2.3 fold higher than the IsoFs measured in the 
liver. Finally, the researchers wanted to look specifically at the formation of IsoFs vs. IsoPs in 
the lungs following high concentrations of oxygen exposure. After 3 hours of 100% oxygen 
exposure there was no significant difference between IsoP levels between the treatment and 
control groups; however, IsoFs increased 5-fold. 
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To date eight regioisomers of IsoFs have been identified from which 256 
enantiomerically pure IsoFs can be formed (Fessel et al., 2002). An IsoF-type compound has 
been identified as an enzymatic oxidation product of arachidonic acid and has been synthesized 
in the lab (Pace-Asciak, 1971; Bild et al., 1978; Just and Oh, 1981). 
In order to provide clarity, standard rules for chemical nomenclature have been applied 
and conform to prostaglandin conventions.  Isofurans are abbreviated to IsoFs, consistent with 
their biosynthetic relative the IsoPs. The IsoFs have been divided into eight classes based on the 
position of the isofuran ring and the alkene of the allylic alcohol. Consistent with prostaglandin 
standards, the C-1 will always be the carboxylate carbon; the number of the first carbon of the 
ring then will denote the position of the isofuran. Consistent with organic natural-product 
nomenclature, the position of the alkene of the allylic alcohol is represented by the ∆ symbol 
followed by a superscripted number of the first carbon of the alkene. Eight families of IsoFs are 
recognized. These families are further subdivided and differentiated based on two considerations: 
the relationship of the alkyl groups of the tetrahydrofuran ring (syn vs. anti), and the relationship 
of the ring hydroxyl to the adjacent alkyl group (cis vs. trans) resulting in 32 differentiated 
subgroups, each comprised of eight enantiomerically –pure diastereomers. 
F2-IsoPs and IsoFs can be quantified in a variety of human and animal fluids and tissues. 
The detection and measurement of these molecules in plasma and urine demonstrate global 
oxidative stress in vivo while quantification of F2-IsoPs and IsoFs in a tissue sample or in a 
specific fluid such as exhaled breath condensate represents local, organ-specific oxidative stress. 
Currently the only methodology used to detect and quantify isofurans is the GC/MS. A 
“standard” per se is not available but rather the retention times generated from the oxidation of 
arachidonic acid are considered consistent with the presence of isofuran (Roberts & Fessel, 
2004). 
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Exhaled Breath Condensate 
It is a goal of the healthcare community to discover safe and effective methods of 
assessing for the presence and/or severity of disease processes with the least amount of risk and 
discomfort to the patient.  For those with debilitating respiratory diseases, traditional means of 
collecting tissue samples could exacerbate distress states. The advent of exhaled breath analysis 
has opened the door to a safe, effective and non-invasive analysis of some significant disease 
states. 
Exhaled breath is the air exhaled from the lungs and consists primarily of water vapor 
with particles of aerosolized airway-lining fluid (ALF). Aerosolized airway-lining fluid is 
comprised of volatile and non-volatile compounds. Many of these compounds can be indicative 
of a variety of physiologic or pathologic process occurring within the body.  
The concept of evaluating exhaled breath dates back to 400 B.C. when Hippocrates, the 
“father of medicine” described fetor oris and fetor hepaticus as a symptoms of disease states 
(Duveen and Klickstein, 1955). In the mid 1800’s, Nebelthau determined the presence of acetone 
in the breath of diabetics (Hubbard, 1920). In 1874, Francis Anstie, an English physician, spent a 
significant portion of his career trying to better understand the effects of alcohol on the body. As 
such he was the first to demonstrate that alcohol could be collected into a rubber football bladder 
from the exhaled breath of one whom had been imbibing.  
In 1927, Dr. Emily Bogen, a practicing physician in Los Angeles during the time of 
Prohibition felt compelled to accurately diagnose the presence of alcohol in those persons 
involved in car collisions, which were on the rise at that time, to avoid wrongfully accusing and 
punishing the innocent. As a result, she developed a breath-collecting device, similar to Dr. 
Anstie’s, to measure the presence and degree of alcohol for those persons involved in car 
accidents (Bogen, 1927). During that same year in Chicago, Illinois, McNalley, a coroner-
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chemist, invented a breathalizer that evaluated changes in color of air moving through chemicals 
in water (Popular Science, 1927).  
In 1938 Dr. Rolla Harger, a professor of biochemistry and toxicology at Indiana 
University, developed the Drunkometer, considered the first roadside breath-testing device to be 
used by police. The exhaled breath would pass over and interact with potassium permanganate 
resulting in a color change. The degree of color change was directly related to the degree of 
intoxication. In 1954 Robert Borkenstein, an Indiana police captain, was credited with 
developing a more practical and portable device that does not require recalibration, allowing for 
ease of use.   
In the1970’s Linus Pauling opened wide the field of breath analysis when he 
demonstrated over 250 identifiable substances in exhaled breath via a gas-liquid partition 
chromoatgraphy mass spectrometry (Dweik and Amann, 2008; Corradi and Mutti, 2012). Over 
80 organic compounds have been identified as directly related to just smoking (Fillpiak, 2012). 
Chromatography and spectrometry expanding the exploration of exhaled breath for detection and 
measurement of compounds and the subsequent development of exhaled breath collection 
devices and assays. As a result of an ongoing evolution of this technology over 5000 compounds 
can be measured in exhaled breath to date. 
Although it had been established for centuries that chemical evidence exists, and is 
measurable, in exhaled breath and that exhaled breath is the greatest source of insensible water 
loss, the use of EBC to assess for physiologic and pathologic processes did not occur until 1980 
when researchers from the former Soviet Union began to publish reports of its use. Sidorenko et 
al (1980) published an article entitled Surface-active properties of the exhaled air condensate, a 
new method of studying lung function. However, it would be well into the 90’s before the United 
States would begin to explore the value of EBC. 
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Collection of exhaled breath condensate is a non-invasive method of collecting 
aerosolized air particles from the lungs in order to assess for the presence of ongoing pathology.  
EBC contains a variety of biomarkers including hydrogen peroxide, ammonia, leukotrienes, 
nitrogen oxides, peptides, cytokines, isoprostanes and isofurans that represent such processes as 
airway and lung redox pathology, acid-base imbalances, degree and type of inflammation in 
acute and chronic asthma, COPD, adult respiratory distress syndrome, occupational disease, 
cancers and cystic fibrosis (Hunt 2002; Horvath et al, 2009). 
Respiratory diseases as well as the prescribed therapeutic regimens influence the degree 
of biomarker concentration obtained (Horvath 2005). While precise assessment of individual 
solute concentrations cannot be made it can provide useful information when concentrations 
differ between health and disease states (Hunt 2007). 
EBC collection devices. Several commercially available collection devices have been 
developed to procure the exhaled breath condensate for biomarker analysis; however, the 
concepts of obtaining a collectate are the same amongst them. The exhaled air passes through a 
condensing unit resulting in the accumulation of fluid, or condensate. Care to avoid salivary 
contamination should be always be taken. Approximately 1-3 milliliters of collectate are required 
to guarantee ability to assay in duplicate or triplicate.  In general it requires ~10-15 minutes of 
tidal breathing to acquire this volume. During normal tidal breathing the levels of aerosolized 
particles ranges between 0.1-0.4 particles/cm3 with a mean diameter of 0.3µm. The amount of 
aerosolized particles from the respiratory tract is dependent upon airway velocity and surface 
tension within the extracellular lining fluid (Mutlu et al., 2001).  
The most widely used EBC collection devices utilized in the United States are the 
EcoScreen® and the RTube™. Both devices collect exhaled breath through tidal breathing into a 
mouthpiece where the exhalant is guided into a cooling chamber for condensation. The 
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EcoScreen® is a large nonportable device that requires access to an electrical outlet to operate 
the cooling chamber. The EcoScreen® requires 30 minutes to reach the cooling standard, in 
between patient cleaning of the mouthpiece and condensing chamber, accessing the cooling 
chamber (oftentimes requires some thawing for removal from chamber), and seven minutes for 
sample collection. The RTube™ does not require cleaning of its parts as the device is single use 
and disposable; multiple samples can be obtained with single patient use and issues with thawing 
sample for storage are not encountered. While the EcoScreen® is better able to maintain a 
constant temperature than the RTube™ the portability and ease of use of the RTube™ makes this 
device extremely advantageous. These features make the RTube™ the device of choice for this 
research project.  
Concerns, such has condensing temperatures and adherence to the collection unit wall, 
have been raised regarding factors introduced by the collection devices that may alter the 
composition and, therefore, measurability of biomarkers in the condensate. In a study by Czebe 
et al (2008) three condensing units were evaluated to determine the efficacy of the EcoScreen®, 
RTube™ and Anacon condensers as well as to test the influence of condensing temperature. The 
results of this research effort demonstrated that condenser type influences sample pH, total 
protein and leukotriene concentrations with the samples from the EcoScreen® being more 
alkaline and contained more protein while the RTube™ and Anacon correlated with regard to 
condensing temperature affects on pH but not protein content. The researchers concluded that 
adherence of the biomarkers to condenser surface and condensing temperature may play a role in 
biomarker variability.  
Montuschi (2007) evaluated the EcoScreen®, EcoScreen II®, and the RTube™ with 
regard to methodological differences. Each poses benefits and limitations. The EcoScreen® and 
EcoScreen II® are able to maintain temperatures to preserve the sample until analysis can occur. 
  80 
The EcoScreen® offers an added benefit of respiratory parameters measurability. The 
EcoScreen® II has the ability to collect EBC derived from the airways or the alveoli at the same 
time. This may allow for the study the origin of biomarkers in the lung compartments.  
The RTube™ offers the advantage of portability making collection possible nearly 
anywhere; the device also prevents salivary contamination (Hunt, 2002) and has a condensing 
sleeve that can be cooled to any temperature. Limitations of the process of using this device 
include maintaining temperature during storage and travel; for those compounds that are 
chemically unstable this can present a problem.  
Exhaled breath condensate pH is typically low in patients with a variety of diseases 
inducing airway inflammation, such as cystic fibrosis, COPD, asthma, etc., (Dupont et al, 2006; 
Hunt et al, 2000; Borrill et al., 2005; Ojoo et al., 2005). In a comparative study performed by 
Koczulla et al., 2009, in which results were repeated on two different days comparing the 
EcoScreen® and the RTube™ for pH analysis results showed no significant differences 
(P=0.754). The results of the study demonstrated repeatability and reproducibility in healthy 
controls, COPD and asthma patients as well as subjects experiencing a common cold. In a 
similar study by Prieto et al, 2007, significantly higher pH values in EBC were noted when 
obtained with the RTube™ compared to the EcoScreen®. 
Rosias et al (2006) evaluated condensers to determine if the properties of the condensing 
units interacted with eicosanoids and proteins resulting in values that were at the lower limits of 
detection. Albumin and 8-IsoP were evaluated for adherence to five different condensing unit 
coatings: silicone, glass, aluminum, polypropylene and Teflon. Results of this study showed that 
in vitro silicone and glass coatings yielded a higher recovery of both albumin and 8-IsoP. In vivo 
the same was true for 8-IsoP with regard to silicone and glass while albumin was only detectable 
in glass. 
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According to a follow up study by Rosias et al, (2008) on biomarker reproducibility in 
EBC, an optimized glass condenser provided more EBC volume and biomarker detection; 
however, biomarker reproducibility in the EBC of healthy adults was not influenced by 
condenser type (glass, silicone, EcoScreen® or optimized glass).  With regard to bioactive lipids 
it has been demonstrated that polypropylene condensers should be considered to avoid the 
concern of absorption that can occur with others (Mutlu, et al., 2001). 
In a letter to the editors, Sapey et al, (2008) provided five challenges to the interpretation 
of the findings in the 2008 Rosias study.  Sapey and colleagues questioned the validity of basing 
the coefficient of variation (CV) on the mean of spiked samples stating such methods artificially 
lowers the CV and, therefore, does not provide a true representation of the inherent variability of 
measuring mediators near the lower levels of detection of said assay. Secondly, they contend that 
the use of CV is not always the ideal way to express variability stating, “When mean values are 
low, CV values can be abnormally high.” Thirdly, the Rosias study stated a “matrix effect is seen 
when samples are spiked with 10 pg/ml of mediator but not at 100 pg/ml; Sapey and colleagues 
contend that spikes of these concentrations would mask a matrix effect. Fourthly, they did not 
find it sensible to address other sources of variability when the assay itself has high variability; 
and finally, Sapey and colleagues took issue with the lack of definition of a lower limit of 
quantification for any assay as they believe that the lower limit of quantification is central to the 
measurement of mediators as well as adhering to strict methodologies as it pertains to a given 
biomarker.  
Standard for assessing alveolar lining. Historically, pathologic processes occurring 
within the lower respiratory tract were evaluated by invasive methods such as bronchoalvealor 
lavage (BAL), sputum induction and bronchoscopy. Bronchoscopy is used to visualize the 
proximal and distal airways; to control alveolar hemorrhage; sampling of fluids; collecting 
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tissues through biopsy; identifying tumors; exploring lesions; investigating hilar lesions; 
assessing mechanical difficulties; inspecting the nasopharynx and larynx; and removal of foreign 
bodies, etc., (Stocks, et al., 2005). The BAL requires the instillation of saline into the smaller 
airways to collect ALF for assessment. The invasive nature of these maneuvers typically requires 
sedation and, though rare, carries the risk of hypoxia, dysrhythmias, pneumothorax, bleeding, 
infection, bronchospasm, laryngospasm, fever and even death (Zimmerman and Klein, 1997; 
Morrow and Agent, 2001). The advent of exhaled breath collection allows for non-invasive 
sampling making these ideal collection devices in a fragile patient subset (Montuschi, 2007). No 
research supports any such risks to patients utilizing exhaled breath condensing devices.  
 Comparing EBC biomarker concentrations to established techniques, such as BAL, could 
be useful in establishing standards and interpreting results. However, to date few studies exist 
that compare the two collection media. Interpreting BAL has its own limitations, such as the 
large range of normal values for each substance being measured resulting in a lack of sensitivity 
in detecting disease. Additionally, abnormalities detected in BAL fluid are rarely related to a 
specific interstitial lung disease.  The BAL is fraught with false positive and negative results. 
The actual technique utilized to collect BAL may result in tissue damage confounding the results 
of the collectate (Leroy et al., 2008).  
 In a study by Jackson et al. (2007) 48 subjects participated in a study to compare EBC 
values to BAL values for 8-IsoP, nitrogen oxides, pH, hydrogen peroxide, total protein, 
phospholipids and keratin. The results demonstrated significantly higher concentrations of 8-
IsoP, nitrogen oxides and higher pH (P<0.001) in EBC. No difference was demonstrated 
between EBC and BAL with regard to hydrogen peroxide concentration. Total protein was noted 
to be significantly higher in BAL (P<0.001). Phospholipids were also higher in EBC, but no 
significance for keratin was detected. No significant correlation was noted between EBC and 
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BAL for any of the biomarkers listed. However, in a study by Piotrowski et al, (2007), a positive 
correlation (r=0.68) was demonstrated between BAL and EBC 8-isoprostane and LTB4. 
 In that same year Piotrowski et al, evaluated 28 patients diagnosed with sarcoidosis and 
compared the results to a control of 17 healthy subjects. Enzyme-linked immunoassay with 
utilized to detect 8-IsoPs in EBC and BAL, as well as a cell count, percentage, and number and 
activity of cells. Results demonstrated a significant elevation of 8-IsoP in the EBC of the 
sarcoidosis group and a positive correlation between EBC and BAL media (r = 0.68, P<0.0001) 
with regard to EBC 8-IsoPs and BAL CysLT may support a possible prognostic value. 
Methodological considerations for EBC collection. In 2005 the American Thoracic 
Society (ATS) and European Respiratory Society (ERS) Task force on EBC convened to develop 
guidelines for the collection and measurement of exhaled biomarkers. Since that time several 
reports (Grob, et al., (2008); Davis, et al., (2012); and Rosias, 2012) have been published, 
however, with little to add to the original report. Due to the inherent nature of the biomarker 
molecule being assessed, the varying storage practices and the specimen assessment tool (assays 
vs mass spectrometry) a singular methodology for EBC collection and biomarker detection has 
been elusive. Provided below are areas considered to have potential influence on the collection, 
maintenance, concentration and detection of biomarkers in exhaled breath. 
Duration and temperature of condensate collection. Generally, 10 minutes of tidal 
breathing will produce 1-3 mL of EBC. Considerations may need to be made for individuals with 
shortness of breath and fatigue easily. According to the report, no differences could be 
determined in biomarker concentrations of H2O2, nitrite/nitrate, 8-isoprostane, adenosine and 
MDA in studies utilizing 10, 15 or 20 minute collection periods for EBC sampling.   
Gessner et al, (2001) demonstrated that not only was EBC volume linearly related to the 
volume expired, but also to the total protein and urea content. This finding suggests that these 
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accumulated in the collection device by a similar mechanism as expired water vapor, but is not 
necessarily accurate for all substances present. Therefore, Gessner and colleagues suggest that 
maybe a volume target should be the goal rather than an amount of time. 
Condensation is best achieved when breathing into a cooled collection device. Note 
should be taken that the act of breathing through a device will inherently increase its 
temperature. The solubility of volatile mediators may be influenced by temperature. Collection 
temperatures should be maintained and recorded.  
Ambient air. Ambient air may contain molecules that may influence EBC composition 
through the following mechanisms: 1) directly contribute to EBC levels; 2) react and, therefore, 
change or consume molecules trapped in EBC; and 3) lead to inflammatory and biochemical 
changes in the airway that are reflected in EBC composition.  
Breathing pattern. When assessing for mediators in individuals with respiratory disease, 
breathing patterns were considered. According to the ATS/ERS Task Force “breathing pattern” 
differences did not contribute to significant differences in mediator levels. However, in a report 
by Montuschi (2007) flow dependence maybe an indicator of where biomarkers originate, in the 
airways or the alveoli. Concentrations of EBC biomolecules dependent upon expiratory flow 
rates are believed to originate from the airways (Schleiss, et al., 2000). In contrast, the lack of 
flow dependence would indicate that a biomolecule is mainly derived from the alveolar region 
where flow has a minor role (Schleiss, 2000). Hydrogen peroxide is flow rate dependent 
(Schleiss, et al, 2000) whereas 8-isoprostane would primarily be detected from activity in the 
alveoli (Montuschi, et al., 2003; Carpenter, et al., 1998). 
 Airway health and lung function. Exhaled breath condensate volume does not depend on 
lung function parameters including FEV1 and FVC in either normal subjects or in those 
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diagnosed with COPD. Currently there is no supporting evidence that changes in airway health 
cause any difference in mediator release or dilution of EBC.  
Age, gender, height and weight. The largest amount of information available on 
biomarkers that affect the EBC is on H2O2.  This mediator does not seem to be age dependent in 
children but does express higher concentrations in older than younger adults. This is likely 
attributable to senescence as well as any pathology. Body height and weight do not seem to have 
a relationship to EBC volume and H2O2; however, it is recommended that further research be 
conducted using other biomarkers. A study performed by Basu, et al, (2009) performed in three 
countries, Sweden, Poland and Italy, it was demonstrated a slight increased in isoprostane 
production in men when compared to women. No studies were identified that linked height and 
weight to changes in biomarker associated with lipid peroxidation.  
Food and drink. To date there is no established data that links volatile mediator 
concentrations to food and/or drink consumption. However, no systematic studies have been 
performed. For the purposes of this study those individuals who ingest antioxidant supplements 
will be blocked when performing statistical analyses. 
 Circadian rhythm. Time of day appears to be relevant for H2O2 in the EBC of normal 
subjects and those with COPD. Further research studies are recommended to determine if this 
translates to biomarkers consistent with lipid peroxidation.  
 Tobacco smoking. Information regarding smoking is only available on cigarette smoking, 
not pipe, cigar or e-cigarette smoking. The effects of EBC biomarkers regarding the absence or 
presence of a filter, or specific brands have not been evaluated. Both acute and chronic smoking 
causes increases in H2O2, isoprostane, nitrate and nitrotyrosin levels, as well as increases in 
chemotactic activity.  In patients with COPD, no difference was observed in the mean EBC 
H2O2 and 8-isoprostant levels between smokers and non-smokers (Horvath, 2005).  The 
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ATS/ERS recommend study participants refrain from smoking for at least three hours prior to 
EBC analysis. Studies on the influence of continued smoking in the presence of diagnosed 
COPD do not demonstrate significant increases 8-isoprostane levels following acute smoking 
consumption (Montuschi, et al., 2000). 
Systemic disease. The Task Force deems it important to consider the potential effect of 
systemic diseases, including extrapulmonary diseases, with regard to EBC mediators. In the 
report prepared by Horvath (2005) it was stated that 20-fold increases in EBC H2O2 levels were 
detected in uremic patients.  
Current research suggests the synthesis of isofuran occurs during periods of increased 
cellular oxygen concentrations. Clearly this occurs as a result of delivery of supplemental oxygen 
therapy, but also can occur as a result of pathology that damages the mitochondria. In a report by 
Fessel et al, (2004) it was demonstrated that mice exposed to 100% oxygen conditions esterified 
isofurans were detected in the lungs, whereas isoprostane levels remained the same. It is 
theorized that diseases with mitochondrial dysfunction cellular tensions of oxygen increase due 
to the diminished capacity of the mitochondria to consume oxygen. This notion bore out in a 
study that discovered that isofurans, but not isoprostanes, are significantly increased in the 
substantia nigra in brains from patients with Parkinson’s and Lewey body disease (Fessel et al, 
2003).  Other mitochondrial/neurodegenerative diseases that should be considered would include 
Alzheimer’s, amyotrophic lateral sclerosis, and Huntington’s disease.  
The origin of biomarker synthesis remains a confounding variable in EBC research. 
Further research is recommended in this area. Developing methodologies that tightly address this 
conundrum are recommended. For purposes of this study all systemic diseases will be recorded. 
 Salivary contamination. Saliva contains many of the mediators present in lower airways. 
Care needs to be taken to avoid sample contamination. Many devices include a saliva trap to 
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control for this confounding phenomenon. The RTube™ offers a saliva trap and is the device 
selected for this project. Many studies have been conducted regarding potential of sample 
contamination to which the inclusion of a saliva trap has all but eliminated the concern. 
Medications. While no study was identified addressing a relationship between steroid use 
and biomarker suppression the use of steroids will be noted for subjects participating in this 
study. Asthmatic patients have been a specific population used to address the potential of 
influence of ingested or inhaled steroids on 8-isoprostane production. Several studies 
demonstrate that despite treatment with oral or high doses of inhaled glucocorticoids patient with 
severe asthma have the highest concentrations of 8-isoprostane in EBC, indicating that this 
marker is relatively resistant to glucocorticoids, inhaled or ingested (Montuschi et al., 1999). 
Kostikas et al, (2002) reported a similar finding when comparing steroid naïve patients to those 
receiving inhaled doses. A study by Antczak et al, (2001) aspirin-tolerant asthma demonstrated 
in increase in 8-isoprostane following treatment of inhaled glucocorticoids. This finding 
demonstrates the possibility of a phenotype influence on biomarker response.  The use of 
antioxidant supplements will be recorded; however, a study by Green and McElvaney (2009) the 
use of a variety of antioxidant therapies, none of which resulted in a reduction of exhaled 8-
isoprostane.  A history of bleomycin therapy will not result in exclusion from study even though 
it has inherent consequences to the lungs. The lack of research does not preclude the possibility 
of influence on biomarker production and therefore will be addressed during statistical testing. 
Condensate storage. Some mediators, such as H2O2, are unstable at room temperature 
and therefore require immediate frozen storage. However, the isoprostanes are stable and less 
vulnerable to issues of timing. However, for purposes of this study samples will be immediately 
placed on dry ice in a cooler with a goal of -70°C. 
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8-isoprostane. The 8-isoprostane biomolecule is considered stable in exhaled breath 
condensate. Sample reproducibility is achieved with enzyme-linked kits with detection limits of 
3.9 pg-ml. The assay was validated directly by gas chromatography/mass-spectrometry 
demonstrating a high correlation between added known amounts of the biomarker. GC/MS is 
considered the most sensitive method of detection and quantification of 8-isoprostane (Maloney 
et al, 2005). Disease states that influence 8-isoprostane concentrations in EBC are asthma, 
ARDS, pulmonary sarcoidosis, obstructive sleep apnea, cystic fibrosis, as well as healthy adults 
following exposure to ozone-inhalation (Horvath, 2005).  
 Isofuran. Isofuran is a biosynthetic relative of the isoprostane. It has been detected and 
quantified in blood, urine, plasma, CSF and exhaled breath condensate. Currently the GC/MS 
has been the only method utilized to detect and quantify its presence.  
 Safety concerns. The collection device utilized in this study will be the RTube™, a 
disposable device, which will eliminate any concern of contamination from one subject to the 
next. There are no reported risks associated with use of the device. 
Content and compounds in EBC. Depending on the existing pathology respective 
compounds can be present within the alveoli when collected by a variety of collection devices 
made of glass, polystyrene, or polypropylene (see Table 3) (Mutlu et al., 2001). Compounds 
within EBC are detected and measured via liquid/gas chromatography and are most commonly 
quantified via mass spectrometry or enzyme-linked immunoassays. EBC does not currently 
represent all of the compounds detected in ALF; however, as assays or tools of measurement 
become more sensitive and a better understanding of the ionic composition of lung lining is 
gained this non-invasive test could prove invaluable (Hunt 2002). 
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Table 3  
Compounds found in EBC 
Pathology Compound 
Cigarette Smoking H2O2, 8-Isoprostane 
COPD H2O2, 8-Isoprostane, serotonin, cytokines (IL-1, sIL-
2R, TNF-α 
Asthma H2O2, 8-Isoprostane, nitrotyrosine thiobarbituric acid-
reactive products, leukotrienes, pH 
Chronic bronchitis Leukotrienes 
Bronchiectasis H2O2 
Cystic Fibrosis H2O2, nitrite, 8-Isoprostane, IL-8 
ALI/ARDS H2O2, 8-Isoprostane, PGE3 
 
EBC Measurement 
 Several methods are used to measure the presence of compounds within exhaled breath 
condensate, to include gas or liquid chromatography, mass spectrometry, and enzyme-linked 
immunoassays. 
An assay is “the analysis of a substance or mixture to determine its constituents or their 
level” (Webster online dictionary, 2013). Specific assays have been developed to detect and 
quantify the presence of target compounds within a mixture. Due to the inherent reactivity of 
biological assays, chemical analysis can become complex creating a challenge for controlling 
variability. This unpredictability can create challenges when interpreting the data. As such, care 
and attention must be given during testing so that variance is avoided. 
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Reproducibility of EBC Collection Methods 
 A method is considered reliable when the results are reproducible. In a study by van 
Beurden et al, (2002) 20 stable COPD patients breathed into a condensing device twice for a 
period of 10 minutes each time. Hydrogen peroxide was measured following collection and then 
again after freezing at -70° C for a period of 10, 20 and 40 days. The study concluded that the 
exhaled air volume and condensate volumes were strongly correlated with reproducible H2O2 
even on samples stored for 40 days.  
 In a pilot study performed by Hoffmeyer et al, (2007) the methodology of EBC sampling 
and processing was evaluated to measure field assessments. Sixteen healthy adults were 
evaluated for four days over two consecutive weeks to determine the effects of sample collection 
(time vs. volume, with vs. without nose clip) and sample processing on volume, pH, NO, and 
LTB4. Within-day, between-day, and between-week reproducibility were assessed. Results 
demonstrated that no significant differences existed with utilization of a nose clip; storage at 4-
6°C for 24 hours had not significant effects on NO and LTB4 concentrations but did result in 
increases in pH.  The study result demonstrated “good” within and between-day reproducibility; 
however, between-week showed elevated results on the Mondays of each week. 
Compound Detection and Measurement  
 Enzyme-linked immunosorbant assay (ELISA). The enzyme-linked immunosorbant 
assay (ELISA) is a type of assay that allows for the detection of a substance in a liquid or wet 
sample (Lequin, 2005). Perlmann and Engvall of Sweden developed the ELISA technique in 
1971. The ELISA evolved from the radioactive-immunoassay (RIA) developed by Berson and 
Yalow in 1960 when evaluating endogenous plasma insulin. Radioactive labeling became very 
popular; however, growing concern of personnel over-exposure to radioactive materials, as well 
as the need to build and maintain safe appropriate laboratories and waste management, prompted 
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change. Initially, weaker radioactive iodine, iodine-125, was developed to address these 
concerns. However, the European RadioimmunoAssay Club (ERIAC) held meetings in the 
1970’s to approach the issue; it was during this time that the idea of using enzyme labels was 
born. Skepticism of how such a large and bulky molecule could attach to an antigen or antibody 
without sterically impeding the necessary chemical reaction was addressed through careful 
planning and execution of experiments. In 1971 Pearlman and Engvall published their first paper 
utilizing the ELISA by measuring rabbit serum IgG with alkaline phosphatase as the biomarker 
label.  
 Essentially, all microbial species have at least one antigen that is unique. As a result these 
antigens can be purified and used to produce specific monoclonal antibodies. Both the antibodies 
and the purified antigens can then be used as a diagnostic tool. The ELISA is such a diagnostic 
tool. There are two forms of this assay: 1) the direct ELISA uses monocolonal antibodies to 
detect the presence of a specific antigen in a sample; and 2) the indirect ELISA is used to 
determine the presence of a specific antibody in a sample. 
 Concerns expressed by Il’yasova et al, regarding the use of ELISA when quantifying 
isoprostanes is the cross-reactivity of the polyclonal antibodies used to bind with the IsoPs will 
bind to other similar molecules resulting in a potentially inflated quantification. They also 
purport that other biological impurities in the sample can interfere with antibody binding with the 
ELISA analysis, which impacts specificity, etc.    
 Mass spectrometry. Mass spectrometry (MS) is a technique that measures the mass-to-
charge ratio of charged particles by separating them according to their masses. This technique is 
used to determine the masses of particles, the elemental composition of a sample or molecule, as 
well as revealing the chemical structures of molecules achieved by ionizing chemical compounds 
to generate charged molecules, ultimately resulting in mass-to-charge ratios. A mass 
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spectrometer consists of three modules: an ion source, a mass analyzer and a detector. The ion 
source converts gas phase molecules into ions. The mass analyzer sorts the ions by their masses 
through the use of an electromagnetic field. The detector measures the value of an indicator 
quality providing the raw data for calculating amounts of each ion present.  
Mass spectrometry generally follows the following steps: 
1. Loading a sample into the MS to undergo vaporization 
2. Sample ionization through electron beam impaction 
3. Ion separation by electromagnetic fields 
4. Ion detection 
5. Ion signal processing through mass spectra 
 A mass spectrometer has both qualitative and quantitative capabilities, such as identifying 
unknown compounds, determining the isotopic composition of elements in a molecule, 
determining the structure of a compound, quantifying the amount of a compound in a sample or 
studying the fundamentals of gas phase ion chemistry (Sparkman, 2000).  
 Chromatography. Chromatography is a method of physically separating mixtures for 
the purpose of identifying compounds and is achieved through two phases: mobile and 
stationary. The mobile phase consists of dissolving the sample mixture into a fluid. The resulting 
solution is then delivered into a holding structure with another predetermined mixture and 
becomes fixed in place, or the stationary phase.  The compounds within the mobile mixture 
travel at varying speeds depending on their inherent properties, causing a separation. Differential 
partitioning of the compounds occurs between the mobile and the stationary phase, resulting in 
measurability of the compounds present in the mixture. Chromatography can either be used as a 
purification process for further analysis or for the analysis of smaller amounts of material to 
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determine relative proportions of analytes. Chromatography techniques include gas and liquid 
media.  
 Many techniques of chromatography can be employed to achieve separation, such as 
displacement, planar, paper, and thin layer chromatography.  There is also column 
chromatography in which the stationary bed is within a tube or column. Sample identification is 
determined by the interaction/retention times occurring between the particles of the mobile phase 
and the content lining the column. Chromatography that employs techniques by physical state of 
mobile phase is called gas-liquid chromatography (GLC). Gas chromatography (GC) is based on 
a partition-equilibrium of an analyte between a solid stationary phase and a mobile gas phase. 
Liquid chromatography (LC) is a separation technique in which the mobile phase is a liquid 
rather than a gas.  
High performance liquid chromatography. High performance liquid chromatography 
(HPLC) is an improved form of column chromatography. Rather than a mobile phase solvent 
dripping through a column under gravity the HPLC utilizes high pressure, up to 400 
atmospheres, resulting in a much faster process. The HPLC also utilizes much smaller particle 
sizes for the column packing material giving it a much larger surface area for interaction between 
the stationary phase and the mobile phase for enhanced separation of the components of the 
mixture. The methods employed by the HPLC are highly automated and extremely sensitive. 
Measurable compounds include amino acids, proteins, nucleic acids, hydrocarbons, 
carbohydrates, drugs, terpenoids, pesticides, antibiotics, steroids, metal-organic species, as well 
as a variety of inorganic substances.  
Gas chromatography. Gas chromatography is an instrument used to separate chemicals 
in a complex sample for the purposes of identification and quantification. Often the gas 
chromatograph is used in conjunction with mass spectrometry to achieve a much finer degree of 
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substance identification than can be achieved when used in isolation. Using these techniques in 
tandem reduces the likelihood of error, as it is very unlikely that two different molecules will 
behave in the same manner in both a gas chromatograph and a mass spectrometer. 
Gas chromatographic techniques vaporize liquid samples as a means of separating them 
based on boiling points. Vaporization of the compound can occur without inciting decomposition 
of the compound. Typical uses of GC include testing the purity of a particular substance, or 
separating the different components of a mixture. In some situations GC can be used to identify a 
compound. 
 Gas chromatography is principally similar to column chromatography and HPLC with 
some notable differences. Separation of compounds is carried out between a liquid stationary 
phase and a gas mobile phase, rather than a solid stationary phase and liquid mobile phase used 
with column and HPLC techniques. The column through which a gas travels is located in an 
oven where the temperature of the gas can be controlled. GC uses the boiling points of 
compounds as a means of detecting their presence and identification. 
 Gas chromatography analysis requires a predetermined volume of analyte be injected into 
the entrance of a column. As the carrier sweeps the analyte through the column movement is 
inhibited by the adsorption of the analyte molecules by either the column walls or the packing 
materials. The rate of movement along the column is dependent upon the strength of adsorption. 
The total time it takes to travel the length of the column is referred to as the retention time. A 
detector is located at the distal end of the column and measures the outlet stream from the 
column. The time it takes each component to teach the outline and the concentration of that 
component can be determined. Substances are generally identified in the order they elute from 
the column and by the retention time of the analyte in the column. 
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 For purposes of this study only gas chromatography-mass spectrometry will be 
addressed, as this will be the technique employed to detect and quantify isofurans in exhaled 
breath condensate. 
Physical components. The following are specific components are required to carry out 
the individual functions of gas chromatography and mass spectrometry. 
Autosamplers: to introduce a sample automatically into the inlet of the analyzer. Automatic, 
rather than manual, insertion enhances reproducibility and maximizes time. 
Inlets: provides the means to introduce a sample into a continuous flow of carrier gas.  
Detectors: component responsible for detecting the presence of the desired compound. The most 
commonly used detectors are the flame ionization detector (EID) and the thermal conductivity 
detector (TCD). Both are considered sensitive to a wide range of components, and both work 
over a wide range of concentrations.  
Chromatogram: A detector responds to the presence of an analyte placed at the end of the 
column, the signal is plotted as a function of time (or of volume of the added mobile phase), and 
a series of peaks is obtained and plotted. This is referred to as a chromatogram. The position of 
peaks on the time axis may serve to identify the components of the sample; the areas under the 
peak provide a quantitative measure of the amount of each component. Once the analyte is 
injected into the system the time it takes to peak once it reaches the detector is referred to as the 
retention time.  
Individual analyte particles during migration through the column will undergo thousands 
of transfers between the mobile and stationary phases. The amount of time spent in either phase 
is initially highly irregular and depends upon the thermal energy gained during the process to 
reverse the transfer. The residence time spent in each phase may be transitory or long. The 
particle is only eluted during the mobile phase contributing to irregular migration times. The 
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consequence of random individual processes is a symmetric spread of velocities around the mean 
value, which represents the behavior of the average and most common particle. The breadth of a 
band (time phenomenon) increases as it moves down the column due to the time allowed for 
spreading to occur. As a result the zone breadth is directly related to the residence time in the 
column and inversely related to the velocity at which the mobile phase flows.  
Experiments must occur to enhance separation and improve particle resolution. Chromatographic 
separation is optimized once the components of a mixture are separated cleanly with minimum 
expenditure. Optimization experiments are aimed at either reducing zone broadening or altering 
relative migration rates of the components.  Column resolution is a quantitative measure of the 
columns ability to separate two analytes. Quantitative analysis is the comparison of either the 
height or the area of the analyte peak with that of one or more standards. Analysis based on peak 
height can be achieved by connecting the base lines, on either side of the peak, with a straight 
line then measuring the perpendicular distance from this line to the peak. Peak heights are 
inversely related to peak widths. Therefore, accurate peak heights are only accurate if variations 
in column conditions do not alter the peak widths during the period required to obtain 
chromatograms for sample and standards. Variables that must be closely controlled for are 
column temperature, eluent flow rate, and the rate of sample injection. The effect of sample 
injection rate is particularly critical for early peaks of a chromatogram. Analysis based on peak 
areas are not affected by column temperature, eluent flow rate, or the rate of injection and, as a 
result, are a more satisfactory analytical parameter than peak heights.  
Calibration occurs through the preparation of standards for comparison. Chromatograms 
for the standards are then obtained and peak heights or peak areas are plotted as a function of 
concentration. The major source of error in this process is the uncertainty of the sample volume 
and can be the rate of injection. The volumes for this process are small (~1µL); uncertainties 
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related to the injection of a reproducible volume of this size with a microsyringe may amount to 
several percent relative. This issue can be handled through the use of a rotate sample valve.  
The utilization of internal standards enhances precision. With this process, a carefully 
measured quantity of an internal substance is introduced into each standard and sample, and the 
ration of analyte to internal standard peak areas or heights serves as the analytical parameter. 
However, in order for this method to be successful it is imperative that the internal standard peak 
be well separated from the peaks of all other components of the sample. The standard peak 
should be close to the analyte peak. A suitable internal standard will yield precisions better than 
1% relative. 
There are over 5000 identifiable substances in exhaled breath. As a result, the 
combination of gas chromatography and mass spectrometry provide an ideal mechanism for 
detection and quantification of IsoP’s and IsoF’s in exhaled breath. For purposes of this study 
GC/MS methodology will be discussed for the detection and quantification of isofuran. 
Method development. Currently there are no commercially available kits or standards 
for the measurement of isofurans. The labs at Vanderbilt University have developed and retain 
exclusive right to the process of detecting and quantifying the presence of isofuran. Since this 
research study is questioning the potential of chronic exposure to supraatmospheric 
concentrations of oxygen in inducing oxidative stress, isofuran is the only appropriate biomarker 
identified to answer that question. Therefore, Vanderbilt University labs will be employed to 
analyze the exhaled breath condensate collected for this study.   
Data Analysis 
The objective of this study is to determine if LFDO as a treatment modality in COPD 
superimposes oxidative lung damage. The specific aims of this study are 1) assess for isofuran in 
the EBC of COPD patients on LFDO; 2) determine if a correlation exists between standard 
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diagnostic spirometry (FEV1/FVC ratio) and exhaled breath condensate (EBC) biomarker 
(isofuran); 3) determine if relationships exist between age, gender, height, weight, length of 
smoking history, length and concentration of oxygen exposure and EBC biomarkers (isofuran 
levels). 
Following a data collection period necessary to achieve an adequately powered sample 
statistical analyses utilizing a Student’s t-test will be utilized to assess mean differences in 
exhaled isofuran levels between the active control and active treatment groups. Significant mean 
differences in isofuran levels between the groups will begin to address the potential of chronic 
exposure to low flows of domiciliary oxygen as a mechanism of in oxidative stress Significance 
will be set at a P-value of <0.05, a confidence interval of 95 and an α= 0.5 to reduce the 
occurrence of a Type I error, detecting an effect that does not exist.  
Next, linear regression analyses will be performed to determine if a relationship exists 
between the study variables (age, gender, height, weight, ethnicity, smoking history, length of 
time and concentration of oxygen therapy, FEV1, FEV1/FVC, FEF25-75% and isofuran levels). 
Should a relationship be detected correlational testing, utilizing the Pearson’s r, will be 
performed to determine the strength of the relationship. As it relates to obstructive disease the 
FEV1, FVC and the FEV1/FVC ratio are standard to assessing the stage of COPD. It is well 
understood that the results of spirometric testing vary with effort and may produce inconsistent 
values as a result. Therefore, participants will be instructed to maximize effort for these specific 
tests to ensure accuracy. It is the desire of this researcher to determine if the isofuran biomarker 
has a future in predicting degree of obstructive disease states.  
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Chapter 3 – Methodology 
 
Purpose 
 Chronic obstructive pulmonary disease in an advanced state often requires oxygen 
supplementation to ameliorate distress. It is well established that prolonged exposure to 
increased oxygen tensions contributes to oxidative stress and subsequent tissue damage. The 
purpose of this study is determine if the level of a specific biomarker of oxidative stress is 
elevated in the presence of exposure to low flow domiciliary oxygen (LFDO) in patients with 
COPD.  
Research Questions  
The research questions guiding this study are: 
1.  Does chronic exposure to LFDO contribute to oxidative stress as evidenced by 
elevated isofuran levels within the lungs of COPD patients? 
2. Does a relationship exist between FEV1, FEV1/FVC, and FEF25-75% isofuran 
levels? 
3. Is there a correlation between length of oxygen exposure and concentration of oxygen 
to isofuran levels? 
Donabedian’s Structure-Process-Outcome Model 
 Donabedian states, “the assumption is made that given the proper settings (structure) and 
instrumentalities (process), good medical care will follow” and, therefore, good and desired 
outcomes. Quality outcomes are only valid if it can be directly linked to the structure and/or 
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process (Donabedien, 1966). The results of the planned methodology and data collection will 
render results that will allow us to assess whether the structure in which care is provided, and the 
treatment modalities it prescribes to their patient’s results in desirable outcomes. Consistent with 
the Donabedian process-structure-outcome model, the purpose of outcomes research is to 
determine if healthcare modalities and/or treatment management optimize patient and societal 
end results (Clancy and Eisenberg, 1998). With this in mind the following hypotheses were 
developed. 
Hypotheses 
The following hypotheses were formulated in response to findings within the literature review: 
1. Ha: Chronic exposure to LFDO will demonstrate ongoing oxidative stress in the lungs   
of COPD patients as evidenced by increased isofuran levels. 
2. Ha: A relationship between FEV1 and isofuran levels will be demonstrated in patients 
diagnosed with moderate to advanced stages of COPD using LFDO 
3. Ha: A relationship between FEV1/FVC ratios and isofuran levels will be   
demonstrated in patients diagnosed with moderate to advanced stages of COPD using 
LFDO. 
4. Ha: A relationship between FEF25-75% and isofuran levels will be demonstrated in 
patients diagnosed with moderate to advanced stages of COPD using LFDO 
5. Ha: A positive correlation between oxygen concentration and isofuran levels will be 
demonstrated on the day of sampling in patients diagnosed with advanced stages of 
COPD using LFDO. 
6. Ha: A positive correlation between length of oxygen exposure and isofuran levels will 
be demonstrated in patients diagnosed with advanced stages of COPD using LFDO. 
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This chapter will describe the research design, study setting, health care providers, 
sample selection process, sample characteristics, instruments, data collection procedures, and 
statistical analyses employed to address the research questions guiding this study. 
Research Design 
 This research study utilized a non-experimental cross-sectional prospective data 
collection design to assess for the presence of oxidative stress for those individuals diagnosed 
with advanced stages of COPD requiring LFDO therapy. The active control group will consist of 
individuals diagnosed with advanced stages of COPD and managed with the standard therapeutic 
agents predetermined by their physician with the exception of LFDO therapy. The study did not 
impact the care or management of the study participants as no manipulation occurred to an 
already prescribed treatment plan. No risks are imposed on the patient as a result of this study. 
No patient identifying information will leave the confines of the clinic in which care is provided 
to the study participant. A coding system will be utilized to identify samples to relevant study 
variables.   
 Noted in the writings of Donabedian, healthcare provision variables are antecedents to 
healthcare outcomes and, therefore, study variables such as administrative demographics and 
mission, patient demographics, healthcare provider variables, pulmonary function test results, 
medicinal regimen, and isofuran biomarker measurements will be considered when evaluating 
outcomes. Those health care providers whose services impact patient care and process will be 
described. Patient demographics, such as age, gender, ethnicity, past and current smoking history 
are potentially confounding variables.  
Independent and dependent variables. The treatment (independent) variable in this 
study is LFDO; the effect (dependent) variable is oxidative stress, represented by the biomarker 
isofuran. Also being assessed for are relationships between the independent variables of FEV1, 
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FVC, FEV1/FVC, FEF25-75, length of oxygen exposure (hrs/day and years), concentration of 
oxygen therapy (L/min), smoking history and isofuran levels (see Table 4). 
Table 4 
Study Variables 
Variable Variable Measurement Statistical Analysis Unit of Measure 
LFDO IV Continuous  t-test L/min 
Length of Oxygen 
Exposure 
DV Continuous 
 
Linear Regression 
Pearson’s r 
Hrs/day 
Years 
Concentration of 
Oxygen Therapy 
 
DV 
 
Continuous 
Linear Regression 
Pearson’s r 
 
 
Liters/minute 
Length of Smoking 
History 
DV Continuous 
Linear Regression 
Pearson’s r 
years 
Isofuran IV/DV Continuous 
Linear Regression 
1-tailed 
Student’s t-test 
Pg/ml 
FEV1 DV Continuous 
Linear Regression 
Pearson’s r 
L/sec 
FVC DV Continuous 
Linear Regression 
Pearson’s r 
L/sec 
FEV1/FVC DV Continuous 
Linear Regression 
Pearson’s r 
L/sec 
FEF25-75% DV Continuous 
Linear Regression 
Pearson’s r 
L/sec 
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Study setting. The setting for this study is a moderately sized medical center in 
Midwestern United States. This 236-bed facility offers acute care services as well as obstetrics, 
pediatrics, oncology services, long term care, skilled nursing facility, inpatient rehabilitation, 
outpatient clinic services and psychiatric treatment. The ethnic breakdown of the town of the 
medical center was as follows, with overall U.S. statistics in parentheses: Males: 55% (50%), 
Females: 45% (50%); Average age: 26 years (36.8); Caucasian: 84.8% (72.4%), Asian: 5.7% 
(4.8), African-American: 4% (12.6%), Hispanic: 2.6% (16.3%); two or more races: 2.4% (2.9%). 
The demographics between this Midwestern town and the United States were similar with the 
exception of average age and Hispanic population. Patients diagnosed with COPD and receiving 
services from an outpatient clinic at Phelps County Regional Medical Center will be recruited for 
participation in the study. 
Population and Recruitment Strategy 
 
In collaboration with Dr. James, Chief Medical Officer at Phelps County Regional 
Medical Center, a convenience sampling will be utilized to recruit participants. A review of 
patient records will be made to identify those patients with advanced stages of COPD, both 
receiving and not receiving LFDO as qualifiers.  As qualifying patients are identified on site 
PCRMC staff to determine interest in participating in the study will approach them. Once interest 
has been solicited I will explain the study and provide a study participation outline. Informed 
consent will be obtained prior to sample collection. The population of interest for this study is 
those COPD patients with advanced symptoms of COPD confirmed by pulmonary lung volume 
measurements, specifically an FEV1/FVC ratio of < 70%, indicating obstructive disease of 
predicted normal volume for age, gender, height and weight. The goal of recruitment is to create 
closely matched comparison groups to avoid confounding variables.  A convenience sample of 
patients with COPD and managed on an outpatient basis from the dates of March 10, 2015 to 
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May 7, 2015 was utilized. Group AC, or the active control group, consisting of those COPD 
patients diagnosed with advanced COPD but not receiving supplemental oxygen therapy, for 
Group AT, or the active treatment group, consisting of those COPD patients diagnosed with 
advanced disease requiring supplemental oxygen therapy.   
  Upon arrival to the outpatient clinic patients were provided a detailed explanation of the 
study outlining participation requirements including study goals and exhaled breath collection 
requirements as well as another opportunity to have any questions answered. 
Inclusion/Exclusion Criteria  
Eligibility for study participation was guided by inclusion/exclusion criteria. 
Inclusion/exclusion criteria served to control for variability and to aid in creating equivalent 
groups. 
Inclusion criteria for the study were as follows:  
1. >18 years of age  
2. Mentally competent to provide informed consent (not currently under the care 
of a physician for such disabilities that preclude ability to consent). 
3. Outpatient status  
4. Diagnosed with advanced stage COPD as evidenced by spirometric FEV1 
<70% of predicted normal for age and gender, height and weight, smoking 
history  
5. With or without supplemental oxygen >6 hours/day depending on group 
assignment 
Exclusion criteria for the study were as follows: 
1. < 18 or > 89 years of age 
2. Pregnant women 
  105 
3. Mentally incapable of providing informed consent (currently under the care 
of a physician for such disabilities that preclude ability to consent). 
4. Refusal to participate  
5. Active, systemic, oral or nasal infections 
6. Patients diagnosed with amyotrophic lateral sclerosis, Huntington’s, 
Alzheimer’s, Parkinson’s or Lewey body disease. 
Data Collection Procedures 
Following Institutional Review Board (IRB) approval from the participating research 
institutions, Virginia Commonwealth University and Phelps County Regional Medical Center, 
study participants will be assigned to either an active control group or an active study group 
based on long-term low flow domiciliary oxygen therapy utilization.  The active control group, 
Group AC, will consist of patients diagnosed with moderate to advanced stage COPD not 
receiving supplemental oxygen therapy; the active treatment group, Group AT, will consist of 
patients diagnosed with moderate to advanced COPD receiving supplemental oxygen therapy for 
a minimum of 6 hours/day. According to the American Thoracic Society guidelines, once criteria 
for oxygen therapy has been met the recommendation for oxygen therapy is for 24 hour use; 
however, in an effort to capture enough study participants a minimum oxygen usage has been of 
6 hours has been selected, as supported by the Nocturnal Oxygen Treatment Trial and the 
Medical Research Council study. 
Data Collection and Analysis Instruments 
The following instruments and chemicals will be utilized for this study:  
1. Futuremed Discovery II Spirometer™ 
2. The Rtube™ EBC collection device (Respiratory Research, Inc., manufacturer) 
3. Gas chromatograph/Mass spectrometry 
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a. Capillary Gas chromatography column (DB-1701. Agilent: Cat. No. 21512067) 
b. Gas chromatograph/mass Spectrometer (with capabilities for negative-ion 
chemical ionization (NICI) mass spectrometry. (Agilent 5973) 
4. Isofuran quantification methods (owned by Vanderbilt University Labs) 
 Collection of exhaled breath condensate (EBC) is a noninvasive means of obtaining 
samples from lungs in order to assess pathologic processes.  Due to the portability and ease of 
use the EBC devices can be used in a variety of settings, such has hospitals, clinics and even in 
the home. For the purposes of this study, a commercially manufactured, FDA approved EBC 
device, the Rtube™, will be used for collecting and storing as the EBC sample can be easily 
removed for storage and transport. The collection tube resides within an aluminum sleeve that is 
cooled by placing it in a freezer maintained at a temperature of -70°. The sleeve results in the 
condensation and collection of the exhaled gas. General guidelines for EBC collection suggest 
10-15 minutes of normal tidal breathing as sufficient for collecting ~3mls of condensate; 
however, the diminished capacity of individuals with COPD may result in an increased time 
requirement to achieve the same volume. Also, in an effort to ameliorate fatigue during the EBC 
collection phase patients may be allowed to maintain nasal cannula oxygen delivery.  
Pulmonary Function Testing 
 Phelps County Regional Medical Center population recruitment target sites include, but 
are not limited to, the Internal Medicine Clinic and the Cardiology clinic. Neither location 
participates in routine pulmonary function testing. Participants identified for study inclusion 
require current pulmonary function testing for comparison to same day IsoF levels. PFTs will be 
obtained using the portable Discovery II Spirometer™ by Futuremed. The Discovery II 
Spirometer ™ measure parameters include the parameters targeted for this study, FEV1, FVC, 
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FEV1/FVC and FEF25-75. The device has a range volume of 12 liters, flow of 0.03-20 l/s, a 
flow resistance of <0.70 cm H20/l/s @ 12 l/s, and an accuracy of ± 2%.  
EBC Sample Collection and Preparation 
Once group assignment is determined, consistent with the most current guidelines offered 
by the European Respiratory Society (ERS) and the American Thoracic Society study, with 
respect to determining a FEV1/FVC ratio of <70% predicted value, participants will be 
instructed to breath into an exhaled breath collection device, the Rtube™, with the following 
methods employed:  
1. Normal tidal breathing into a mouthpiece attached to a collection chamber wrapped 
by a cooling sleeve for approximately 10-15 minutes, or until ~2-3 milliliters of 
condensate will be obtained. Sleeves will have been cooled over night in a -70° 
freezer maximizes analyte collection volume. The cooling sleeve will be wrapped 
with a protective cover. 
2. Utilization of a nose clip will be employed for those who can tolerate it and/or 
required its use for adequate sample retrieval. 
3. Utilization of a saliva trap to minimize salivary contamination of the analyte. 
4. Storage of analyte in a -70° freezer until analysis can be made. Samples cannot be 
frozen, thawed and refrozen.  
Approximately 5-15 minutes of normal breathing into the device should result in a 
volume adequate for measuring exhaled biomarkers.  Nose clips can be utilized to minimize 
escape of exhaled air through the nose; however, compliance is of concern because they can be 
perceived as uncomfortable. Utilization of a saliva trap is necessary to minimize salivary 
contamination of the analyte; however, salivary contaminants have not proven to have significant 
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effects on the biomarkers of interest (Hutterman et al., 2011). A cooling sleeve is placed around 
the collection chamber to facilitate condensation.  
The Rtube™ is designed to provide maximum sample collection with minimal time. 
Exhaled air is directed through a one-way valve and into a cooled collection chamber where 
vapors, aerosols and moisture in the breath condense along the protected walls. The one-way 
valve is then used as a plunger that collects droplets stuck to the inside wall. The samples are 
conveniently stored and shipped in the collection sleeve. No risks are introduced to the study 
participant as a result of breathing into the condensate collector. 
The clinic staff and the PI will share in the responsibility of overseeing adherence to 
collection techniques and timing.  Samples will be labeled to identify group membership. 
Samples will be logged with identifying code along with the relevant demographics of age, 
gender, race, height, weight, LFDO concentration, and oxygen exposure timeline. Samples will 
be securely sealed in transport coolers at a temperature of -70° C for transport to lab until 
analysis can be made. 
Laboratory Analysis 
 The labs at Vanderbilt University will be employed to analyze the exhaled breath 
condensate, as there currently are no commercially available isofuran standards available for 
public acquisition. The technique utilized by Vanderbilt University to detect the presence and 
quantification of isofuran in exhaled breath is through GC/MS, currently the only method 
established for detecting and quantifying isofurans.  Therefore, the methods employed to perform 
this test are described below. 
 Gas chromatography permits the separation of closely related components of complex 
mixtures. The GC method is noted for its sensitivity, adaptability to accurate quantitative 
determinations, its suitability for separating nonvolatile species or thermally fragile species, and 
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its widespread applicability to substances that are of prime interest to the industry, science and 
the public.  
 Chromatography methods occur in two phases: mobile and stationary. In column 
chromatography, which will be used in this study, the stationary phase is held in a narrow, 
coiled, heated tube through which the mobile phase travels. As the mobile phase comes in 
contact with the stationary phase and separation of compounds occurs. This separation results in 
the ability to identify and quantify targeted substances. The use of mass spectrometry adds 
sensitivity and specificity as it identifies the compounds based on molecular weight. 
 Sensitivity is achieved by the GC/MS technique through the ability to resolve the peaks. 
Resolution occurs by adjusting flow rates and mobile phase composition. Adjusting flow rates 
allows for the separation of peaks for accurate identification. Mobile phase packing allows for 
the separation of polar from non-polar compounds, thus enhancing sensitivity. When using the 
GC/MS for detection of both IsoPs and IsoFs quantification can only occur when they are in the 
free acid form. In tissues a plasma arachidonic acid oxidation products are generally esterified in 
glycerophospholipids. The glycerophospholipids must be subjected to alkaline hydrolysis to 
release the compounds into the free fatty acid form to ready them for GC/MS analysis (Milne, et 
al., 2013).  
 The GC/MS methodology is considered robust and has been used for over 20 years. 
According to Milne et al (2013) “this particular method offers the lowest limit of quantification 
of any reported mass spectrometric methodology for IsoPs.”  Due to the fact that these particular 
molecules are measured in terms of picograms (or similar derivations) in plasma, CSF, EBC and 
other biological fluids in which low levels of IsoPs are found the GC/MS is ideal as a means of 
detection and quantification of these groups of molecules. The low limit of detection for 
isoprostane is 5 pg/ml. 
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 For the purposes of compound identification many reagents may be employed, as well as 
the equipment necessary to perform the functions. A detection and quantification standard for 
isofuran is not currently available to the public for purchase and use. Researchers at Vanderbilt 
University discovered isofuran and the methods for its detection and quantification the list 
provided are those reagents commonly used when identifying by-products of non-enzymatic 
lipid peroxidation, such as the IsoPs, at the Vanderbilt Laboratory. The following agents have 
been provided regarding the identification process for IsoPs, which can be applied to the 
identification of IsoFs with the delineating difference being the eluting times. 
Instrumentation. The following instruments were used to identify and quantify IsoF: 
• Capillary gas chromatography column (DB-1701, Agilent) 
• Gas chromatograph/mass spectrometry (GC/MS, with capabilities for negative-
ion chemical ionization (NICI) mass spectrometry) 
While many different means can be utilized to detect the presence and amount of IsoPs, 
such as LC/MS and immunoassays, only GC/MS has been identified as accurately detecting and 
measuring IsoFs.  Identifying and quantifying the F2-IsoPs by mass spectrometry has advantages 
over immunoassay procedures, such as the ELISA. While the ELISA methodology is cost 
effective and provides quality analysis, the antibodies used to bind to the F2-IsoPs may exhibit 
cross-reactivity with many other molecules similar in structure, confounding the result. Also, 
biological impurities can interfere with antibody binding. Mass spectrometry offers high 
sensitivity and specificity resulting in enhanced detection and accuracy of desired compounds.  
Once specimens arrive in the lab GC/MS analysis will be performed in triplicate to gain 
accurate results of the isofuran biomarker. The three results will be averaged in an effort to most 
accurately represent the results. The results then will be logged into a data bank to include group 
membership, age, gender, race, LFDO concentration utilized, and oxygen exposure timeline.  
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Data Analysis 
The objective of this study is to determine if LFDO as a treatment modality in COPD 
superimposes oxidative lung damage. The specific aims of this study are 1) assess for isofuran in 
the EBC of COPD patients on LFDO; 2) determine if there is a correlation between standard 
diagnostic spirometry and exhaled breath condensate (EBC) biomarker (isofuran) levels; and 3) 
determine if relationships exist between duration and concentration of oxygen exposure and EBC 
biomarker isofuran levels.   
Following a thorough literature review evaluating methodologies described in this paper 
for this study it was determined that a large effect size exists between control and treatment 
groups regarding the generation of isoprostanes, consistent with oxidative stress. Since isofurans 
are derived from isoprostanes the assumption holds that the effect of the treatment, LFDO, will 
result in a large effect size regarding isofuran production.  
To determine the significance of isofuran in the EBC of the active treatment group, 
severe stage COPD patients on LFDO, compared to the active control, severe stage COPD 
patients not receiving LFDO, a Student’s t-test will be performed, with the assumptions of 
bivariate independent variables, a continuous dependent variable, independent observations of 
the dependent variable, and normal distribution being met. A power analysis was performed 
utilizing the software G*Power Analysis for a 1-tail t-test to compare group means of the active 
control and active treatment groups with a α=0.5 to control for Type I errors and a ß= 0.80 to 
control for Type II errors with an effect size of 0.8, and generated an n = 52.  
Pulmonary function testing includes a variety of assessments that provide for the specific 
interpretation of their results, such as changes in lung volumes and capacities, respiratory flow 
patterns and rates, as well as diffusion capacity, or the exchange of nutrients between the alveoli 
and the capillary beds. In an effort to better assess where oxidative stress exerts its derangement 
  112 
it is necessary to determine a relationship between the presence of oxidative stress and the 
parameters most affected by its presence. This study will directly assess for the relationship 
between isofuran, a validated biomarker of oxidative stress, and the standard diagnostic 
pulmonary function parameter of FEV1 and FEV1/FVC. However, all spirometry parameters 
will be collected and evaluated as a mechanism of discovery and future evaluation. Linear 
regression will be performed to determine if a relationship between FEV1/FVC exists, and the 
strength of that relationship determined with correlation analysis. Assumptions of linear 
regression include linearity and additivity, statistical independence of the errors, 
homoscedasticity of the errors and normality of the error distribution will be met. If a 
relationship is identified through linear regression a Pearson’s r will be utilized to assess for 
strength of the relationship between the demographic independent variables and the dependent 
variable, isofuran. Considerations may have to be made when assessing isofuran levels and the 
age demographic as senescence can result in diminished antioxidant ability. 
In order to better understand the impact of LFDO on COPD patients with regard to 
ongoing oxidative stress relationships between duration of oxygen therapy (hours/day of use) and 
concentration of oxygen (L/min flow) need to be explored. Linear regression will be performed 
to determine if a relationship between length of exposure and concentration of oxygen relates to 
isofuran levels. Should a relationship be identified the strength of that relationship will be 
determined through correlation analysis, the Pearson’s r. Assumptions of linear regression 
include linearity and additivity, statistical independence of the errors, homoscedasticity of the 
errors and normality of the error distribution will be met.  
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Chapter 4 – Results 
 
Introduction 
The purpose of this study was to determine if oxidative stress is occurring in the 
lungs of individuals with COPD as a result of chronic exposure to low flow domiciliary 
oxygen (LFDO) therapy as evidenced by a specific biomarker, isofuran (IsoF). A 
methodology was developed to address this phenomenon and statistical analyses 
employed to interpret the findings. Each result will be preceded by the research question 
it intended to address. 
A power analysis, utilizing scientific Graph Pad Prism 6.0 software, revealed a 
sample size of 52 necessary to sufficiently power this study. A convenience sample of 54 
subjects was identified at Phelps County Regional Medical Center, collected from March 
12, 2015 to May 7, 2015 that met study inclusion criteria. Two subjects were removed 
from the active treatment (AT) group due to insufficient exhaled breath condensate 
sample volume necessary to detect and quantify IsoF. The active control (AC) group 
consisted of 26 participants, 15 males (58%) and 11 females (42%); and 26 participants 
in the active treatment, 10 males (38%) and 16 females (62%) individuals all of whom 
had an FEV1/FVC <0.70 and FEV1 <80% of predicted normal (See Table 5). The AT 
group utilized LFDO for a minimum of 7 hrs/day. No current research exists regarding 
risks of prescription LDFO therapy, therefore, duration of oxygen (hrs/day) exposure did 
not impact study inclusion. All study participants were Caucasian. 
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Table 5  
Study Participant Demographics 
 Control (COPD no Oxygen) Treatment (COPD with Oxygen)  P value 
Number   26    26 
Age (years)   62 ± 29   65± 16.5  0.3655 
Male/Female   15/11    10/16   0.1717 
Height (inches)  66 ± 5    65 ± 7.5  0.3079 
Weight (lbs)   190 ± 87.5   217 ± 119  0.0900 
Caucasian   26    26 
Smoking History  22/26    22/26 
Current Smokers  13/26    0/26 
*Age, height and weight are reported as the mean ± standard deviation 
Study participants enrolled in the study from the cardiology clinic received 
pulmonary function testing the day of data collection by the PI utilizing the Discovery II 
Spirometer™. Study participants enrolled in the pulmonary function lab received 
pulmonary function testing the day of data collection by certified respiratory therapists. 
Vmax Encore Software v21-2A by CareFusion is utilized by the PCRMC to interpret 
pulmonary function test results. A t-test was performed to compare group means between 
the AC (COPD without LFDO) and the AT (COPD with LFDO) (see Table 6).  
Table 6  
Study Participant Spirometry Results 
  Control (COPD no Oxygen) COPD (w/ Oxygen)   
  Mean + SEM   Mean + SEM          P value 
 
FEV1   60.19 ± 2.73   60.08 ± 3.92   0.9819  
FVC   75.81 ± 3.67   70.42 ± 4.60   0.3615
 FEV1/FVC  64.63 ± 2.86   68.38 ± 2.81   0.3544
 FEF25-75  34.93 ± 3.99   51.38 ± 6.06   0.0265 
  
 
It was the intention of this study to create closely matched study groups with 
regard to age, gender, height, weight, ethnicity and the spirometric tests FEV1, FVC, 
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FEV1/FVC and FEF25-75, (with the notable exception of LFDO therapy) to enhance 
interpretability of the results. Student’s t-tests were performed to compare group means 
for each parameter. No significant differences were noted between any of the parameters 
in the AC and AT groups with the exception of the FEF25-75 results, which 
demonstrated a P = 0.0265. This difference warrants future investigation. 
The following research questions were addressed through statistical analyses. 
Research Question 1 
Does chronic exposure to LFDO contribute to oxidative stress as evidenced by elevated 
isofuran levels within the lungs of COPD patients? 
 Using the statistical software package, Graph Pad Prism 6, a one-tailed t-test was 
performed to determine the mean difference in exhaled breath IsoF levels between the 
AC and AT groups. The descriptive statistics are provided below (see Table 7). 
Significance was set at a P value <0.05, an α=0.05, with a 95% CI. The results 
demonstrated a t=1.61, with df=50, and a nonsignificant P = 0.056 with a SEM 35.81± 
4.91 of IsoFs in the active control, and a SEM 51.35±8.27 of IsoFs in the treatment group 
(see Table 8). The R2 value of 0.049 suggests that only 4.9% of the variance could be 
explained by LFDO therapy. An F test to compare variances was performed resulting in a 
P=0.0115, indicating significant differences in variances between groups. An unpaired t-
test with a Welch’s correction for unequal standard deviations was performed generating 
a nonsignificant P=0.0569 (see Table 9, Figure 1). Based on these findings it cannot be 
supported that LFDO therapy results in statistically significant increases in exhaled 
breath IsoF levels in COPD patients. 
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Table 7 
Descriptive Statistics  
 
 N  Mean Standard Deviation Std Error Mean 
Active Control 
IsoFs 
 
26 
 
35.81 25.062 4.908 
Active Treatment 
IsoFs 26 51.35 42.170 8.270 
 
Table 8  
Unpaired One-Tailed t-test comparing group means, 95% Confidence Interval 
 
One-Tailed  
t-test table 
Isofuran 
Mean ±SEM  df 
Difference 
between the 
Mean ±SEM P value 
Control 
Group 
35.81±4.91 
 25 15.54±9.62 P = 0.0562 
Treatment 
group 51.35±8.27 25   
 
Table 9  
Unpaired One-tailed t-test with Welch’s correction 
One-Tailed  
t-test table 
Isofuran 
Mean ±SEM  t df 
Difference 
between the 
Mean ±SEM P value 
Control 
Group 
35.81±4.91 
 1.616 40.67 15.54±9.62 P = 0.0569 
Treatment 
group 51.35±8.27 
    
 
Figure 1: AC IsoF & AT IsoF Means Comparison 
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The t-test descriptive statistics revealed an AC group standard deviation (SD) of 
25.03 and an AT SD of 42.17. Clearly, a larger SD is noted in the AT group, meaning a 
wider dispersion of obtained values. A between groups data dispersion comparison was 
made (see Table 10). Evidenced by the dispersion data a significant difference is noted 
between the maximum values obtained between the groups. No a priori knowledge 
existed suggesting cause for exclusion of the 181pg/ml sample obtained and, therefore, 
the result remained. 
Table 10  
Between Groups Data Dispersion 
 
          AC pg/ml      AT pg/ml 
Minimum 10.0 11.0 
25% Percentile 16.75 18.75 
Median 27.5 33.5 
75% Percentile 44.0 79.25 
Maximum 96.0 181.0 
 
The mean AC group exhaled breath IsoF level was 35.82 pg/ml with a one SD 
range of 10.78 to 60.84 pg/ml, and a relatively small SEM (4.91) suggesting less 
variation in the AC group when compared to the AT group. The AT group mean exhaled 
breath isofuran level was 51.35 pg/ml with a one SD range of 9.18 to 93.52 pg/ml, a 
comparatively larger SEM (8.27), suggesting more unexplained variance in the AT group 
than in the AC group.   
Research Question 2 
Does a relationship exist between FEV1, FVC, FEV1/FVC, FEF25-75% and isofuran 
levels? 
 The following relationships were explored through simple linear regression 
utilizing the statistical software package SPSS, version 23. An analysis of the statistical 
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results, including a Pearson’s r correlation, coefficients, model summary and ANOVA is 
provided. Tables, graphs and figures may accompany the explanation to enhance clarity 
of the findings. It is the intention of the PI to determine the clinical application of IsoF as 
replacement for standard pulmonary function testing. Therefore, in the following analyses 
IsoF is the situated as the predictor variable, while the PFTs are the outcome variables. 
The results of the linear regression analysis are reported below. 
A simple linear regression was calculated to determine if a relationship exists 
between FEV1 in COPD patients receiving LFDO therapy and exhaled breath isofuran 
levels. A line of best-fit analysis revealed a relatively flat slope of -0.07314 to 0.3125 and 
a goodness of fit R2=0.075 indicating a very weak correlation to the best-fit line (see 
Figure 2), an assessment supported the B value revealing that every 1 unit of increase in 
isofuran would only generate a 0.132 unit of change in the FEV1. According to the R2 
coefficient of determination only 7.5% of the model variation could be explained by 
exhaled breath IsoF levels, leaving approximately 92.5% of the variance unexplained. A 
model summary was performed revealing a Pearson correlation (r =0.274) (see Table 11), 
synonymous with the Beta coefficient (see Table 12), demonstrating a weak relationship 
between IsoF levels and FEV1. A subsequent ANOVA analysis of the model summary 
was performed with a resulting nonsignificant P=0.176, confirming that isofuran levels 
do not correlate to FEV1 values (see Table 13). In summary, no significant correlation 
was established between IsoF levels from individuals with COPD on LFDO to FEV1.  
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Figure 2: AT IsoFs & AT FEV1 
Table 11  
AT IsoF and FEV1 Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .274 .075 .036              .075 1.941 1 
 
Table 12  
AT IsoF and FEV1 Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
54.147 
.132 
 
6.244 
.095 
 
 
.274 
1.941 .176              
 
Table 13 
AT IsoF and FEV1 ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
774.173 
9571.673 
10345.846 
1 
24 
25 
774.173 
398.820 
1.941 .176              
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A simple linear regression was calculated to determine if a relationship exists 
between IsoF levels and the FVC in COPD patients receiving LFDO therapy. A line of 
best-fit analysis revealed a relatively flat slope of -0.1937-0.2732 and a goodness of fit 
R2=0.001 indicating a very weak correlation to the best-fit line (see Figure 3), assessment 
supported by the B value revealing that every 1 unit of increase in IsoF levels would only 
generate a 0.015 unit of change in the FVC. According to the R2 coefficient of 
determination only 0.1% of the model variation could be explained by exhaled breath 
IsoF levels, leaving approximately 99.9% of the variance unexplained. A model summary 
was performed revealing a Pearson correlation (r =0.028)  (see Table 14), synonymous 
with the Beta coefficient (see Table 15), demonstrating a weak relationship between 
isofuran levels and FVC. A subsequent ANOVA analysis of the model summary was 
performed showing no statistical difference (P=0.892), confirming that IsoF levels do not 
correlate to FVC values (see Table 16). No significant correlation was established 
between IsoF levels from individuals with COPD on LFDO to FVC.  
 
Figure 3: AT IsoFs & AT FVC 
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Table 14 
AT IsoF and FVC Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .028 .001 -0.041 .001 0.019 1 
 
 
Table 15 
AT IsoF and FVC Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
69.212 
.015 
 
7.396 
.112 
 
 
.028 
9.358 .000 
.892              
 
Table 16 
AT IsoF and FVC ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
10.462 
13429.538 
13440.000 
1 
24 
25 
10.462 
559.564 
.019 .892              
 
A simple linear regression was calculated to determine if a relationship exists 
between FEV1/FVC in COPD patients receiving LFDO therapy and exhaled breath  
IsoF levels. A line of best-fit analysis revealed a relatively flat slope of -0.08833-0.1949 
and a goodness of fit R2=0.051 indicating a very weak correlation to the best-fit line (see 
Figure 4), an assessment supported the B value revealing that for every 1 unit of increase 
in IsoF levels would only generate a 0.076 unit of change in the FEV1/FVC. According 
to the R2 coefficient of determination only 5.1 % of the model variation could be 
explained by exhaled breath IsoF levels, leaving approximately 94.1% of the variance 
unexplained. A model summary was performed revealing a Pearson correlation (r  
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Figure 4: AT IsoFs & AT FEV1/FVC 
=0.227)  (see Table 17), synonymous with the Beta coefficient (see Table 18), 
demonstrating a weak relationship between IsoF levels and FEV1/FVC. A subsequent 
ANOVA analysis of the model summary was performed showing no statistical difference 
(P=0.265), confirming that IsoF levels do not correlate to FEV1/FVC values (see Table 
19). No significant correlation was established between exhaled breath IsoF levels from 
individuals with COPD on LFDO to FEV1/FVC. 
Table 17 
AT IsoF and FEV1/FVC Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .227 .051 0.012 .051 1.302 1 
 
Table 18 
AT IsoF and FEV1/FVC Regression Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
64.091 
.076 
 
4.399 
.067 
 
 
.227 
14.570 
1.141 
.000 
.265              
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Table 19 
AT IsoF and FEV1/FVC ANOVA for Regression Analysis 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
275.732 
4750.268 
5008.000 
1 
24 
25 
257.732 
197.928 
1.302 .265              
 
A simple linear regression was calculated to determine if a relationship exists 
between FEF25-75% in COPD patients receiving LFDO therapy and exhaled breath IsoF 
levels. A line of best-fit analysis revealed a relatively flat slope of -0.1784-0.4298 and a  
goodness of fit R2=0.038 indicating a very weak correlation to the best-fit line (see Figure 
5), an assessment supported the B value revealing that for every 1 unit of increase in IsoF 
levels would only generate a 0.146 unit of change in the FEF25-75. According to the R2 
coefficient of determination only 3.8 % of the model variation could be explained by 
exhaled breath IsoF levels, leaving approximately 96.2% of the variance unexplained. A 
model summary was performed revealing a Pearson correlation r =0.194 (see Table 20), 
synonymous with the Beta coefficient (see Table 21), demonstrating a weak relationship 
between IsoF levels and FEF25-75%. A subsequent ANOVA analysis of the model 
summary was performed showing no statistical difference (P=0.265), confirming that 
IsoF levels do not predict FEF25-75% values (see Table 22). While significant between 
group differences were noted on pulmonary function test FEF25-75 parameters no 
significant between group differences were noted with regard to exhaled breath IsoF. No 
significant correlation was established between IsoF levels from individuals with COPD 
on LFDO to FEF25-75. 
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Figure 5: AT IsoFs & FEF25-75 
Table 20 
AT IsoF and FEF25-75% Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .194 .038 -.003 .038 .935 1 
 
Table 21 
AT IsoF and FEF25-75% Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
44.710 
.146 
 
9.934 
.151 
 
 
.194 
4.501 
.967 
.000 
.343              
 
Table 22 
AT IsoF and FEF25-75% ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
943.994 
24224.045 
25168.038 
1 
24 
25 
943.994 
1009.335 
.935 .343              
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Research Question 3 
Is there a correlation between length of smoking history, and length of oxygen exposure 
and concentration of oxygen to isofuran levels? 
The following relationships were explored through simple linear regression 
utilizing the statistical software package SPSS, version 23. An analysis of the statistical 
results, including a Pearson correlation, coefficients, model summary and ANOVA is 
provided. Tables, graphs and figures may accompany the explanation to enhance clarity 
of the findings. The results of the linear regression analysis were as follows: 
A simple linear regression was calculated to determine if a relationship exists 
between length of smoking history (yrs) in COPD patients receiving LFDO therapy and 
exhaled breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of  
-1304-0.2243, and a goodness of fit R2= 0.012 indicating a very weak correlation to the 
best-fit line (see Figure 6), an assessment supported the B value revealing that every 1 
unit of increase in IsoF levels would only generate a 0.047 unit of change in the smoking 
history. According to the R2 coefficient of determination only 1.2% of the model 
variation could be explained by exhaled breath IsoF levels, leaving approximately 98.8% 
of the variance unexplained. The model summary revealed a Pearson correlation r =0.111 
(see Table 23), synonymous with the Beta coefficient (see Table 24), demonstrating a 
weak relationship between IsoF levels and length of smoking history. A subsequent 
ANOVA analysis of the model summary was performed showing no statistical difference 
(P=0.590), confirming that IsoF levels are not significantly correlated with length of  
smoking history (see Table 25). Not all individuals in the AT group had a history of 
smoking. Four individuals reported having never smoked. No significant correlation was 
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Figure 6: AT IsoFs & Length of Smoking History 
Table 23 
AT IsoF and Length of Smoking History Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .111 .012 -.029 .012 .299 1 
 
Table 24 
AT IsoF and Length of Smoking History Regression Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
27.049 
.047 
 
5.665 
.086 
 
 
.111 
4.775 
.547 
.000 
.590              
 
Table 25 
AT IsoF and Length of Smoking History ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
98.144 
7878.317 
7976.462 
1 
24 
25 
98.144 
328.263 
.299 .590              
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established between IsoF levels from individuals with COPD on LFDO to length of 
smoking history (yrs). 
A simple linear regression was calculated to determine if a relationship exists 
between length of daily oxygen exposure (hours/day) in COPD patients receiving LFDO 
therapy and exhaled breath IsoF levels. A line of best-fit analyses revealed a relatively 
flat slope of -0.03538-0.09946 and a goodness of fit R2=0.039, indicating a very weak 
correlation to the best-fit line (see Figure 7), an assessment supported the B value 
revealing that every 1 unit of increase in IsoF levels would only generate a 0.032 unit of 
change in the length of oxygen therapy (hrs/day). According to the R2 coefficient of 
determination only 3.9% of the model variation could be explained by exhaled breath 
IsoF levels, leaving approximately 96.1% of the variance unexplained. A model summary 
was performed revealing a Pearson correlation r =0.196 (see Table 26), synonymous with 
the Beta coefficient (see Table 27), demonstrating a weak relationship between IsoF 
levels and length of daily oxygen exposure (hours/day). A subsequent ANOVA analysis 
of the model summary was performed showing no statistical difference (P=0.590), 
confirming that IsoF levels are not correlated to length of daily oxygen exposure (hrs) 
 
 
Figure 7: AT IsoFs & AT Length of Daily Oxygen Exposure (hrs) 
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Table 26 
AT IsoF and Length of Daily Oxygen Exposure (hrs) Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .196 .039 -.002 .039 .962 1 
 
Table 27 
AT IsoF and Length of Daily Oxygen Exposure (hrs) Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
12.739 
.032 
 
2.154 
.033 
 
 
.196 
5.916 
.547 
.000 
.336              
 
(see Table 28). No significant correlation was established between isofuran levels from 
individuals with COPD on LFDO to length of daily oxygen exposure (hrs). 
Table 28 
AT IsoF and Length of Daily Oxygen Exposure (hrs) ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
45.646 
1138.508 
1184.154 
1 
24 
25 
45.646 
47.438 
.962 .336              
 
A simple linear regression was calculated to determine if a relationship exists 
between oxygen delivery (L/min) in COPD patients receiving LFDO therapy and exhaled 
breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of -0.003896 
-0.007623 and a goodness of fit R2=0.018 indicating a very weak correlation to the best-
fit line (see Figure 8), an assessment supported the B value revealing that every 1 unit of  
increase in IsoF levels would only generate a 0.002 unit of change in the oxygen delivery 
(L/min). According to the R2 coefficient of determination only 1.8% of the model  
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Figure 8: AT IsoFs & AT Oxygen Delivery (L/min) 
variation could be explained by exhaled breath IsoF levels, leaving approximately 98.2% 
of the variance unexplained. A model summary was performed revealing a Pearson 
correlation r =0.135 (see Table 29), synonymous with the Beta coefficient (see Table 30), 
demonstrating a weak relationship between IsoF levels and oxygen delivery (L/min). A 
subsequent ANOVA analysis of the model summary was performed showing no 
statistical difference (P=0.511), confirming that IsoF levels are not correlated to oxygen 
delivery (L/min) (see Table 31). No significant correlation was established between IsoF 
levels from individuals with COPD on LFDO to oxygen delivery (L/min). 
Table 29 
 
AT IsoF and Oxygen Delivery (L/min) Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .135 .018 -.023 .018 .446 1 
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Table 30 
AT IsoF and Oxygen Delivery (L/min) Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
2.366 
.002 
 
.184 
.003 
 
 
.135 
12.861 
.668 
.000 
.511              
 
Table 31 
AT IsoF and Oxygen Delivery (L/min) ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
.154 
8.307 
8.462 
1 
24 
25 
.154 
.346 
.446 .511              
 
A simple linear regression was calculated to determine if a relationship exists 
between duration of oxygen therapy (yrs) in COPD patients receiving LFDO therapy and 
exhaled breath IsoF levels. A line of best-fit analysis revealed a relatively flat slope of 
0.06711 -0.01327 and a goodness of fit R2=0.074 indicating a very weak correlation to 
the best-fit line (see Figure 9), an assessment supported the B value revealing that every 1 
unit of increase in IsoF levels would only generate a -0.027 unit of change in the duration 
of oxygen therapy (yrs). According to the R2 coefficient of determination only 7.4% of 
the model variation could be explained by exhaled breath IsoF levels, leaving 
approximately 92.3% of the variance unexplained. A model summary was performed 
revealing a Pearson correlation r =0.272 (see Table 32), synonymous with the Beta 
coefficient (see Table 33), demonstrating a weak relationship between IsoF levels and 
duration of oxygen therapy (yrs). A subsequent ANOVA analysis of the model summary  
was performed showing no statistical difference (P=0.180), confirming that IsoF levels 
are not correlated to duration of oxygen delivery (L/min) (see Table 34). No significant  
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Figure 9: AT IsoFs & AT Length of Oxygen Therapy (yrs) 
Table 32 
 
AT IsoF and Duration of Oxygen Therapy (yrs) Model Summary 
 
Model R R Square Adjusted R Square 
Change Statistics  
R Square 
Change 
 
F Change 
 
df1 
1 .272 .074 .035 .074 .1.911 1 
 
Table 33 
 
AT IsoF and Duration of Oxygen Therapy (yrs) Regression Coefficients 
 
Model 
Unstandardized 
Coefficients 
Standardized  
Coefficients 
t Sig B Std. Error Beta 
1        (Constant)  
Active Treatment IsoF 
4.799 
-.027 
 
1.284 
.019 
 
 
-.272 
3.738 
-1.382 
.000 
.180              
 
Table 34 
 
AT IsoF and Duration of Oxygen Therapy (yrs) ANOVA for Regression Analysis 
 
Model Sum of Squares df Mean Squares F Sig 
1          Regression  
Residual 
Total 
32.215 
404.610 
436.825 
1 
24 
25 
32.215 
16.859 
1.911 .180              
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correlation was established between isofuran levels from individuals with COPD on 
LFDO to duration of oxygen therapy (yrs). 
Secondary Findings 
In an effort to better understand whether “years” of exposure of LFDO influenced 
the IsoF levels, “time” (years of exposure) was subdivided into three categories: 0-2 years 
(n=14), 3-6 years (n=8), and 7-20 years (n=4) (see Figure 10). An ANOVA was 
performed to compare group means between the three established time frames. A P value 
was set at a significance level of 0.05 at a CI 95%. The results generated were means of 
65.57, 33.63 and 37.00 respectively, with a P = 0.1795 (see Table 35). In summary, 
“time” in terms of years of exposure showed no statistical significance with regard to 
exhaled breath IsoF levels in the lungs of COPD on LFDO therapy. 
 
Figure 10: AT Duration of Oxygen Therapy (yrs) 
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Table 35 
One-way Analysis of Variance for Years of Oxygen Exposure 
ANOVA table SS DF MS F(DFn, DFd) P value 
Treatment 
(between 
columns) 
6169 2 3084 F (2,23) = 1.853 P = 0.1795 
Residual 
(within 
columns) 
38289 23 1665   
Total 44458 25    
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Chapter 5 – Summary & Discussion 
 
 
 
Introduction 
 This chapter summarizes the results of this research study and provides discussion 
regarding the findings. The results were examined in the context of the literature review and the 
theoretical framework guiding this study. Description of the data collection site and population 
demographics is presented first with the integration of the theoretical framework to follow. 
Quantitative results are discussed as they relate to the individual research questions and the 
theoretical framework. A methodological review will be presented. Finally, limitations, 
implications of the study and suggestions for future research are presented. 
Purpose 
The purpose of this study was to elucidate whether or not LFDO contributes to ongoing 
oxidative stress in the lungs of COPD patients. Supplemental oxygen is a known inducer of 
oxidative stress. Oxidative stress is a central mechanism in the pathologic processes resulting in 
the parenchymal changes in the lungs commensurate with chronic bronchitis and emphysema. It 
is understood that oxygen therapy clearly improves symptomatic dyspnea associated with the 
disease in individuals with COPD; however, the medical research community would be remiss to 
ignore the nocuous potential of chronic oxygen exposure.  
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Synthesis of Quantitative Results 
No research to date has been conducted utilizing IsoF as a marker of oxidative stress in 
the lungs of COPD patients. Actually, no research has been conducted utilizing any biomarker to 
determine if LFDO presents an oxidative risk. This study is foundational in that regard. The  
results of this study provide benchmark information about baseline IsoF levels in the COPD 
population subset, with and without LFDO. Isofuran is a biosynthetic relative to the validated 
oxidative stress biomarker, IsoP, whose formation is favored in the presence of elevated oxygen 
tensions. This particular sensitivity to oxygen tension makes it an ideal biomarker to examine the 
potential of oxygen therapy. A simple first step approach to uncovering this potential was to 
create closely matched groups with regard to age, gender, COPD diagnosis and ethnicity and to 
compare the mean IsoF levels between the active control (no LFDO) and treatment groups (with 
LFDO). 
Research Question 1. The first research question asks if chronic exposure to LFDO 
contributes to oxidative stress in the lungs of COPD patients as evidenced by elevated exhaled 
breath IsoF levels. The resulting study groups demonstrated no statistically significant 
demographic differences, which serves to minimize threats to internal validity. No statistical 
difference in mean IsoF levels was determined between the AC and AT groups (P=0.057); 
therefore, the null hypothesis was accepted.  
While inferences may not be drawn from this result, questions are raised. What is 
responsible for IsoF levels greater than one standard deviation from the mean in four participants 
in the control group and five participants in the treatment group? Are there other factors, such as 
concomitant comorbidities, that contribute to IsoF formation detectable in exhaled breath? How 
long does it take for IsoF levels to return to basal following cessation of therapy? Is IsoF an 
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appropriate biomarker to address supplemental oxygen as a contributor of oxidative stress? Does 
length or concentration of oxygen exposure explain these variations? The latter question will be 
addressed in a subsequent section; however, regarding relevant comorbidities, little information 
has been established in exhaled breath biomarker research implicating known sources of 
confounding IsoF results with the exception of those with known mitochondrial diseases, such as 
amyotrophic lateral sclerosis (ALS), Alzheimer’s, Lewy body and Parkinson’s diseases (Fessel 
et al., 2003). Even then, what is understood about the significant presence of IsoF in these 
diseases was tested in the substantia nigra of individuals diagnosed with Parkinson’s and Lewy 
body disease, not exhaled breath. As a result, minimal exclusions were imposed except for those 
diagnosed with ALS, Alzheimer’s, Lewy body and Parkinson’s diseases.   
When considering significant sources of increased tissue oxygen tension alveolar 
macrophages (AMs) must be included, as they responsible for producing large quantities of 
ROS. According to Barnes (2004) the conditions imposed by AM activation in the lungs leads to 
a cascade of processes that “together could account for all of the pathophysiological features of 
COPD.” A mechanism of defense incited by AMs is respiratory burst, a marked increase in 
superoxide (an oxygen radical) to serve as a bactericide. Vacchiano et al (1997) demonstrated in 
rat culture a mean 8-IsoP macrophage production of 14 ± 1 pg/ml when exposed to air, and a 25 
± 2 pg/ml when exposed to 100% oxygen. This evidence supports macrophage contributions to 
increased oxidant load, and, subsequently, oxidative stress when unchecked. Relevant to note in 
the same study, however, are the findings that show no increase from baseline in mean 
macrophage production of 8-IsoP following exposure to 50% oxygen. This finding supports that 
concentrations ≤ 50% FiO2 do not contribute to ongoing oxidative stress at normal partial 
pressures (at sea level or 1 ATA). When compared to the current study, it suggests this IsoF 
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levels obtained are likely a result of the original disease process and not the addition of LFDO 
therapy as no study participants were exposed to >36% at 1 ATA.  
A significant challenge, with regard to accurately interpreting the results, in the current 
study is that no data exists defining baseline exhaled breath IsoF levels in healthy subjects or in 
individuals diagnosed with COPD. Only three studies to date have employed exhaled breath IsoF 
as a biomarker of oxidative stress, all of which utilized different study groups (refer to Table 36). 
The three studies are presented below with comparisons made in order to discern any existing 
inferences between them.  
A study by Dworski et al (2009) demonstrated a basal exhaled breath IsoF level of 3.9 ± 
3.3 pg/ml (mean ± SD) in known human allergic asthmatics. The study demonstrated that 
asthmatics who were exposed to an inhaled antigen challenge (IAC) showed an increase in 
exhaled breath IsoFs at all time points, with significance being reached at 2 h (P=0.036) and 4 h 
(P=0.025) post challenge (7.7 ± 6.7 and 6.8 ± 4.7 pg/ml respectively).  While the population for 
the current study (adults with COPD) differed from the Dworski study (children with asthma) it 
is the only published study utilizing exhaled breath as a medium for which to evaluate and 
compare the results of the oxidative stress biomarker, IsoF. The mean exhaled breath IsoF level 
for the control group in the Dworski study (3.9 pg/ml) was significantly lower than that the mean 
obtained in the active control group in the current study (35.8 pg/ml). The disparity in control 
means may reflect an overall disparity in disease states of the participants: adults with advanced 
COPD compared to asthmatic children in a quiescent state. 
In an unpublished study by Vacchiano (2005) the EBC IsoF levels of naval pilots who 
were exposed to 100% oxygen intermittently during high altitude flight over the course of their 
flying careers were compared to age, gender and smoking matched naval pilot candidates 
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(control group) whom had never been exposed to supplemental oxygen  (personal 
communication). The control group mean EBC IsoF levels obtained from the pilot candidates 
was reported to be 3.1 ± 3.5 SD pg/ml. The results obtained are very similar to the control mean 
obtained in the Dworski study, 3.9 ± 3.3 SD pg/ml, suggesting they may be reflective of basal 
IsoF levels in healthy lungs. The AC group (COPD patients without LFDO) mean EBC IsoF 
value obtained in the current study of 35.8 ± 25.0 SD represents diseased lungs. The oxygen 
exposed pilot group in the Vacchiano study generated a mean EBC IsoF level of 38.8 ± 116.5 SD 
(15.86 SEM) pg/ml, similar to the AC group EBC IsoF values obtained in the current study (see 
Table 36). In addition, there was a further marked increase in EBC IsoF levels, from their 
already increased baseline levels, in the actively flying pilot group following a training flight 
during which 100% oxygen was inspired for an average of 1.5 hours. It was reported in the 
personal communication that the oxygen exposed pilots percent (%) predicted FVC and FEV1 
values were lower than expected for the entire aviator group at 3 measurement periods (preflight 
and 2 post-flight periods).  There was also a statistically significant decrease compared to 
preflight baseline in both % predicted FVC and FEV1 at the 1st post flight measurement period in 
aviators with 2200 to 3500 hours of total flight time breathing 100% oxygen.  This suggests that 
this group of aviators had developed signs of restrictive lung disease during the course of their 
careers. It can be speculated that chronic intermittent high concentration supplemental oxygen 
exposure is central to that development. The control group for the current study and the treatment 
group for the Vacchiano study reflect basal IsoF levels in diseased lungs. Both have incurred 
lung damage but from different instigators of oxidative stress. The COPD patients have 
developed their disease due to first or second hand smoke, or environmental pollutants while the 
pilots appear to have incurred lung damage as a result of inspiring sufficient supplemental  
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Table 36. 
Exhaled Breath Isofuran Studies 
Study N 
Control  
IsoF Mean ± SD 
pg/ml 
Treatment 
IsoF Mean ± SD 
pg/ml 
Population 
Dworski  
(2009) 27 3.9 ± 3.3  
7.7 ± 6.7 
6.8 ± 4.7  
Children with 
human allergic 
asthma 
Vacchiano 
(2005) 48 3.1 ± 3.5  38.8 ± 116.5 
Naval pilot 
candidates 
Naval pilots 
Stulce  
(2015) 52 35.8 ± 25.0  51.4 ± 42.2  
COPD w/o 
LFDO 
COPD with 
LFDO 
  
oxygen required to achieve a blood oxygen partial pressure to maintain normal cognitive 
function at high altitude. Explanations for the increased exhaled breath IsoF mean (51.4 ± 42.2) 
in the current study treatment group remains unclear; however, they follow a similar trend as in 
the Vacchiano study, increasing from baseline following oxygen therapy, possibly indicating that 
supplemental oxygen may be responsible for the observed increases in exhaled breath IsoF.  
As reported in the literature review, no medications are known to impact IsoP formation 
in humans, and, presumably then IsoF, as it is a biosynthetic relative of IsoP would similarly not 
be affected. Corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic 
acid (ASA) inhibit prostaglandin synthesis via the cyclooxygenase pathway. Prostanoid isomers, 
such as the isoprostanes, are produced as a result of non-enzymatic processes and, therefore, 
corticosteroids, NSAIDs and ASA presumably have no significant impact on their formation. 
However, it has been demonstrated that ASA significantly reduced 8-IsoP production by primary 
cultures of rat alveolar macrophages under laboratory conditions but has not been substantiated 
in human studies (Vacchiano, Osborne and Tempel, 1997).  This finding suggests an alternative 
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mechanism of ASA in regard to ameliorating oxidant load, such as scavenging of reactive 
oxygen species (ROS) or through the NADPH oxidase inhibition, the enzyme responsible for the 
production of superoxide as a result of respiratory burst. In the current study ASA use did not 
preclude study participation. Medication lists were reviewed as a method of confirming co-
morbidities, however, no subjects were excluded due to medication use. The six participants in 
the active control group that reported daily low dose aspirin use generated an IsoF range of 15-42 
pg/ml; in the active treatment group the six participants reporting daily low dose aspirin use 
generated an exhaled breath IsoF range of 11-77pg/ml.  The AC IsoF group mean ± SEM was 
35.81 ± 4.92; the AT group mean ± SEM was 51.35 ± 8.27.  Daily aspirin use did not appear to 
exert a negative influence on IsoF synthesis in either group, suggesting that ASA may not have 
ROS scavenger or NADPH oxidase inhibitor capabilities in this population subset likely due to 
the degree of lung pathology. 
In summary, the lack of significant findings in this study are a result of 1) the 
methodology employed was not suitable to address the research questions; 2) IsoF, a biomarker 
influenced by multiple sources, lacks specificity with regard to source, rendering it unsuitable for 
purposes of evaluating LFDO as an instigator of oxidative stress; or 3) LFDO at concentrations 
less than 36% do not contribute to ongoing oxidative stress in the lungs of individuals of COPD. 
The contribution of this study to the large gap in literature on IsoF as a biomarker of oxidative 
stress is, however, as a benchmark with which to compare future research. The comparison of the 
three studies (Dworski, Vacchiano, Stulce) begins to shed light on baseline EBC IsoF in a variety 
of populations. Exhaled breath biomarker analysis is in its infancy, with exhaled breath IsoF 
analysis nearly non-existent.  A recent PubMed search reported 692 research studies since 1992 
utilizing “exhaled breath” as a search term; of those, 58 studies were conducted in 2015. A 
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PubMed search utilizing “isofuran” as the search term yielded 21 studies, only one of which 
evaluated exhaled breath as the medium for IsoF analysis. The current study may provide insight 
into the scope of its value. 
Research Question 2. The second research question asks whether or not a relationship 
exists between FEV1, FVC, FEV1/FVC, FEF25-75% and IsoF levels. The noninvasive nature of 
exhaled breath condensate collection makes it an ideal method for the assessment of pathologic 
processes occurring in individuals in fragile health states, such as those with advanced COPD. In 
light of this concept, multiple studies have been conducted to correlate exhaled breath 
biomarkers to those pulmonary function test parameters consistent with diagnosing and 
quantifying disease states of individuals with COPD, but without real success. Until this study 
none had attempted to correlate exhaled breath IsoF levels to standard diagnostic spirometry, 
such as FEV1, FVC, FEV1/FVC, and FEF25-75%.  
To address this question current PFTs were obtained to compare and correlate to exhaled 
breath IsoF levels to assess for clinical application. In order to obtain accurate PFT results 
maximal effort is required, and often times multiple maneuvers, all of which can be very 
challenging for the individual with COPD, particularly those with advanced disease. If an actual 
correlation between a validated exhaled breath biomarker and pulmonary function parameters 
could be identified, individuals could theoretically be spared from this rigorous PFT process. 
IsoF was selected as the predictor variable with the intention of replacing conventional 
pulmonary function testing. 
A linear regression statistical model was employed to explore possible relationships 
between FEV1, FVC, FEV1/FVC, and FEF25-75% and exhaled breath IsoF levels. No 
significant relationships were revealed between any of the tested pulmonary function parameters 
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and exhaled breath IsoF. As mentioned, multiple studies have been performed to determine if a 
correlation exists between exhaled breath oxidative biomarkers and pulmonary function test 
results without success with the exception of a study conducted in 2010 by Carraro et al, which 
evaluated 20 children diagnosed with asthma, comparing their exhaled breath 8-IsoPs to 
FEV1/FVC and FEF25-75% parameters to identify whether or not a correlation exists. The 
analysis demonstrated that 8-IsoP in the exhaled breath condensate was significantly increased in 
children with problematic asthma (p=0.05) with a negative correlation to both the FEV1/FVC 
and FEF25-75% (r= -0.5), and both statistically significant (P=0.03). Although these findings did 
not utilize IsoF as the oxidative stress biomarker, it is closely related to 8-IsoP, suggesting a 
potential relationship could be established in the same setting.  As such, support for continued 
research and refinement in determining whether or not exhaled breath biomarker analysis as a 
noninvasive means of predicting disease states has a place as a diagnostic tool should continue. 
While no correlation was established in the current study between IsoF and FEF25-75% 
(r=0.194, P=0.34) it is of interest to note a significant difference in FEF25-75% existed between 
the AC and AT groups (P=0.0265). Two methods were employed to collect PFT data, the 
Discovery II Spirometer™ conducted by the PI, and in the PFT lab conducted by certified 
respiratory therapists. Error may have been introduced as a result; however, no significant 
differences in the remaining test parameters were noted.  
In summary, studies have failed to consistently correlate standard spirometric testing with 
validated oxidative stress biomarkers. The current study also failed to identify a correlation 
between FEV1, FVC, FEV1/FVC and FEF25-75% parameters and the oxidative stress 
biomarker, IsoF. However, the ideal noninvasive conditions offered by exhaled breath analysis to 
individuals with advanced lung disease make it desirable as a diagnostic and prognostic tool. 
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Exhaled breath biomarker analysis is still in the early stages; as more research is conducted and 
methodologies improved there may come a time when correlations can be made between exhaled 
breath biomarkers and current standard diagnostic testing. 
Research Question 3. The third research question asks whether or not exhaled breath 
IsoF levels were correlated to length of oxygen exposure, smoking history and/or concentration 
of oxygen delivery (L/min). Understanding the relationships between the relevant variables of 
time of exposure and concentration of oxygen delivery to IsoF levels could provide crucial 
insight into the potential of LFDO as a mechanism of ongoing oxidative stress.  It is intuitive that 
time would be a relevant factor in promoting oxidative stress as longer exposure provides more 
opportunity to incite oxidative stress. However, in the current study, chronicity did not result in 
significant elevations in exhaled breath IsoF levels. In fact, an individual who had been on 
oxygen for 20 years generated an exhaled breath IsoF level of 13 pg/ml, one of the lowest values 
obtained in the study, while the individual generating the highest exhaled breath IsoF level (181 
pg/ml) reported oxygen use for only 3 weeks. Perhaps the crucial assessment period, with regard 
to “time”, is at the initiation or introduction of LFDO therapy.  
It is also intuitive to believe that dose (or concentration) would influence IsoF production, 
as more of the offending substance is available to incite pathology. The relevance of 
concentration may exist, however, with the higher concentrations/doses. There are many studies 
implicating high concentrations (≥ 50%) of supplemental oxygen exposure to oxidative stress, 
however, there are no studies evaluating low flow/concentration (L/min) of oxygen therapy for 
individuals on LFDO therapy as a mechanism of oxidative stress. The L/min flows of oxygen 
therapy reported in the current study were between 2-4 L/min (28-36% concentration). Two 
L/min was the lowest reported concentration of oxygen therapy in the current study, it generated 
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both the lowest and the highest IsoF values at 11 pg/ml after LFDO 12 hrs/day for 3 years and 
181 pg/ml with LFDO 24 hrs/day for 3 weeks. The single participant reporting 4 L/min of daily 
oxygen use (9 hrs/day for 5 years) generated an exhaled breath IsoF of 77 pg/ml. The disparity in 
the range in IsoF compared to concentration suggests LFDO does not influence oxidative stress. 
It is well established, particularly in diving and aviation literature, that oxygen is toxic 
when breathed at a partial pressure in excess of 0.4 ATA (40% O2 at atmospheric pressure) for a 
sufficient period of time. As partial pressures exceed 0.4 ATA, oxidant load increases and 
pathology ensues. Nagatomo et al (2012) exposed male Wistar rats to 14.4%, 20.9%, 35.5%, 
39.8%, 62.5% and 82.2% oxygen at 1 ATA for 24 hours. Derivatives of reactive oxygen 
metabolites (dROMs) in plasma were utilized as an index of oxidative stress. It was concluded 
that 14.4%, 20.9% and 35.5% oxygen did not affect dROM levels; however, rats exposed to 
39.8% 62.5% and 82.2% oxygen had significant (P<0.05) increases in dROMs, with the highest 
level in the 82.2% oxygen exposure group. Vacchiano et al (1997) had a similar finding with no 
significant increase in alveolar macrophage mean concentration of 8-IsoP at 50% oxygen 
exposure at 1 ATA. These studies demonstrate safe oxygen therapy administration <40% oxygen 
at 1 ATA. With regard to the current study, these findings support LFDO concentrations ranging 
from 28-36% as a safe therapy. Concentrations this low minimally impact blood oxygen partial 
pressures, particularly in the presence of diseased lungs with a decreased diffusion capacity. 
There is evidence, however, that brief exposure (30-60 minutes) to low concentrations of 
oxygen (28%) results in significant increases (P<0.05; P<0.001) in validated exhaled breath 
oxidative stress biomarkers (BMAC; 8-Isoprostane and IL-6) in healthy adults (Phillips, 2003; 
Carpagnano, 2004). The target population in the Phillips study was exclusively healthy adults 
while the Carpagnano included both healthy adults and adults with COPD. Both studies 
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employed a pre and post EBC analysis after breathing ambient air and 28% supplemental 
oxygen. While these time points (30-60 minutes) do not represent chronicity they do address the 
concept “low concentrations/flow” as a mechanism of oxidative stress. The results from the 
Phillips and Carpagnano studies are in conflict with what is currently understood about minimal 
oxidant load occurring as a result of concentrations <40% at sea level. With regard to the current 
study, there may be some similarities to those reporting brief or sporadic exposure generating the 
highest results. The individual reporting sporadic use in the two months prior to sample 
collection generated an exhaled breath IsoF of 148 pg/ml. The individual reporting three weeks 
of 24 hrs/day 2L/min of oxygen use reported 181 pg/ml. These results, along with those reported 
in the Phillips and Carpagnano study, support investigating oxidative stress associated with an 
introductory phase of LFDO therapy, and subsequently, the mechanisms responsible for return to 
baseline in its continued presence.   
To explore the concept of “time” further to determine if IsoF levels were influenced by 
length of exposure in terms of years a one-way analysis of variance (ANOVA) was performed. 
Lengths of exposure were defined as 0-2 years (n=14), 3-6 years (n=8) and 7-20 years (n=4). 
These range bins were determined to meet the criteria necessary to perform an ANOVA. 
Significance differences between groups was not found (P = 0.1795), meaning time in terms of 
years of exposure did not implicate LFDO as a mechanism of oxidative stress. Consistently the 
variables of potential influence on oxidative stress have not been substantiated in this study. 
Again, indicating that the IsoF levels obtained in the study are likely a result of preexisting 
diseases, not LFDO.  
In summary, with what is currently understood regarding IsoF as a biomarker sensitive to 
elevated tissue oxygen tensions it could not be demonstrated that concentration of oxygen 
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delivery (L/min), or duration of therapy in terms of hours/day or years predictably influenced its 
production. Low flow domiciliary oxygen prescription flow rates fall between 1-5 L/min (24-
44%). It has been substantiated that concentrations < 40% oxygen delivery at 1 ATA are safe. 
The current study had no participants utilizing greater than 36%; therefore, it would not be 
expect to observe an elevation in IsoF. There may be evidence suggesting oxidative stress may 
occur during an initiation phase of oxygen therapy. As more is understood regarding the 
variables influencing oxidative stress, and hence the biomarkers of oxidative stress, the more 
specific methodologies can be developed and employed, bringing healthcare provision closer to 
quality outcomes. Until then, the current study suggests that LFDO does not contribute to 
ongoing oxidative stress, but rather that the IsoF levels are a reflection of disease.  
Theoretical Framework 
The overarching goal, as it relates to health sciences research, is patient safety. An 
organized and methodological approach is ideal when attempting to determine if practice 
modalities/treatments are optimal in promoting, maintaining and restoring health. Donabedian’s 
Structure-Process-Outcome framework postulates that if the institutional “structure” and 
“process” are constructed and conducted in the appropriate way then quality outcomes will 
certainly follow. To assess whether LFDO therapy is appropriately prescribed and managed at 
Phelps County Regional Medical Center the Structure-Process-Outcome model was utilized. 
Qualitative Observations. Donabedian’s model of Structure-Process-Outcome provides 
a framework by which to evaluate the effectiveness and/or quality of healthcare. “Structure” 
refers to the context in which care is delivered, such as hospital buildings, administration, staff, 
economic resources and equipment. Phelps Country Regional Medical Center is active in and 
supportive of research as a mechanism by which to provide those they serve with the most 
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appropriate and effective care. The Chief Medical Officer at PCRMC supported this research 
endeavor in the form of allowing the PI access to all areas of the hospital that offered and 
managed the care of individuals with COPD in an effort to better understand any potential risks 
associated with the use of prescribed LFDO therapy as a treatment modality. This level of 
engagement demonstrated the administration’s attitude and commitment toward providing 
quality care.  
Areas accessed for this research project included the cardiology, internal medicine, and 
the pulmonary function clinics. The clinics were appropriately staffed with licensed practical 
nurses, registered nurses, and nurse practitioners, registered physical therapists, and certified 
respiratory therapists and physicians. All areas were equipped with emergency equipment and 
protocols to address untoward medical emergencies. The cardiac and internal medicine clinics 
were housed in the Medical Office Building directly attached to the hospital, while the 
pulmonary function lab was housed within the hospital itself. The location of the clinics 
facilitated ease of transport and quick access to acute care. The “structure” aspect, which 
promotes quality outcomes, was sufficient. 
“Process” refers to the sum of all interactions between patients and providers throughout 
the delivery spectrum that translates to healthcare. It is during the “process” phase that diagnoses 
are made, treatments are formulated and delivered, and patient education takes place. The 
manner in which care is delivered significantly influences patient satisfaction and perception of 
quality. The “process” of delivery at PCRMC is collaborative between disciplines per protocol. 
Phelps County is committed to the evolution of improved communication to enhance outcomes. 
Witness to this process was observed firsthand during the data collection phase. This assessment 
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was not only made as a primary observer, but also as a result as the consistent feedback obtained 
from client surveys of the respective clinics as part of their quality assurance commitment.  
“Outcome” refers to those measurable or discernable changes in health status, behavior, 
or knowledge as well as overall patient satisfaction and health-related quality of life 
improvements. Improving health states is the primary goal of healthcare; therefore, assessing 
outcome with regard to this central parameter is necessary. Health “state” can be defined broadly 
or narrowly. With regard to this study, a very specific assessment of a prescribed treatment was 
utilized to determine the “outcome” of said treatment. The benefits of LFDO therapy are well 
understood; however, until recently, there had not been a specific mechanism by which to assess 
for pathology related to LFDO. Utilizing new techniques to measure IsoF allowed us to examine 
the outcome of a prescribed treatment of LFDO offered by PCRMC to their constituents.  
In summary, according to Donabedian, outcome is conceptually defined as the end result 
of the process of care to include “those things, either favorable or adverse, in the actual or 
potential health status of persons, groups, or communities that can be attributed to medical care” 
(Donabedian, 1985, p.256). Based on the results of this study, when utilizing IsoF as an outcome 
measurement of LFDO, quality can be assumed, as ongoing oxidative stress as a result of LFDO 
therapy was not substantiated.   
Methodologic Review 
The final inquiry for this study is whether or not the methodology employed is suitable 
for future research. The response is a mixed yes and no. The exhaled breath condensate 
collection protocol utilized in the current study is consistent with recommendations by the 
American Thoracic Society and European Respiratory Society (ATS/ERS), and consistent with 
the protocol at Vanderbilt Eicosanoid Core labs, currently the only known lab in the United 
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States equipped to identify and quantify IsoFs. Therefore, no changes are currently indicated 
with regard to the actual sample collection, storage and analysis methodology. 
 Refinement of inclusion/exclusion criteria for participant selection is required. Greater 
insight is warranted regarding the impact acquired mitochondrial disease and alveolar 
macrophages contributes to increased tissue oxygen tensions and, thus, IsoF formation. Until this 
is realized it will be difficult to precisely assess exogenous oxygen as the mitigator of oxidative 
stress when utilizing the IsoF biomarker. 
 Confounding study results circle around the highest IsoF values obtained (181 and 148 
pg/ml) by individuals reporting either less than a month or sporadic use of LFDO in the two 
months prior to data collection. Is it a function of time? Are there compensatory mechanisms that 
explain the lack of findings? Are there particular disease processes that result in greater IsoF 
synthesis? As a result of these, and other questions, a methodology addressing these confounders 
requires development.  
 Exhaled breath condensate analysis was included in the methodology in the current study 
to evaluate LFDO as a mechanism of ongoing oxidative stress due to its noninvasive low risk 
profile. Historical approaches to diagnosing and prognosing pulmonary disease states include 
bronchoscopy with bronchoalveolar lavage and/or biopsy. Risks associated with the procedure 
vary depending on the overall health state of the individual. Individuals with COPD who are 
chronically hypercarbic with symptomatic shortness of breath are at risk for post procedure 
ventilatory support (Rand et al, 2013). As COPD progresses even mild insults can result in 
exacerbations. Exhaled breath condensate collection as an approach of assessing disease states in 
this fragile population makes it desirable.  
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Limitations 
A significant limitation of this study was the lack of a standardized protocol for exhaled 
breath condensate collection. Due to the inherent nature of the individual biomarker compounds 
being assessed, the varying storage practices and the specimen assessment tool (assays vs. mass 
spectrometry) makes establishing a singular methodology for exhaled breath condensate 
collection and biomarker detection challenging. As a result, the ATS/ERS have only developed 
recommendations versus a standardized protocol. Recently, Mastrigt et al (2015) conducted an 
extensive literature search utilizing the Medline, Embase and PubMed databases on the analysis 
and applications of volatile organic compounds (VOCs) in exhaled breath (EB) and EBC on 
children. They retrieved 1165 papers, nine of which contained original data on VOCs in EB and 
84 on biomarkers in EBC. Following an analysis of the studies obtained it was concluded that, 
while EBC analysis adds value to the diagnostic process and follow-up care of individuals with 
respiratory disease, the lack of standardization of collection methods and analysis techniques 
impedes the introduction of EBC use into clinical practice. This assessment is consistent with 
those determined by Horvath et al in 2005, Montuschi in 2007 and supported by the ATS/ERS. 
After approximately 13 years of EBC research clinical application has not been achieved. The 
results of the current study did not substantiate clinical use of EBC analysis with regard to either 
LFDO as an instigator of oxidative stress or as a substitute for pulmonary function testing. 
Currently no studies have been conducted that define basal levels of exhaled breath IsoF 
in individuals diagnosed with COPD, making the inability to interpret the obtained results is a 
crucial limitation. Not only are there no exhaled breath basal IsoF levels established in 
individuals with COPD, there are no exhaled breath IsoF levels established in healthy individuals 
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either. While this is considered a significant limitation of this study, the obtained results will aid 
in establishing that benchmark knowledge for future studies to compare. 
Isofuran production is currently understood to occur in response to elevated oxygen 
tensions (Roberts et al, 2004). Elevated oxygen tension levels within the body can occur from 
both endogenous and exogenous sources. This study aimed to discern if oxidative stress was 
occurring as a result of prescribed LFDO therapy, an exogenous source of reactive oxygen 
species production. Endogenous sources of molecular oxygen can result from genetic or acquired 
mitochondrial diseases, such as amyotrophic lateral sclerosis (ALS), Huntington’s, Alzheimer’s, 
Lewy body and Parkinson’s diseases (Fessel et al, 2003). Study candidates were surveyed for 
these particular diseases with none reported or observed. However, other more common diseases 
that are linked to mitochondrial dysfunction, such as diabetes and hypertension, were not 
controlled for.   
Acquired mitochondrial dysfunction occurs as a result of adverse effects from drugs, 
infections or other environmental factors (Ellinas and Frost, 2011). Diseases of the mitochondria 
appear to cause the most damage to cells of the brain, heart, liver, skeletal muscles, kidney and 
the endocrine and respiratory systems (Ellinas and Frost, 2011). The most common co-
morbidities reported by the participants in this study were COPD (100%), hypertension (87%), 
diabetes (40%), coronary artery disease (56%), and hyperlipidemia (56%). Oxidative stress is 
central to many of these disease processes with acquired mitochondrial dysfunction as a 
contributing factor. It is unknown at this time to what degree, if any, these disease processes 
contribute to elevated IsoF levels as a result of liberated molecular oxygen from disrupted 
mitochondria. The limited understanding of contributing sources of elevated tissue oxygen 
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tensions make it challenging to interpret which source, endogenous or exogenous, is responsible 
for and to what degree of IsoF synthesis in this study. 
A limitation of biomarker analysis is the lack of specificity with regard to which tissue it 
represents. It has not been established that biomarker levels are exclusive to specific disease 
processes when obtained via blood, plasma or urine. It is speculated that compounds collected in 
exhaled breath condensate are representative of the alveolar lining, but, it does not necessarily 
preclude the possibility that portions of a particular biomarker aren’t representative of other 
systemic oxidative stress processes. As a result, it is recommended that exhaled breath analysis 
of oxidative stress should not occur in the presence of an active infection, specifically sepsis and 
pneumonia. No individuals with either current or recent pneumonias or other systemic infections 
were considered for study inclusion. Candidates were excluded for active oral infections and 
current use of antibiotics. Those who reported current antibiotic therapy were excluded for 
concern of lingering inflammatory processes that might contribute to an oxidant load and 
confound the result. 
 Limitations of this study with regard to PFT testing were the mixed-provider mixed-tool 
methodology. Multiple clinic sites (Cardiology Clinic, Internal Medicine Clinic, Pulmonary 
Rehab Clinic, Pulmonary Function Lab) were available for recruiting participants. Only the PFT 
lab provided same day PFT testing; all other recruitment sites required obtaining PFT utilizing a 
portable spirometer. This mixed provider approach utilizing two different tools introduced a 
potential measurement error, a threat to internal validity. Ensuring consistent effort provided by 
study participants during PFT testing outside of the pulmonary function lab was difficult. The 
portable Discovery II™ spirometer, while considered sensitive and accurate, lacked the 
sophistication of the software employed in the PFT lab. The lack of previous experience with 
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administering pulmonary function testing by the PI introduced an initial limitation; however, 
proficiency was realized early on.  
 The sample size generated for this study was based on an effect size determined through 
examining 8-IsoP research. Isofuran may have a smaller effect size requiring a larger N with 
which to power a study. A larger sample size would allow for the detection of patterns in 
comorbidities as it relates to IsoF levels as well as possible explanation of the significant outliers 
in the active treatment group. 
Recommendations for Future Research 
While known genetic mitochondrial diseases (Lewy body, Alzheimer’s and Parkinson’s 
Diseases) were excluded from this study, current research implicates mitochondrial pathology in 
many of the same diseases correlated to oxidative stress, such as diabetes and hypertension, etc. 
Acquired mitochondrial mutations manifest within the human in the form of cellular senescence, 
such as aging, heart disease, and diabetes, etc. Cytochrome c oxidase is responsible inside the 
mitochondria for converting molecular oxygen to two molecules of water. In the presence of 
cytochrome c oxidase mutations this feature is retarded and molecular oxygen goes unchecked, 
contributing to oxidative stress within the cell. Future research to aid in a better understanding 
the relationships between mitochondrial disease, cytochrome c oxidase mutations and IsoF 
production could lead to an enhanced understanding of the origin of IsoF synthesis and 
validating it as a useful tool in oxidative stress research.  
It is of interest to consider that IsoF concentrations may decline at some undefined point 
in time following initiation of LFDO. It would be of value to know the mechanism(s) responsible 
for stabilizing isofuran synthesis following an “introductory phase” of therapy. Tolerance or 
adaptation within the body manifests in many different ways. Mechanisms of systemic 
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tolerance/adaptation, such as endogenous free radical scavenging systems activity, up and down 
regulation, or potential reductions in cytokine activity, as a mechanism of stabilizing IsoF levels 
following prolonged LFDO use, should be explored. 
Identified contributors of increased oxidant load include mitochondrial disease, AM 
activity and supplemental oxygen. With what is currently understood about IsoF there is no way 
of discerning which source of ROS is responsible for IsoF synthesis.  Currently, over 250 
isomers of IsoFs have been identified. Continued research in delineating these isomers could 
provide insight into their unique qualities regarding specificity and sensitivity to specific 
processes/diseases. Until then, in light of what is currently known, IsoF is not a sensitive 
biomarker of supplemental oxygen therapy. 
A methodology recommendation would be to utilize a longitudinal repeated measures 
pre-post test design. Develop a study design that targets individuals being prescribed LFDO, 
obtaining baseline IsoF levels prior to LFDO initiation, then again at predetermined time points 
following initiation (24 hours after initiation, then at 1, 2, 3, 5 and 6 months). A determination 
could be made pending the need for continued IsoF evaluation of IsoF. Such an approach would 
be better able to identify whether or not supplemental LFDO is a mechanism of ongoing 
oxidative stress. 
Summary 
The purpose of this chapter was to present the results of this study in such a way that was 
meaningful to researchers and healthcare providers. It was intended to encourage the reader to 
consider the implications of traditional therapies/practices employed. This study did not 
demonstrate LFDO as a mechanism of ongoing oxidative stress; however, as more is learned 
about the variables contributing to IsoF synthesis we may be able to optimize its unique feature 
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of oxygen tension specificity in gaining greater insight into oxidative stress and related diseases, 
specifically COPD.  
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Appendix A 
 
 
 
 
Low-flow domiciliary oxygen therapy as a mechanism of ongoing oxidative stress in 
COPD patients  
Study Participant Data Collection Sheet 
Active Control Group ID #___________ Active Treatment Group ID #__________ 
 
Age: _____ 
 
Gender:  M or F 
 
Height: (in feet and inches): _________________________________________ 
 
Weight: (in pounds): _______________________________________________ 
 
Ethnicity: ________________________________________________________ 
 
Current Smoker?   Y    N 
 
How long ago did you quit? _________________________________________ 
 
How many years did you smoke? ____________________________________ 
 
How many packs per day did you smoke? _____________________________ 
 
Do you have alpha-1 antitrypsin deficiency?  Y    N 
 
Are you currently on oxygen therapy at home?  Y    N 
 
If yes, how long have you been on home therapy? ______________________ 
 
How much oxygen (liters per minute) are you on? _____________________ 
 
Are you currently receiving antibiotics?  Y    N 
 
If yes, do you currently have a nose or mouth infection?   Y    N 
 
Please provide a complete list of medications you take daily: 
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Appendix B 
 
 
 
 
Sample Storage Data Sheet 
 
 
 
Sample ID#: ________________________ 
 
Sample Collection Date: ______________ Sample Collection Time: ______________ 
 
Cooler Temperature: _________________ 
 
Ship Date: __________________________ 
 
Comments: 
___________________________________________________________________ 
 
 
 
____________________________________________________________________ 
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Appendix C 
 
Informed Consent 
 
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of 
oxidative stress. 
 
Investigators:  Jill Stulce, MSN, CRNA 
 
Informed Consent 
Before you agree to take part in this study, it is important that you read the following 
description of the study.  This paper describes the purpose, methods, benefits, and risks of 
the study. It is always your right to change your mind and decide not to be in the study at 
any time.   
 
Purpose of Research 
To determine if home oxygen therapy contributes to ongoing lung inflammation for 
people diagnosed with COPD. 
 
Explanation of Procedures 
This is a study that compares the exhaled breath of individuals diagnosed with COPD 
receiving home oxygen therapy to those individuals diagnosed with COPD not receiving 
oxygen therapy to determine if oxidative stress is occurring within the lungs as a result.  
 
There will be two groups of patients. The groups include 1) patients diagnosed with 
advanced COPD not receiving home oxygen therapy; and 2) patients diagnosed with 
advanced COPD receiving home oxygen therapy.  If you are selected to participate in this 
study you will be assigned to one of these two groups.  Group selection will be decided 
by use of home oxygen therapy. A PhD candidate from Virginia Commonwealth 
University is conducting this study.   
 
The care given to the patient will not be changed in any way other than the collection 
exhaled breath into a collecting device, which will take approximately 10 minutes. The 
patient will be asked to breath into a spirometry device to determine lung function. 
Information needed for the study will be collected from the principle investigator, project 
manager or staff.  This information will include but not be limited to age, height, weight, 
ethnicity, smoking status and history, oxygen therapy history. 
Participants Initials:__________ 
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Appendix D 
 
 
 
 
Informed Consent 
 
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of 
oxidative stress 
 
Investigators:  Jill Stulce, MSN, CRNA 
 
Risks 
No risks are associated with study participation. 
 
Benefits 
There may be no direct advantage to being in this study.  Information from this study 
may help make the care better for future patients. 
 
Participant Selection 
We are asking only those individuals who have been diagnosed with COPD who may or 
may not be on oxygen therapy. 
 
Withdrawal Without Prejudice 
You do not have to be in this research study. You can agree to be in the study now and 
change your mind later. Your decision will not affect your care. 
 
Confidentiality 
Information collected will remain private.  The information collected from your chart 
may be printed for scientific purposes.  This information includes the your medication 
list, age, height, weight, ethnicity, pulmonary function test results, smoking status and 
history, oxygen therapy history.  Your identity will not be revealed.  The researchers will 
be the only ones with access to the study information. 
 
Costs and/or Payment to Subject for Participation in Research 
There will be no costs for taking part in the study.  Also, you will not be paid to take part 
in this study. 
 
 
Participant’s Initials:__________ 
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Appendix E 
 
 
 
 
Informed Consent 
 
Title of Research: Chronic exposure to low flow home oxygen therapy as a mechanism of 
oxidative stress 
 
Investigators:  Jill Stulce, PhDc, CRNA 
 
Questions 
Any questions regarding study participation should be made directly to Jill Stulce, PhDc, 
CRNA at 314-691-1310. 
 
Agreement 
This agreement states that you have received a copy of this informed consent.  Your 
signature below says that you agree to participate in this study. 
 
 
 
 
_______________________________________          __________________ 
Signature of Participant       Date 
 
 
 
 
_______________________________________           
Participant Name (printed) 
 
 
 
_______________________________________          ___________________ 
Signature of Researcher or Anesthesia Provider Date 
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Appendix F 
 
 
Exhaled Breath Collection Instruction Sheet 
To better understand processes occurring within the lungs of COPD patients receiving 
oxygen therapy we are asking you to participate in a research project by providing your 
exhaled breath for analysis. Below is a list of what is required by you to ensure success in 
this evaluation. 
 Thank you for your participation. 
1. Rinse mouth prior to introducing RTube™ mouthpiece into mouth. 
2. Secure lips around mouthpiece and breath in and out through your mouth 
3. Approximately 10 minutes is required to obtain an adequate amount of exhaled 
breath condensate for analysis 
 
 
 
 
 
 
 
 
 
 
 
  181 
 
 
Vita 
 
Jill Stulce was born in the city of St. Louis in 1965 and grew up in a suburb of the city, 
Ferguson, Missouri. She earned a Bachelors of Science in Nursing degree from the 
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